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Abstract 
The main objective of the thesis is to use advanced MRI techniques to look for 
biomarkers that separate neuromyelitis optica spectrum disorders (NMOSD) 
from MS to improve diagnosis. NMOSD, a severe inflammatory disease which 
causes demyelination of the central nervous system, is characterised by optic 
neuritis (ON) and acute myelitis. Because of similarities with MS, NMOSD is 
not always correctly diagnosed at onset. As it is both more aggressive and faster 
progressing than MS, an early accurate diagnosis is crucial. For this thesis, three 
different MRI techniques were used, together with clinical assessments, to gain 
a better understanding of the differences between the two diseases. The first 
was neurite orientation dispersion and density imaging (NODDI), a diffusion 
MR technique used to analyse the microstructure of dendrites and axons. When 
applied to a single-shell dataset of RRMS patients, it was shown to detect more 
regions of diffusion abnormalities than FA maps. The second technique used is 
phase-sensitive inversion recovery (PSIR), to look for grey matter lesions. This 
first application to NMOSD patients led to the detection of grey matter lesions 
in nearly 50% of this group, as well as showing differences in leucocortical and 
juxtacortical lesions between NMOSD and MS, with juxtacortical lesions 
emerging as potential markers to differentiate between these diseases. The final 
part applies magnetisation transfer ratio (MTR) to the optic nerve to assess 
myelin integrity in both MS and NMOSD patients, together with optic 
coherence tomography (OCT) for the macula the retinal nerve fibre layer and 
visual assessments. Significant differences in MTR and OCT values were found 
in MS and NMOSD patients with ON compared to healthy controls (HC). 
Significant differences were found between the unaffected nerve of NMOSD 
patients and HC, but not between groups for either MTR values (after correction 
for age) and OCT measurements. 
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Introduction: the NMOSD vs MS study 
The data for this thesis were obtained as part of a larger study aiming to develop 
and apply novel imaging biomarkers to MS and NMOSD, using advanced MRI 
techniques combined with other tests. The study was looking for biomarkers 
that could separate NMOSD from MS, and would therefore improve diagnosis. 
 Rationale for the study 
Neuromyelitis optica (NMO), like multiple sclerosis (MS), is an inflammatory 
disease causing demyelination of the central nervous system. Both diseases 
have similar characteristics, including optic neuritis and myelitis, making an 
accurate early diagnosis difficult. While the discovery in 2004 of an NMO 
specific antibody, the auto-antibody neuromyelitis optica immunoglobin G 
(NMO-IgG) which binds to the antigen aquaporin-4 (AQP4) and the subsequent 
development of accurate detection tests greatly improved diagnosis accuracy, it 
did not fully solve the problem of NMOSD patients being initially 
misdiagnosed with MS: as Jarius and colleagues1 report, even after the 
introduction of the NMO-IgG test, 20% of NMOSD patients received an initial 
diagnosis of MS. The issue of misdiagnosis, especially in the early stages of the 
disease, remains true today2 and is particularly problematic as some drugs used 
for the treatment of MS (interferon-β, natalizumab, and fingolimod) may 
aggravate NMO3,4. Therefore finding new markers which could ensure a correct 
diagnosis at the earliest possible stage is crucial in order to provide patients with 
the most efficient treatment. 
 Patients recruitment 
In order to recruit the required number of NMOSD patients, recruitment was 
conducted at The Walton Centre in Liverpool besides the National Hospital for 
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Neurology and Neurosurgery. All MS patients were recruited at the National 
Hospital for Neurology and Neurosurgery. 
 Study protocol 
The study is divided in three sections, the first looked at the brain, the second 
into the effect of optic neuritis, while the last focused on the cervical spinal 
cord, with each part including both MR scans and various assessments: 
Brain: 
• Proton density (PD)/T2-weighted imaging. 
• Phase Sensitive Inversion Recovery (PSIR). 
• Susceptibility-weighted imaging (SWI). 
• 3D-T1 weighted imaging. 
• Cognitive assessments: National Adult Reading Test (NART), delayed story 
and figure recalls, Hayling Sentence Completion Test, Brixton Spatial 
Anticipation Test, Symbol Digit Modalities Test (SDMT) and Paced 
Auditory Serial Addition Test (PASAT). 
Effects of optic neuritis: 
• Dynamic T2-weighted imaging of the optic nerves. 
• Magnetisation transfer ratio (MTR) of the optic nerves. 
• Optic coherence tomography (OCT): measurements of the macular volume 
and retinal nerve fibre layer (RNFL) thickness. 
• Visual acuity assessment (letter charts and 100-hue test). 
Cervical spinal cord: 
• Proton density/T2-weighted imaging. 
• Coronal T2-weighted imaging. 
• Magnetic resonance spectroscopy (MRS) optimised for myo-inositol. 
• 3D-Fast Field Echo (FFE), commonly known as 3D gradient-echo. 
• Diffusion tensor imaging (DTI). 
• Posturography to assess balance. 
• Assessments of hand grip and sensitivity to vibrations. 
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Clinical assessment: 
A clinical assessment, covering disease history and Expanded Disability Status 
Scale (EDSS) for all patients, was carried out by two neurologists, Dr Floriana 
De Angelis and Dr Rosa Cortese, who also did the visual acuity and spinal cord 
assessments. 
 Data analysis 
For the purpose of this thesis, the data from the Phase Sensitive Inversion 
Recovery (PSIR) scans, together with the data collected for the section covering 
the effects of optic neuritis were analysed and are presented in Chapter 5 and 
Chapter 6 respectively.  
For the spinal cord spectoscropy, too few valid spectra were obtained in the 
patient groups for the full data analysis to be feasible: only 7 out of 20 spectra 
from MS patients and 4 out of 18 from NMOSD ones were usable.  
Dr Rosa Cortese analysed the data for the other spinal cord scans as well as the 
SWI scans in the brain. The latter was looking for central vein signs in the WM 
lesions, to assess whether they differed between the two diseases. The results 
for these three studies were presented as posters at both the American 
Accademy of Neurology and ECTRIMS5-7. 
 Neurite Orientation Dispersion and Density index (NODDI) 
An additional study was conducted in parallel to the acquistion of the NMOSD-
MS data: the application of Neurite Orientation Dispersion and Density index 
(NODDI)8 to a selection of relapsing-remitting multiple sclerosis (RRMS) 
patients and matched healthy controls who underwent dMRI scanning as part 
of a previous study9. The aim of this study was to assess the sensitivity of 
NODDI indices to changes occurring in normal appearing white matter 
(NAWM) when compared to fractional anisotropy (FA). The prospect of 
detecting microstructural changes in NAWM at an early stage could prove 
useful in the quest of new markers to differentiate NMOSD from MS since MS 
patients generally have a much higher WM lesion load than NMOSD ones 
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(4.85ml in MS patients vs.0.99 in NMOSD ones in the cohort recruited for this 
thesis), therefore a higher rate of changes in NAWM is also likely to occur. The 
results of this study are presented in Chapter 4. 
Since the focus of this thesis is to investigate new ways to distinguish between 
NMOSD and MS, it will be useful first to get an overview of the current 
understading of the similarities and difference between these two diseases, as 
well as the evolving perception of NMOSD and its diagnosis. Therefore the 
next chapter will give an overview of NMOSD and MS, from their key 
characteristics to the usefulness of MR techniques for diagnosis purposes and 
gaining a better understanding of the underlying disease mechanisms. 
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From Devic’s disease to neuromyelitis 
optica spectrum disorders (NMOSD):           
the evolving face of a complex disease 
 
 Main characteristics of NMOSD and how they compare to MS 
Neuromyelitis optica (NMO), like multiple sclerosis (MS), is an inflammatory 
disease causing demyelination of the central nervous system. It is characterised 
by optic neuritis (ON) in at least one eye and acute myelitis, happening either 
simultaneously or more commonly sequentially1-4. Unlike MS, it can be both 
monophasic (optic neuritis and myelitis occurring either simultaneously or 
within of short period, without any suggestion of recurrence) or relapsing, but 
seldom secondary progressive. However, the monophasic course is infrequent 
(<10% to 20% depending on studies findings1-3), while the clinical 
characteristics of the relapsing-remitting course is very similar to MS. It is also 
extremely rare, with incidence ranging from 0.053 to 0.4 per 100,000 people 
and prevalence from 0.51 to 4.4 per 100,000 people5,6, with estimates that 
NMOSD account for about 0.5% to 1% of patients seen in MS clinics4. A good 
illustration of its rarity is the number of NMOSD patients in the UK in 2013: 
4008. This scarcity of patients also makes the disease much more difficult to 
study.  
The similarities with MS makes NMOSD difficult to diagnose, but there are 
also some key differences between these two diseases that make an early 
accurate diagnosis crucial, including the fact that NMOSD is much more 
aggressive, with a very small percentage of patients (24%1) making a full 
recovery after the first attack, an average that goes down to 17% when all 
attacks are taken into account1. Optic neuritis in particular is much more severe, 
leaving a much larger proportion of NMOSD patients with serious visual 
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impairments: after a median of 7.7 years from disease onset, 60% of NMOSD 
patients experience either unilateral or bilateral blindness, compared to only 4% 
of MS patients after 15 years9. Furthermore, bilateral ON (either simultaneously 
or sequentially) is much more prevalent in NMOSD patients. Another 
difference is that in NMOSD the posterior parts of the optic nerve, including 
the optic chiasma are also more often affected than in MS10.  
Further dissimilarities are found at the level of disease progression, which is 
more rapid in NMOSD than MS: if not treated, more than 50% of NMOSD 
patients will be either suffering from severe visual loss in in one or both eyes 
or requiring ambulatory help within 5 years from onset, while the survival rate 
over the same period can be as low as 68%11. An accurate diagnosis leading to 
early treatment can greatly reduce these numbers, as shown in a retrospective 
study of AQP4- and AQP4+ NMOSD patients who received 
immunosuppressant therapy at the Mayo Clinic. The following estimates for 
what would be expected 5 years after onset are given by Jiao and colleagues: 
28% of AQP4- and 22% of AQP4+ patients were expected to need a cane to 
walk, while no AQP4- and only 8% of AQP4+ cases were likely to be restricted 
to a wheelchair12.  
Furthermore, immunosuppressant therapy also led to a sharp decline in the 
relapse rate: for AQP4+ patients, the annual average was 2.2 (SD: 2.7) relapses 
for untreated patients vs 0.7 (SD: 0.9) for those on therapy (p=0.0001). 
Interestingly, this difference was much lower in the AQP4- group, with an 
average annual relapse rate of 2.1 (SD: 2.7) while not on therapy vs 1.0 (SD: 
1.6) on therapy (p=0.44)12. As will become clear below, there appear to be quite 
a few differences between AQP4- and AQP4+ patients. Independently of 
serostatus, Jiao and colleagues findings clearly illustrate the importance of an 
accurate diagnosis, something which remain a pressing issue, since according 
to Jarius and colleagues1, 20% of patients are wrongly diagnosed with MS 
before getting a NMO diagnosis. This not only means potential delays in patient 
receiving the correct treatment, but also exposes them to the risk of being treated 
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with interferon-β, natalizumab, or fingolimod, which appear to aggravate 
NMOSD activity, in particular increasing the recurrence of relpsases4,13,14. 
There are however some obvious differences between the two diseases that 
should be mentioned. One of them is the age at onset, as NMOSD patients are 
on average 10 years older than MS ones, with a mean age at onset around 40 
for NMO and 30 for MS1,15; another is the female to male ratio (2:1 in MS, 9:1 
in NMO16), but these ratios can vary quite a lot: from 2:1 to 10:14. Wingerchuk 
also mentions the fact that it had been suggested that NMOSD is proportionally 
more common in patients of non-white ancestry, such as African American, 
Afro-Caribbean and Asians, and that a percentage of cases of Asian ‘optic-
spinal MS’ are likely to be NMOSD, but he argues that further population-based 
data is required to establish this as a fact; particularly since the prevalence and 
incidence rates reported across various populations worldwide are relatively 
similar4. A view shared by the authors of two reviews looking at the prevalence 
and incidence of NMOSD6,17, and certainly backed up by the fact that the 
prevalence of 4.4 per 100,000 people mentioned above was in Denmark, with 
the population studied predominately white6.  
There are also some clinical characteristics that differ between MS and 
NMOSD, such as the extended spinal lesions spanning three or more vertebral 
segments, known as longitudinally extensive transverse myelitis (LETM) 
compared to shorter lesions of mostly one vertebral segment in MS4, which will 
be discussed in details in the diagnosis section below, but first it would be useful 
to look at how our understanding of NMOSD changed over time.  
 A brief history of NMOSD  
The term neuromyelitis optica, initially neuromyelitis optica acuta, is the 
translation of the Fench term neuro-myélite aigüe coined by the French 
neurologist Eugène Devic (1858-1930), who together with his student, Fernand 
Gault (1873-1936) described a novel syndrome combining severe transverse 
myelitis and optic neuritis (Devic presented a paper at the Congrès Français de 
Médecine, while Gault published his doctoral thesis, both in 1894). Devic’s 
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paper was based on the study of 16 cases in whom he found both acute myelitis 
and optic neuritis, which he felt justified the creation of a new syndrome. 
Devic’s paper will also lead to the disease being renamed after him, as Devic’s 
disease, following a suggestion made by the Turkish physician Peppo Acchioté 
(1870-1916) in a paper on a case of NMO he presented at the Société de 
Neurologie de Paris in 1907. As Jarius and Wildemann note, Acchioté’s choice 
of the term maladie (disease) when proposing the new name departed from 
Devic’s use of syndrome or type clinique rather than disease18. This is not just a 
detail of historical interest, but one among many variants that are encountered 
when looking at how NMOSD has been defined over time. 
Interestingly, while Devic may be the first to have given a name to the 
combination of transverse myelitis and optic neuritis, his paper was not the first 
description of NMOSD. The first account of a patient with visual loss and spinal 
cord inflammation was also published by a French anatomist and pathologist, 
Antoine Portal (1742–1832) in 180419, while a potential ‘neuroencephalitis 
optica’ (another disease which was thought by Gault to have similarities with 
NMO) was published in 1829, in the second enlarged edition of John 
Figure 2-1 Eugène Devic (1858-1930) who named NMO and Wilhelm Heinrich Erb (1840-1921), whose 
report published in 1880 triggered interest among neurologists and ophthalmologists about the rare 
syndrome that will become known as neuromyelitis optica (Anonymous photographs, open source). 
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Abercrombie’s (1780–1844) Pathological and Practical Researches on 
Diseases of the Brain and Spinal Cord, in which he describes a case of 
intractable vomiting, relapsing visual loss, and spinal pain, all of which are key 
features of NMOSD4,18. Jarius and Wildemann list three more reports predating 
Devic’s paper. The first one is by the Genoese physician Giovanni Battista 
Pescetto (1806–1884), who described a case in 1844, the second by the British 
physician Christopher Mercer Durrant (1814–1901), appeared in the precursor 
of the British Medical Journal in 1850. The third, published in The Lancet in 
1862, was by the British neuroanatomist, neuropathologist and neurologist 
Jacob Augustus Lockhart Clarke (1817–1880). His report is a good illustration 
of how early recordings of what is likely to be NMO cases used a wide array of 
designations, as his paper was entitled ‘On a case of paralysis’, but described a 
patient with both bilateral optic neuritis and longitudinally extensive transverse 
myelitis20. Another interesting paper was published in 1870, 24 years before 
Devic coined the term neuromyelitis optica, by Thomas Clifford Allbutt (1836-
1925). In it, he reports cases of changes in the optic nerve following spinal 
injuries (never the other way round), and while he wrote ‘I have never seen true 
optic neuritis with active proliferation as a sequel of spinal disease’21, one of 
the patients described had acute myelitis with an eye disorder, which 
subsequently created an interest for NMO among neurologists and 
ophtamologists18. Jarius and Wildemann also mention some papers published 
in the early 20th century as the first accounts using the term neuromyelitis optica 
or acute optic neuromyletis, while a neurological textbook by William Richard 
Gowers (1845-1915) published in 1904 included a report on the disease, but 
without using the term neuromyelitis18.  
However, the report which eventually led Devic to coin the term neuro-myélite 
aigüe was published in 1880 by the German neurologist Wilhelm Heinrich Erb 
(1840-1921): the interest it elicited among neurologists and ophthalmologists, 
led to the publications of more than a dozen of reports of similar cases. These 
papers were later collected and summarised by Devic and Gault, and used to 
corroborate their own cases of the new syndrome as Devic called it20. 
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However, even with a name, the concept of NMO, as it was then called, kept 
changing throughout the 20th century. As Jarius and Wildemann note, certain 
descriptions excluded some of the criteria which are now known to be typical 
of the disease, such as a relapsing course, unilateral optic neuritis, symptoms 
other than optic neuritis and transversal myelitis (even though Devic and Gault 
described brainstem lesions in some of their patients)18. Throughout the 20th 
century, there was also uncertainty about whether NMO was a distinct disease, 
as Devic and Gault believed, or a subtype of MS as Russell Brain concluded in 
193018. The latter view was also the one adopted by neurological textbooks such 
as McAlpine’s Multiple Sclerosis (3rd ed., 1998), Merrit’s Neurology (10th ed., 
2000) and Adams and Victor's Principles of Neurology (6th ed., 1997)22, while 
a study conducted by O'Riordan and colleagues in 1996 to clarify this issue 
concluded that NMO is indeed a separate disease23. The latter were proven 
correct in 2004, when Lennon and colleagues discovered an NMO specific 
antibody, the auto-antibody neuromyelitis optica immunoglobin G (NMO-IgG) 
which binds to the antigen aquaporin-4 (AQP4)24. 
 Neuromyelitis optica immunoglobin G (NMO-IgG) 
The discovery of NMO-IgG and the subsequent development of very accurate 
tests for its detection, brought a very significant increase in correct diagnosis 
(according to Jarius1, 54.2% of patients were misdiagnosed with MS before the 
test became available in 2005). The early tests using enzyme-linked 
immunosorbent assay (ELISA) were prone to false positive and had a limited 
sensitivity, but the cell-based assays which replaced them are more sensitive as 
well as highly specific (97%). They also increased AQ4-IgG detection rates to 
nearly 90% compared to 56-68% for non-cell based assays10,25, subsequently 
increasing the percentage of seropositive NMOSD patients to 80-90%. 
However, since testing for NMO-IgG/AQ4-IgG is recommended only in the 
cases where NMOSD is suspected, other diagnosis tools are necessary26, 
including radiological features, making MR techniques crucial for diagnosis as 
will become clear below. 
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Furthermore, there has been suggestions that there may be differences between 
seropositive and seronegative patients. A study by Jarius and colleagues1 
involving 175 patients found that seronegative patients were more likely to be 
monophasic, while a study by Kiyat-Atamer and colleagues found that 
seronegative patients had significantly more brain lesions at onset, but that this 
difference disappeared at follow-up since seropositive were also developing 
brain lesions as the disease progressed27. A recent review of the existing 
literature by Bernard-Valnet and colleagues concluded that these patients form 
a distinct subpopulation, with what they describe as the classical Devic 
syndrome and warn of the danger of such patients being reclassified as MS28 
 Myelin oligodendrocyte glycoprotein (MOG) 
There is another antibody, myelin oligodendrocyte glycoprotein (MOG), which 
has been detected in approximatively 10-15% of AQ4-IgG negative patients. 
These patients differ from the AQ4-IgG ones in that bilateral optic neuritis is 
more common, but they also appear to respond particularly well to steroid 
treatment29-31. Interestingly, a paper by Zamvil and Slavin raises the question 
whether MOG positive patients with bilateral optic neuritis should really be 
classified as NMOSD, arguing that the term MOG Ig1 AQP4-seronegative 
NMOSD is particularly disconnected from our current understanding of 
NMOSD as an astrocytopathy32. Pittock raised a similar issue in a paper 
discussing the use of clinical and radiological criteria, rather than molecular 
ones, as the basis of a NMOSD diagnosis. He argues that this approach could 
potentially lead to the risk of grouping together various disorders with 
heterogeneous aetiologies, clinical courses, prognoses as well as responses to 
treatment33. 
The complexity of correctly classifying MOG positive patients is further 
illustrated in a very thorough study published by Jarius and colleagues in 
September 201614. They look at the clinical, radiological and serological criteria 
of 50 MOG positives patients with either both ON and myelitis (44%), only ON 
(40%) or only myelitis (12%). The remaining 2% had other symptoms, mostly 
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brainstem involvement (found in nearly 30% of the cohort, so mostly associated 
with other symptoms). When they look at diagnoses, 33% of the cohort met the 
2010 McDonald criteria for MS, 28% Wingerchuk’s 2006 revised diagnostic 
criteria for NMO and 32% the 2015 international consensus criteria for 
NMOSD, with 16% patients fulfilling the criteria for both diseases. Their 
conclusion is that since there is a substantial phenotypic overlap with both 
AQP4-IgG-positive NMOSD and MS, which suggests that all MOG-positive 
patients belong to the same immunopathogenetically defined disease spectrum, 
MOG-positive patients should not be included in the AQP4-IgG-negative 
NMOSD group. They even argued that MOG-IgG seropositivity should be used 
as an exclusion criteria. The debate on the place of MOG-IgG seropositivity in 
NMOSD is obviously ongoing, and while it falls beyond the spectrum of this 
thesis, it is something that needs to be investigated further. 
 NMOSD diagnosis criteria: an evolving story 
As can be expected with the changing perception of the disease, diagnosis 
criteria have also been evolving. The latest diagnosis criteria, published in 2015, 
produced by the International Panel for NMO Diagnosis (IPND)34 was 
reviewing the criteria proposed by Wingerchuck and colleagues in 200635, 
which itself was a revision of the 1999 diagnosis criteria also proposed by 
Wingerchuck and colleagues11. While the 2006 revision was needed following 
the discovery of the NMO-IgG antibody, the latest criteria reflect the current 
understanding of the disease in all its complexity and heterogeneity. It also 
abandons the term NMO, replacing it with neuromyelitis optica spectrum 
disorders (NMOSD), using NMOSD with AQ4-IgG for seropositive patients 
and NMOSD without AQ4-IgG for seronegative ones. The concept of a broader 
spectrum named NMOSD, used for patients with atypical clinical presentations, 
was first described in a 2007 paper by Wingerchuck and colleagues16. It follows 
the suggestion they made in the conclusion of the diagnosis paper that the 
concept of pure NMO should be abandoned because their data revealed a wide 
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array of neurological symptoms preceding or accompanying NMO, which were 
not necessarily associated with a recognisable CNS lesion35 
Tables 2.1 & 2.2, adapted from Bennet’s paper on the evolution of NMO 
diagnosis7, give the criteria and methodology used for each classifications. 
Optic neuritis and transversal myelitis remain crucial clinical features 
throughout, as do the spinal cord lesion extending over three vertebral segments 
detected by MRI, while criteria such as bilateral optic neuritis or severe vision 
loss are no longer deemed to have sufficient diagnostic sensitivity7. After the 
discovery of AQP4-IgG, the revised diagnosis had one absolute requirement, 
which was the simultaneous or sequential occurrence of optic neuritis and 
transversal myelitis, together with 2 of 3 supporting criteria (brain MRI 
inconsistent with MS, MRI spinal cord lesion extending over three or more 
vertebral segments and AQP4-IgG positivity). These criteria also improved 
both the sensitivity and specificity of the 1999 diagnosis, with a sensitivity of 
94% and a specificity of 96% compared to 85% and 48% for the 1999 criteria35. 
The latest diagnosis criteria were formulated by an International Panel for NMO 
Diagnosis (IPND), are based on clinical, neuroimaging and neurophysiological 
data as well as laboratory testing. As mentioned above, the panel also decided 
to adopt the term NMOSD together with the specification of the patient 
serostatus. For a diagnosis of NMOSD with AQP4-IgG, at least one of core 
clinical characteristics, which include syndromes such as such as area postrema 
syndrome and acute brainstem syndrome, as well as optic neuritis and myelitis 
(see Table 2.1 for the full list) is needed, together with the exclusion of any 
alternative diagnosis. For a diagnosis of NMOSD without AQP4-IgG or in the 
cases where the AQP4-IgG status is unknown, at least two core clinical 
characteristics occurring as a result of one or more clinical attacks and meeting 
a list of specific requirements (also listed in Table 2.1), which include data from 
brain and spinal cord MRI, are needed34. In order to avoid the risk of 
misdiagnosis in the absence of AQP4-IgG seropositivity, the panel also 
emphasised the importance of a list of so-called ‘red flags’ detailing findings 
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atypical for NMOSD incorporating clinical features and laboratory findings as 
well MRI characteristics for both the brain and the spinal cord34, one of which 
is cortical lesions. 
Diagnosis criteria 
Wingerchuk 1999 NMO Criteria Wingerchuk 2006 NMO Criteria IPND 2015 NMOSD Criteria 
All absolute criteria and 1 major or 
2 minor supportive criteria 
Absolute criteria 
1 Optic neuritis 
2 Acute myelitis 
3 No evidence of clinical 
disease outside optic nerve 
or spinal cord 
Supportive criteria 
Major 
1 Negative brain MRI at onset 
2 Spinal cord MRI with lesion 
extension over 3 vertebral 
segments 
3 CSF pleocytosis of 50 
WBC/mm or 5 
neutrophils/mm 
Minor 
1 Bilateral optic neuritis 
2 Severe optic neuritis with 
fixed visual acuity worse 
than 20/200 in at least one 
eye 
3 3. Severe, fixed, attack 
related weakness (MRC 
grade 2) in one or more 
limbs 
All absolute criteria and 2 
supportive criteria 
Absolute criteria 
1 Optic neuritis 
2 Acute myelitis 
Supportive criteria 
1 Contiguous spinal cord MRI 
lesion extending over 3 
vertebral segments 
2 Brain MRI not meeting 
diagnostic criteria for MS  
3 AQP4-IgG–seropositive 
status 
NMOSD with AQP4 IgG 
1 At least 1 core clinical 
characteristic 
2 Positive test for AQP4IgG 
using best available 
detection method* 
3 Exclusion of alternative 
diagnoses  
NMOSD without AQP4 IgG 
1 At least 2 core clinical 
characteristics occurring as a 
result of one or more clinical 
attacks and meeting all of 
the following requirements: 
a) At least 1 core clinical 
characteristic must be 
optic neuritis, acute 
myelitis with LETM, or 
area postrema syndrome 
b) Dissemination in space (2 
or more different core 
clinical characteristics) 
c) Additional MRI 
requirements, as 
applicable  
2 Negative tests for AQP4IgG 
using best available 
detection method* or testing 
unavailable  
3 Exclusion of alternative 
diagnoses  
Core clinical characteristics: 
Optic neuritis; acute myelitis; area 
postrema syndrome (hiccups; 
nausea and vomiting); acute 
brainstem syndrome; symptomatic 
narcolepsy or acute diencephalic 
clinical syndrome with NMOSD 
typical diencephalic MRI lesions 
(Figure 2.2); symptomatic cerebral 
syndrome with NMOSD typical 
brain lesions (Figure 2.2)  
*AQP4IgG serology: Cell-based 
assay is strongly recommended 
AQP4IgG: anti–aquaporin4 immunoglobulin G; CSF: cerebrospinal fluid; IPND: International Panel for NMO 
Diagnosis; LETM: longitudinally extensive transverse myelitis; MRC: Medical Research Council; MRI, 
magnetic resonance imaging; MS: multiple sclerosis; NMO: neuromyelitis optica; NMOSD: neuromyelitis optica 
spectrum disorder; WBC: white blood cell 
Table 2-1 Historical classification of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder 
(Adapted from Bennett, 20167). 
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Methodology 
Wingerchuk 1999 NMO Criteria Wingerchuk 2006 NMO Criteria IPND 2015 NMOSD Criteria 
Criteria were defined by chart 
analysis of the clinical, radiologic, 
and laboratory data from 71 
patients with NMO at the Mayo 
clinic; there was no independent 
validation cohort 
Criteria were defined by the 
evaluation of data from 129 
patients ascertained through the 
Mayo Clinic MS Centres in 
Rochester, MN, and Scottsdale, 
AZ, and tested for NMO IgG; 
there was no independent 
validation cohort 
Criteria were developed by an 18 
member panel of NMO physicians 
from 9 countries; working groups 
in clinical presentation, 
neuroimaging, laboratory 
studies/serology, paediatrics, 
systemic autoimmunity, and 
opticospinal MS conducted 
systematic literature reviews, and 
initial characteristics for NMOSD 
were rated and further refined by 
panel members using electronic 
surveys and clinical vignettes; 
those characteristics endorsed by a 
two thirds majority were used to 
develop criteria for AQP4IgG-
seropositive and AQP4IgG-
seronegative NMOSD 
Table 2-2 Historical classification of Neuromyelitis Optica and Neuromyelitis Optica Spectrum 
Disorder: methodology used (Adapted from Bennett, 20167) 
Figure 2-2 MRI in neuromyelitis optica spectrum disorders. A. Sagittal T2 of longitudinally extensive 
cervical cord lesion extending into dorsal medulla. B. T2 and B′. post-contrast T1 of central spinal cord 
lesions. C. Post-contrast T1 of an extensive enhancing lesion of the optic nerve. D. Post-contrast T1  
of bilateral prechiasmal and chiasmal optic nerve inflammation. E. Bilateral FLAIR lesions involving 
the dorsal medulla (area postrema). F. Bilateral confluent T2 lesions in mid-pons. G. Sagittal FLAIR 
of periependymal lesions around the 4th ventricle. H. Sagittal FLAIR image of diffuse hypothalamic 
inflammation. Axial FLAIR images of bilateral, confluent deep white matter (I, J) and thalamic (J) 
lesions. (Adapted from Bennett, 20167) Reproduced with permission from Wolters Kluwer Health, Inc. 
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Bennett also notes the greater sensitivity of the new diagnosis criteria, both for 
identifying AQP4-IgG negative patients and faster detection of AQP4-IgG 
positive ones, enabling treatment to be started earlier7. 
Clearly, MRI plays an important role in the diagnosis of NMOSD, especially 
with the new criteria. The next section will be a brief overview of key findings 
which led to the inclusions of these features.  
 Usefulness MRI to distinguish between NMOSD and MS 
 Spinal cord 
Extensive lesions resulting from LETM are one of the most commonly cited 
radiological difference between MS and NMOSD, but as Wingerchuk notes, 
such lesions may break into smaller non-consecutive lesions or even disappear 
completely over time4, so unless MRI scans acquired during the acute phase are 
available, this feature may not be an entirely reliable an indicator. Furthermore, 
the percentage of patients with such lesions varies from 64% to 93% (found in 
the largest cohort)1,36-38, while short transverse myelitis (STM) lesions have also 
been found in some patients39. The distribution of lesions is also extremely 
variable: only two studies found cervical cord spinal lesions in all NMOSD 
patients40,41, in the others the percentage of patients with this type of lesions 
varies from less than 30%42 to 87%43, while thoracic spine lesions are less 
common in NMOSD: Jarius and colleagues found them in 20% patients1 and 
Cabrera-Gómez in 26% of NMOSD patients42. On the other hand, hypointense 
lesions appear to be specific to NMOSD patients40,44. 
Wang and colleagues also looked at spinal cord atrophy (SCA) and its impact, 
and found an interesting association between atrophy and the localisation of 
lesions in NMOSD patients: of those with SCA, 87% had lesions in the cervical 
spine but only 13% in the thoracic spine, while in those without SCA, 48% had 
cervical lesions and 38% thoracic ones. Furthermore, they also found that the 
presence of SCA was independent of longitudinally extensive transverse 
myelitis (LTEM)45.  
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The application of dMRI techniques to the spinal cord led to the detection of 
further differences between NMOSD and MS: fractional anisotropy (FA) and 
axial diffusivity (AD) were found to be significantly reduced in lesions and in 
upstream/downstream sections in both MS and NMOSD, while mean 
diffusivity (MD) and radial diffusivity (RD) were significantly increased. These 
changes were also found to be significantly larger in NMOSD when compared 
to MS41,44,46,47. Looking at 'unaffected' tracts, Klawiter and colleagues also 
found a decrease in FA and an increase in RD in MS patients, but no changes in 
NMO patients47. Another study, which looked at the different columns in C2 
and C7, found highly localised increases in FA and RD wich were also 
significantly higher in MS than in NMOSD48. Looking at specific type of 
lesions as potential biomarkers is commonly explored, but not always 
successfully as a recent study looking at ring-enhancing lesions: while it 
differentiated NMOSD from other causes of LETM, they were not significantly 
different from MS49. There is however a study by Yonezu and colleagues who 
discovered a type of lesions they describe as "bright spotty lesions" which were 
nearly exclusively found in NMOSD patients50. 
 Brain and visual pathways 
The different parts of the visual pathways have been extensively studied as 
abnormalities have been reported in both diseases from the 19th century onward. 
However, beyond the fact that the optic chiasm appeared to be affected solely 
by NMOSD, no further significant differences between the two diseases were 
found51,52. A study looking at patients during the acute phase of optic neuritis 
found that longitudinally extensive optic neuritis (LEON), defined as an acute 
gadolinium enhancing lesion extending for at least 17.6 mm, could help 
differentiate between the diseases as it is much more common in NMOSD than 
MS (81% vs 23%)53 while another study also looked at the extent of 
inflammation on the optic nerve and found that lesions were both more 
extensive as well as involving the more posterior part of the visual pathway 
(from the cranial section of the optic nerve to the optic tract)54. Finally, dMRI 
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studies also found increased MD and decreased FA in the optic radiation in 
NMOSD patients when compared to healthy controls55-57, further supporting a 
greater involvement of the posterior section of the visual pathway as a 
characteristic of NMOSD. 
 Brain 
MRI studies of the brain have been of particularly useful in extending the 
diagnosis criteria for NMOSD. While the 1999 criteria had ‘No evidence of 
clinical disease outside optic nerve or spinal cord’ as an absolute criteria, the 
2006 diagnosis had ‘Brain MRI not meeting diagnostic criteria for MS’ as a 
supportive criteria. The 2015 criteria include a whole list of neuroimaging 
characteristics encompassing the brain as well as the spinal cord and optic nerve 
and including descriptions of the types of brain lesions typical of NMOSD34. 
These characteristics were previously reported in many studies using 
conventional MR techniques, which detected either brain abnormalities or 
lesions in 20% to 70% of NMOSD patients. Overall, the majority of lesions 
detected tend to be non-specific and are mostly found in deep white matter, with 
the following regions most commonly reported as locations of abnormalities: 
corticospinal tract (in particular the posterior limb of internal capsule)55-59, 
periventricular areas42,55,57,60,61 and the medulla55,58,61-63, all of which are now 
included in the latest NMOSD diagnosis criteria. However these localisations 
are also common in MS, therefore the appearance of lesions and other signs are 
necessary to differentiate between the two diseases. Among possible additional 
markers, Sinnecker and colleagues looked at the position of lesions in relations 
to veins and found that while MS lesions are nearly exclusively centred on small 
veins, this rarely happened in NMOSD64. These finding were reproduced by Dr 
Rosa Cortese using the SWI data from the same cohort of patients used for this 
thesis65.  
Further evidence of the usefulness of combining location and lesions 
appearance comes from a study by Lu and colleagues, which looked at lesions 
in the brainstem and found that only those located in the pons and medulla were 
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significantly different between MS and NMOSD, but that the lesions 
appearance could be a potential marker, as in MS they had well defined margins 
while in NMOSD the margins were poorly defined66. Variations in appearance 
and shape of lesions have been suggested as potential markers by other studies, 
but need to be applied carefully since, as Matsushita and colleagues report, 
some overlap between the two disease remains common: they found ovoid 
lesions in more than 80% of MS patients but also in more than 30% of NMO 
ones67. 
As is made clear by the new diagnosis criteria, NMOSD patients often have 
lesions located in specific parts of the brain. The medulla is one of this regions 
where lesions are both more common and more numerous in NMOSD than in 
MS, as evidence by the large cohort studied by in Jarius and colleagues, in 
which 26% of NMOSD patients had medullary lesions1, while a much smaller 
study Lim and colleagues found some lesions of this type in 1 of the 3 NMO 
patients who had brain lesions, but none in any of the 36 MS patients they 
scanned68. Interestingly, the hypothalamus is another region where lesions, 
while rare, appear to be significantly more common in NMOSD than MS68-70.  
It has also been suggested that the absence of cortical lesions or abnormalities 
in NMOSD patients could be a reliable marker to differentiate the two 
diseases36. However, as it will be explained in Chapter 5, which report on the 
application of phase inversion recovery (PSIR) to look for GM cortical lesions 
in both MS and NMOSD, this is very much an open issue. Five studies applying 
a variety of techniques: from VBM to measure atrophy71, to DIR36 and MR 
spectroscopy72, as well two which used a 7T scanners64,73, failed to detect either 
lesions or significant changes in NMOSD patients cortical grey matter. Another 
study by Popescu and colleagues used histology to look at cortical 
demyelination in NMOSD and did not find any74. On the other hand, two studies 
by Rocca and colleagues, one using fMRI75 and the other a combination of MTR 
and dMRI75 found changes in NMOSD patients cortex when compared to 
healthy controls. Similarly, Yu and colleagues also found cortical abnormalities 
when looking at normal appearing brain tissues using dMRI62 and a study by 
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Kim and colleagues looking for cortical lesions in NMOSD found some in a 
small subset of patients76. Finally, a study by Saji and colleagues used histology 
to look at cortical degeneration in NMOSD and did find it. They also confirmed 
Popescu and colleagues findings that demyelination does not occur in the cortex 
of NMOSD patients77. 
MTR, dMRI and MR spectroscopy have also been used to look at either normal 
appearing white matter (NAWM) or specific areas of the brain, but often 
comparing NMOSD patients to healthy controls rather than MS patients. Using 
dMRI, multiple studies found reduced FA and increased MD in the corpus 
callosum, multiple WM tracts, including the corticospinal tract, as well as 
higher FA in the thalamus and putamen40,55-57,62,78,79. This suggests that dMRI 
could be a useful approach, particularly with new techniques such as neurite 
orientation dispersion and density index (NODDI), which was assessed on MS 
patients as part of this thesis (Chapter 4). For MTR, besides the study looking 
at GM mentioned above, there are only two additional studies, possibly because 
neither found any significant difference between NMOSD patients and healthy 
controls when looking changes in normal appearing brain tissues79,80, while a 
significant decrease in MTR was found in MS patients brain when compared to 
healthy controls by Filippi and colleagues80. As these studies were done on 1.5T 
scanners, it would be interesting to do a new study on 3T or even 7T scanner to 
see if the increased signal yields different results. Last but not least, there had 
been four studies using MR spectroscopy: two looked at NAA in NMOSD 
patients and compared them to healthy controls without finding any differences 
between the two groups81,82. The third study, by de Seze and colleagues, looked 
myo-inositol as well as NAA and choline, but again failed to detect any 
significant difference between NMOSD and healthy controls72, while the last 
study, by Aradi and colleagues, looked at differences for glutamate/glutamine, 
creatine as well as NAA, choline and myo-inositol in WM lesions compared to 
healthy controls. They only found significant differences for NAA and myo-
inositol83.  
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Finally, cognitive decline in NMOSD patients is an aspect of the disease in 
which there currently is a lot of interest as no less than 18 studies have been 
published since 2008, which was also the first study looking at this topic. Quite 
a few are case studies (5) and one is a systematic review, but of the remaining 
11, 8 are combining cognitive assessments with MRI. The most interesting 
paper when looking at the differences between MS and NMOSD is the 
systematic review and meta-analysis done by Meng and colleagues, which 
looked specifically at studies comparing cognitive impairment (CI) between 
NMOSD and MS patients and concluded that none of them found a significant 
difference between the two groups84. As they note, most studies are comparing 
NMOSD patients to healthy controls. Of the studies combining MRI and 
cognitive assessments, all found some degree of impairment in NMOSD 
patients when compared to healthy controls, but not all of them found 
correlations between the abnormalities detected on the MRI scans and the 
impairments measured. As mentioned above, Kim and colleagues detected 
cortical thinning in NMOSD, as well as CI in NMOSD patients, but did not find 
correlations between the two76, similarly Liu and colleagues also found both CI 
and brain abnormalities when using a multimodal MR approach, but they did 
not find any correlation between cortical thickness and CI. They did however 
find correlations between specific brain regions and the z scores calculated from 
the cognitive assessments85. Other studies that found correlations include one 
done by Blanc and colleagues which used voxel based morphometry (VBM) to 
detect focal brain atrophy and found correlations between some areas and 
specific cognitive assessments86. Similar results were obtained by He and 
colleagues using dMRI87 as well as by Wang and colleagues when making 
comparison between CI and grey matter volumes (both cortical and deep grey 
matter)88. 
This brief overview of the type of studies done using MR techniques to look at 
various aspects of NMOSD clearly demonstrates both the scope and versatility 
of MR approaches, which are further enhanced through the development of new 
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MR acquisition protocols as well as analysis techniques. The next chapter will 
introduce those techniques which were used for the purpose of this thesis. 
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A short introduction to magnetic resonance 
imaging (MRI) and to the techniques used 
 What is Magnetic Resonance Imaging 
In order to understand what exactly Magnetic Resonance Imaging (MRI) is, it 
is worthwhile to look briefly at how it was discovered. In 1945, Felix Bloch and 
Edward Mills Purcell demonstrated the key properties of the atomic nucleus 
(using water and paraffin respectively) which are at the heart of MRI. They 
showed that an oscillating magnetic field influences the orientation of proton 
spins. This was called nuclear magnetic resonance (NMR).  
The next stage occurred in the late 1960s, when Raymond Damadian discovered 
differences between the NMR parameters of tumours when compared to healthy 
tissues. The usefulness of this finding was limited by the fact that he could not 
spatially locate the position of the various tissue types. This problem was solved 
in 1971, when the chemist Paul Lauterbur realised that NMR signals could be 
converted into images with spatial information by using gradients for phase and 
frequency encoding during acquisition. A Fourier transform is then applied to 
reconstruct the image. Damadian and his group went on to build the first NMR 
scanner in 1977, and produced the first MR scan of the human body. 
As NMR became more widely used for medical purposes, its name was 
changed. The term ‘nuclear’ was dropped, due to concerns that the public would 
think that the technique involved harmful radiations, and Magnetic Resonance 
Imaging or MRI became the new appellation. Since then, MRI has become a 
very important tool for both diagnosis and research because it offers non-
invasive ways to acquire high resolution images, as well as encompassing 
techniques enabling quantitative measurements of metabolic changes. The fact 
that it is radiation free means that scans can be repeated when needed in order 
to follow disease progression, assess recovery or drug effectiveness. 
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Now we need to look at how MRI actually works, and for this it is necessary to 
look at physical principles that makes it possible to distinguish between tissue 
types as well as precisely locate significant changes such as lesions or tumours 
when looking at the brain (or damage in other parts of the body since MRI is 
widely used for diagnostic purposes). 
 MRI physics: some basic principles 
In the brief history of the development of MRI given above, proton spins, 
magnetic field, gradients, frequency encoding were mentioned. The following 
sections will explain these terms. A lot of the information used here was taken 
from Allen D. Elster’s Questions and Answers in MRI1, Chapter 2 of All You 
really need to know About MRI Physics by Moriel NessAiver2 and ‘mri: 
Physics: For anyone who does not have a degree in physics’ by Evert J. Blink3.  
 Protons, spins and magnetic field  
Just like the Earth, protons are spinning around an axis (Figure 3-1a). Besides, 
as they have a positive electric charge, the spin, also described as angular 
momentum, creates its own small magnetic field. As shown in Figure 3-1b, 
when left of their own, the spin axes are randomly aligned. This random 
 
Figure 3-1 (a) Schematic representation of spinning hydrogen atom. (b) Spinning protons with 
random axes (state of equilibrium) (From Kantzas [et al.]4). Reproduced with permission from 
PERM Inc. 
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distribution also means that the protons are in an overall state of equilibrium, 
resulting in a net magnetisation of zero4. The protons used for MRI are those 
from hydrogen atoms in water molecules, ideal as the human body contains on 
average 60% of water.  
As it can be seen in Figure 3-2, when an external magnetic field B0 is applied, 
proton spins align either with it (low energy state) or against it (high energy 
state). The interesting thing is that the two groups are not equal: a small majority 
of protons, described as the net magnetisation or net magnetisation vector M 
(~10x10-6 at 3.0 Tesla), align with the magnetic field. This number may be 
small, but because of the substantial amount of protons comprised within a 
single voxel, this small difference means that the actual number of protons 
aligning with the magnetic field will in fact be very large. This differential 
amount is directly linked to the external B0 magnetic field and will therefore be 
smaller at 1.5 Tesla (4.5x10-6) and will become higher with ultra-high-field 
scanners such as 3T and above. Finally, because such large amounts of protons 
are involved, quantum mechanics can be mostly ignored when looking into MRI 
physics, and classical mechanics description applies as what happens at the 
level of single protons ceases to be relevant in the context of MRI. Similarly, 
M behaves like a regular vector, which is tilted during MRI acquisition as will 
be explained below.  
 
Figure 3-2 Spins lining up in the presence of an external magnetic field (B0), with the small majority 
producing the net magnetization vector (M)  (From Kantzas [et al.]4). Reproduced with permission 
from PERM Inc. 
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The other important thing to know is that this arrangement is not static: the 
protons also rotate around the axis of the magnetic field while spinning, as 
shown in Figure 3-3. This is called precession and its frequency is directly 
proportional to the strength of the magnetic field B0 and the gyromagnetic ratio 
(a particle-specific constant incorporating size, mass, and spin). It is determined 
by the Larmor Equation: 
ω0 = γ B0 
where:  
ω0 is the precessional or resonance frequency, sometimes also called angular 
frequency, measured in radians per seconds, or cyclic frequency f0, which is 
measured in cycles/sec or Hertz [Hz].  
γ is the gyromagnetic ratio, a constant unique to every atom (42.58 MHz/T for 
hydrogen).   
B0 is the magnetic field strength (T). 
The resonance frequency is proportional to the scanner strength, so for example 
for a 3.0 Tesla (T) scanner, it will be 42.58 MHz/T x 3.0 T= 127.74 MHz. 
Conveniently, hydrogen is the atom with the highest gyromagnetic ratio as well 
as being so widespread in the human body, thus making it particularly suitable 
as an NMR source1. 
 
Figure 3-3 Precession 
occurring when a magnetic 
field is applied 
(From Gerard5). 
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 Radio frequency pulse and excitation 
In order to acquire images, protons will be first subjected to the external 
magnetic field until the net magnetisation has reached a steady state of 
equilibrium, where M is aligned with the main magnetic field (B0), which is 
always the Z axis in the rotation frame described below. 
The next stage is to apply an electromagnetic radio frequency (RF) field at the 
resonance (Larmor / precession) frequency, which will transfer energy to the 
protons. As a result, the net magnetisation vector M is tilted away from the Z 
axis, with changes in directions described using a frame of rotation with 3 axes: 
as mentioned above, the Z-axis is always pointing in the direction of the main 
magnetic field, while the two other axes, X and Y, are pointing at right angles 
from Z, as shown in Figure 3-4. 
The reason why M is tilted after the application of RF field at or near the Lamor 
frequency is that the effects of B0 disappear and the precession of M is now 
locked to B1, and consequently tipped within the X-Y plane. As Figure 3-5 
shows, the flip or tip angle experienced by M can go all the way to 180º. The 
flip angle, often represented by the Greek letter alpha α, is determined by both 
the strength and duration of the RF field/pulse.  
Figure 3-4 Frame of rotation for the Net magnetisation vector Mz (on the z axis), as well as the 
two other axes of reference: x and y. 
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There are two different frames of reference when descibing what is happening 
to M. The laboratory frame of reference, which can also be described as the one 
of the external observer and the rotating frame, where the observer is inside the 
frame just like we are on our rotating planet. However, as we cannot leave the 
earth to experience the laboratory frame, a better analogy is the merry-go-round. 
Observing things from the laboratory frame is like being on the ground looking 
at the merry-go-round revolving, while if you are sitting on the merry-go-round 
watching the world spinning around you, you are inside the rotating frame. For 
this frame, the coordinate system x', y', z' are used.  
The rotating frame is the one used to describe the effects of B1, since, as can be 
seen in Figure 3-6, you need to be in this frame in order to determine the 
position of M. This means that when describing the tipping angle or T2 
relaxation for example, the axes should be x'-y'-z'. However, to keep things 
simple, I followed the example of the many authors who use the regular x, y, z 
at all times. 
 
90º pulse                             180 º pulse                  Pulse ∞ 
Figure 3-5 Tipping angles with different RF pulse: 90º, 180º and illustrating the fact that M position 
will be anywhere from 1º to 180º (Adapted from Fonseca6). © 2013 Gonçalves Fonseca M . 
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3.2.2.1 From excitation to relaxation 
The phase during which the magnetisation vector M absorbs energy is described 
as the excitation phase. The initial position, when M is aligned to B0, is 
described as the longitudinal magnetisation, while the post-tipping position is 
called the transverse magnetisation. This absorption of energy state caused by 
B1 generate the nuclear magnetic resonance (NMR). 
When the RF puslse is turned off, the energy absorbed by protons is released in 
the form of RF waves and M progressively returns to equilibrium, where it is 
once again aligned to B0. This process is called relaxation. The RF waves 
released are the actual source of the MR signal. The process, from the 
application of the RF pulse to the relaxation is show in Figure 3-7.  
(a) 
 
(b) 
 
(c) 
 
Figure 3-7 Changes from equilibrium to relaxation (a) State of equilibrium with M aligned with Z,      
(b) tipping following the RF field applcation, (c) relaxation phase, with return to equlibrum and emission 
of RF wave (From The science of medical imaging: magnetic resonance imaging (MRI)7).     
©  
(b) (a) 
Figure 3-6 The laboratory frame (a) and the rotating frame (b). Viewed from the laboratory frame, the B1 
field and spins are all rotating very quickly. The B1 arrow is shown in a fixed position for clarity purposes, 
but it is actually rotating just as fast as the spins and thus should also be blurred. In the rotating frame, the 
frame is rotating at the Larmor frequency just as B1 is. Consequently, this creates a strobe-like, "stop action" 
image that allows us to model the position of M (Adapted from Elster1). Courtesy Allen Elster, 
MRIquestions.com 
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 Relaxation 
There are two types of relaxation, occurring simultaneously but independently 
of each other: T1 and T2. Both are time constants, with T1 describing the return 
to equilibrium as M realigns with z, whereas T2 characterises the decay of the 
signal as the excited protons begin to dephase, with changes occurring on the x 
and y planes that will be explained below. The two forms of relaxation are 
illustrated in Figure 3-8.  
T1 relaxation is also known as the longitudinal or spin-lattice relaxation 
because in the early NMR experiments a crystalline lattice of atoms was used. 
Today, the surrounding tissue in which energy is released is described as the 
lattice. It is also sometimes described as thermal relaxation because the energy 
dissipates as heat. T2 relaxation, on the other hand, is also called transverse or 
spin-spin relaxation, because it is the transient and random interaction occurring 
between two excited spins that causes the loss of phase, which in turn leads to 
the loss of signal.  
3.2.3.1 T1 relaxation 
T1-relaxation time, which is unique to each tissue, is determined by the way in 
which protons are bound and is generally longer at higher field strengths. In 
Figure 3-8 (a) T1 relaxation, showing the recovery of Mz along the B0 axis (b) T2 relaxation, with signal 
decay and dephasing (Adapted from Elster1). Courtesy Allen Elster, MRIquestions.com 
(a) 
(b) 
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adipose tissues for example, the protons are tightly bound and will therefore 
release the energy in their surroundings much faster than loosely bound protons, 
like those in cerebrospinal fluid (CSF). In other words, the speed at which 
tissues release the energy/relax will determine the value of T1. 
The time constant T1, modelled as an exponential growth curve (Figure 3-9), 
corresponds to the time needed after the excitation pulse for M to reach 63% of 
its initial value. Finally, the fact that T1 values vary with tissue types is also the 
rationale behind the good contrast resolution in MRI scans. 
3.2.3.2 T2 relaxation 
The first thing to remember when looking at T2 relaxation is that after the RF 
pulse has been applied, the spins have been tilted in the xy plane (Mxy), and all 
Figure 3-9 T1 relaxation curve. M reaches 63% of its maximum value (M0) at t = T1 and is very 
close to maximal at t = 5 x T1 (From Ester1). Courtesy Allen Elster, MRIquestions.com 
Figure 3-10 T2 relaxation, showing the progressive dephasing, with all spins aligned on the Mxy plane 
in (1) and their progressive dispersion or dephasing (2-4) (From Kantzas [et al.]8). Reproduced with 
permission from PERM Inc 
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proton spins are both synchronized and precessing at the same frequency. This 
is the stage where protons are in phase. As mentioned above, it is the loss of 
this synchronisation, or dephasing, which causes the T2 relaxation. The process 
is illustrated in Figure 3-10.  
So why this dephasing does occur? As stated earlier, the T2 relaxation is also 
called spin-spin relaxation, and the reason for this is because the dephasing is 
caused by interactions between spins. There will be transfer of energy from 
excited protons to nearby non-excited ones. This affects the speed at which each 
proton spins, and causes progressive inhomogeneity that leads to signal decay. 
Just like T1 relaxation, the signal decay occurring during T2 relaxation can be 
modelled as an exponential curve, similar to the concept of radioactive decay, 
with a half-life measured in tens of ms, as shown in Figure 3-11.  
The time constant T2 corresponds to the length of time elapsing between the 
excitation and the point at which the signal has been reduced to 36.8% of its 
original value (or has lost 63.2% of its amplitude). In other words, it is the 
opposite of T1 where 63.2% of Mz recovery is the benchmark for the T1 
constant.  
Figure 3-11 T2 relaxation curve. The T2 relaxation time is defined as the time required after excitation 
for the magnetisation to be reduced to 37% of its initial value (From MRImaster.com9). Reproduced 
with permission from the author. 
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Moreover, just as is the case for T1, the value of T2 is unique for every kind of 
tissue and is determined primarily by the chemical environment. So taking the 
examples used for T1, adipose tissue will de-phase quickly, while the process 
will be much slower for CSF. T2 values are also much less affected by field 
strength than T1. 
Finally, it should be noted that T2 relaxation happens much faster than T1 
relaxation: it only takes tens of milliseconds compared to up to seconds for T1.  
3.2.3.3 Free Induction Decay (FID) 
It was mentioned above that the MR signal is linked to T2 relaxation. This 
signal is called Free Induction Decay (FID). Its initial amplitude is determined 
by the degree to which M has been flipped on the xy plane, with the highest 
signal obtained when the vector has been flipped to 90º. The signal is modelled 
with a decay curve (Figure 3-12), which contains the actual signal. The signal 
itself is oscillating at the resonance frequency in the MHz range. A curve as the 
Figure 3-12 T2 and T2* relaxation processes. The signal is at its peak when M (red arrow) has been 
flipped to 90º where the spins are in phase. As the protons spin de-phases (black arrows), the signal 
quickly decays. FID is shown in dashed lines, while T2* is in red lines. Both T2 and T2* are exponential 
processes with times constants T2 and T2* respectively (From Ridgway10). © Ridgway; licensee 
BioMed Central Ltd. 2010 
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one shown in Figure 3-12 would occur if nothing is affecting the homogeneity 
of the magnetic field. Obviously, such homogeneity does not happen in the real 
world, as the magnet is likely to have some flaws in its manufacture, and tissues 
variability means that each tissue has a different magnetic susceptibility, which 
causes field distortions at tissue borders. As a consequence of all this, the signal 
decays faster than the T2 relaxation would predict and the actual signal is called 
T2*, as can be seen in Figure 3-12.  
MR signals can also be produced using spin echo and gradient echo, as will be 
explained in the next two sections. 
 Spin Echo (SE) and Echo Time (TE) 
A Spin Echo (SE) is generated when a second 180º RF-pulse applied a short 
time after the 90º one. The effect of this pulse is to rotate the entire system 
upside-down (an analogy used is "flipping a pancake"), causing the spins to 
rephase, and thus producing a large signal: the Spin Echo. In order to have the 
optimal effect, the 180º pulse has to be applied at a specific time in the sequence. 
Corresponding to the middle time point between the first RF pulse and the peak 
of the spin echo. This time interval is called Echo Time (TE), and can be 
Figure 3-13 Creation of a spin echo by two RF pulses. The first RF pulse generates an FID, while the 
2nd pulse generates the Spin Echo. The echo time (TE) is twice the inter-pulse interval (From Elster1). 
Courtesy Allen Elster, MRIquestions.com 
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anything in the range of 5 to 250 ms. The time at which the 180º pulse must be 
applied is defined as TE/2. The whole sequence is shown in Figure 3-13. 
What happens to the protons when the system has been turned on its head is that 
the faster precessing spins are now at the back of the pack. A good analogy that 
is often used is one of a race in which participants have a great variety of speeds. 
At the start of the race, they are all aligned or in MRI terms, in phase. Once the 
race starts (at t = 0), the contestants all start moving at their fastest pace, and 
soon find themselves at different spots. At a given point (TE/2 in the MRI 
sequence), they are told to turn around without losing speed, which means that 
the starting line is now the finish. As the fastest contestants will be furthest away 
from the starting/finishing line and the slowest ones the closer, if they all keep 
going at the same speed as they did before, they should all reach the finishing 
line at the same time. For the protons, this will be another TE/2, after which 
they will be in phase once more. 
Once all the spins are back into phase, they immediately start to dephase again. 
However, a second 180° pulse can be applied, using the same TE, to generate a 
second echo. The process can be repeated until the time at which T2 relaxation 
has caused the signal to decay completely as illustrated in Figure 3-14. It should 
Figure 3-14 Exponential decrease of spin echoes maxima caused by T2 decay 
 (From: Flögel]11) Reproduced with permission from Uli Flögel. 
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be noted here that while the 90°-180° sequence gives the strongest signal, spin 
echoes can be generated with others flip angles.  
 Gradient Echo (GRE) 
Gradient echo, sometimes also called gradient-recalled echo, differs from spin 
echo in two important ways: first, the flip angle is usually less than 90° (from 
of about 10° to 80°) and second, the 180° RF rephasing pulse is not needed. So 
how is the echo generated and how does the signal differ from the spin echo 
one?  
The signal is generated through the application of a bipolar gradient, which 
consists of a pulse with a positive polarity followed by one with a negative one, 
which dephase and rephase the spins respectively. First the positive gradient 
leads to rapid dephasing of the transverse magnetisation, and brings the FID 
signal to zero, then the second gradient with a negative magnetic field is applied 
to reverse the dephasing caused by the first gradient. This gradient will 
generally be twice as long as the first one, and will have an effect similar to the 
one of the second pulse in the spin echo, with the rephasing and recovery of the 
FID signal generating a gradient echo. The double length of the second gradient 
is necessary to produce a full cycle of first rephasing/FID, followed by 
dephasing to zero. The process is illustrated in Figure 3-15. 
What happens at the protons level is that the dephasing speed of the spins is 
reversed, with the fastest one slowed down, and the slower ones sped up until 
they are in phase again. Another important fact with this sequence is that the 
use of lower flip angles means a lower amount of magnetisation tipping in 
transverse plane, and consequently a shorter longitudinal/T1 recovery. 
Practically, this means that the sequence is faster than spin echo ones. The flip 
side is that the recovery is equivalent to the T2* decay rather than the T2 one, 
as is the case with the spin echo sequence. This is because GRE cannot correct 
for magnetic field inhomogeneity, and therefore leads to lower signal intensities 
and higher amounts of artefacts.  
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Nevertheless, the GRE sequence can be repeated, leading to several dephasing 
and rephasing, as long as the T2* relaxation is not complete. Each new echo 
will be smaller, as since T2* relaxation is faster than T2, only 3-4 usable echoes 
can be produced. 
There is one more sequence that can be used to produce MR signals that needs 
to be introduced: Inversion Recovery 
 Inversion Recovery (IR) and Inversion Time (TI) 
As can be seen from Figure 3-16, Inversion Recovery (IR) is a standard spin 
echo (SE) sequence that is preceded by a 180° inverting pulse. The 180° 
excitation pulse is called inverting because it flips the direction of the 
longitudinal magnetisation, so that it points in the opposite direction of the main 
magnetic field (B0). After the initial 180° pulse, the T1 relaxation of the 
magnetisation starts from a negative or inverted value, rather than from zero as 
would be the case when the 90° pulse is applied in the SE sequence, and 
therefore will also be twice the length of what it would be in SE. The time 
Figure 3-15 Gradient echo sequence. The magnetic field gradients applied, their effect on protons 
and FID with the T2* relaxation curve (From Ridgway10). © Ridgway; licensee BioMed Central 
Ltd. 2010 
< 
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between the 180° inverting pulse and the 90° one, known as the inversion time 
(TI), can be varied in order to adjust the contrast. 
The increase in T1 relaxation times when compared to SE, combined with the 
fact that different tissues will have different T1 recovery time means that IR 
provides a better discrimination between tissues than SE. The degree of 
separation between different tissues in both SE and IR is illustrated in Figure 
3-17. IR can also be used to suppress the signal of a specific tissue, like fat or 
CSF for example. To achieve this, the selected TI duration will match the T1 
relaxation time of the targeted tissue. The sequence used to suppress the signal 
from fat is called Short Tau Inverse Recovery (STIR), while the one suppressing 
CSF signal is the Fluid Attenuation Inverse Recovery (FLAIR) sequence. In the 
context of this thesis, the application of IR with a different type of 
reconstruction, phase-sensitive inversion recovery (PSIR), is used to look at 
grey matter lesions. This technique will be the topic of section 3.4. 
There is another sequence that had been used in the context of this thesis, echo 
planar imaging (EPI). As it specifically used for diffusion MRI, it will be 
explained in that section. For now, there is one more generic feature of MR 
Figure 3-16 Spin Echo (SE) and Inversion Recovery (IR) sequences. The IR sequence is basically a SE 
sequence preceded by a 180° inverting pulse at time TI (From Elster1). Courtesy Allen Elster, 
MRIquestions.com 
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acquisition that needs to be discussed: the repetition time briefly mentioned 
when discussing the spin echo. 
 Repetition Time (TR) 
The repetition time (TR) is the time elapsing between the repetitions of the 
sequence. So for the SE sequence, it will between the 90º pulses (as shown in 
Figure 3-17). For the gradient echo one, it will the time between the flipping 
angle pulses and for IR sequence between the 180º pulses. The combination of 
different TR and TE is also used to determine the contrast, as will be explained 
in the next section. 
 Image contrasts: T1, T2 and proton density (PD) 
In SE sequences, the image contrast depends on the combination of TE and TR 
values, with three combinations used: 
 Short TR/Short TE → T1-weighted 
 Long TR/Short TE → PD-weighted 
 Long TR/Long TE → T2-weighted 
Figure 3-17 The dynamic ranges of SE and IR sequences. The longer T1 relaxation time of IR means 
that IR can potentially discriminate tissues on more subtle variations than SE  (From Elster1) Courtesy 
Allen Elster, MRIquestions.com 
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The short TR/long TE combination is not used because as shown in Figure 3-
17 it produces a poor contrast. 
T1, T2 and PD can also be obtained when using GRE sequences, except that 
here the contrast is determined by different combination of the flipping angle 
(α) and TE.  
 High α/Short TE → T1-weighted 
 Medium α/Short TE → PD-weighted 
 Low α/Long TE → T2-weighted 
Standard IR sequences will give T1 images, however sequences such as FLAIR 
can be used to produce both T1- and T2-weighted images. 
For the purpose of this thesis, T1-weighted images were used for image co-
registration, while PD/T2-weighted ones are used to mark lesions in MS and 
NMOSD patients. An example of T1, T2, PD contrast in the same patient is 
shown in Figure 3-19. 
Figure 3-18 TE and TR combinations in SE sequences and the image contrasts obtained (From Elster1). 
Courtesy Allen Elster, MRIquestions.com  
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Having discussed how images are produced, the next step is to understand how 
the localisation of the signal can be detected. 
 Spatial localisation 
When the sequences mentioned above are used, they do not provide any 
information about the location of the signal. So in order to include spatial 
localisation of the signal, its x, y and z coordinates need to be specified. As 
mentioned in the introductory section, Lauterbur showed that this can be done 
using gradients. So what are those gradients and how are they produced? The 
term gradients (G) is used to describe fields with a magnetic gradient: that is 
they vary in magnitude or direction between two points in space. They are 
defined as the change in field (ΔB) divided by the change in distance (Δs)1.  
 So: G= ΔB/ Δs  
Gradients are generated by spatial encoding coils, known as gradient coils, 
which can produce secondary magnetic fields in the x, y, and z directions. These 
fields, which are much weaker than the main magnetic field B0, slightly distort 
it in a predictable manner (their effect can be seen in Figure 3-20), causing 
spatial variations in the resonance frequency of protons which can then be used 
for spatial encoding. 
T1 T2 PD 
 Figure 3-19 T1-, T2- and PD-weighted images in a patient with MS showing large periventricular 
lesions. 
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Spatial encoding has three stages: slice selection, frequency-encoding, and 
phase-encoding. 
3.2.9.1 Slice selection 
This is done using a slice encoding or slice selection gradient, GS, together with 
a simultaneous RF pulse at the Lamor frequency determined by the selected 
slice. Consequently, only the protons in the chosen slice will be excited. Since 
each slice contains a range of frequencies or bandwidth, the RF pulse 
transmitted needs to comprise the whole range. The thickness of the slice itself 
is determined by a combination of the strength/steepness of the gradient 
together with the range of frequencies/bandwidth in the RF pulse. The process 
is illustrated in Figure 3-21. 
Now that the source of the signal has been located in a specific area, further 
encoding is necessary to know its position within the slice, which is the reason 
why a phase encoding gradient is applied next. 
Figure 3-20 The effects of the application of x, y and z gradients on B0 (From Elster1). 
Courtesy Allen Elster, MRIquestions.com 
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3.2.9.2 Phase encoding 
The phase encoding gradient (GP) is applied for a specific period in the vertical 
direction, causing the protons to rotate at different frequencies depending on 
their position along the gradient. Precession will increase where the gradient 
increases, and similarly decrease in the part of the slice where the gradient 
causes a decrease in the magnetic field. In other words, the protons will have 
different phases depending on their position, and this persists after the gradient 
is switched off. So now all the protons are precessing with the same frequency 
but have different phases. To obtain an image, multiple repetitions with 
different encoding gradients, which are progressively incremented is necessary, 
as can be seen in Figure 3-22.  
Figure 3-21 Slice selection: this is achieved through the application of a magnetic field gradient GS 
together with a RF excitation pulse. The Larmor frequency used is determined by the location along 
the gradient (here along the z axis) and excitation only occurs where the tissue frequency matches the 
RF pulse one (From Ridgway10). © Ridgway; licensee BioMed Central Ltd. 2010 
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So now there is just one more direction that needs encoding, and for this 
frequency encoding is used.  
3.2.9.3 Frequency encoding 
Last, the frequency encoding gradient (GF) is applied at right angle from the 
previous gradient. It affects protons frequencies according to their positions 
along the gradient direction and therefore modifies the Larmor frequencies in 
the remaining direction for the duration of its application, while the phase 
changes from GP remain after the pulse is turned off. Figure 3-23 summarises 
what happens to the protons through the spatial location sequence, while Figure 
3-24 illustrate the whole sequence. 
Having looked through the different aspects of image acquisition, the next stage 
is to see how the image is reconstructed.  
(a) (b) (c) 
Figure 3-23 Changes in precession phases of protons through spatial location stages (a) After slice 
selection (b) After phase encoding (c) After frequency encoding, with the signal of each voxel 
uniquely encoded (Adapted from Adair [et al.]13).  
Figure 3-22 Two phase encoding gradients and their effects on protons phases  
(From MRI shark12). Reproduced with permission from the author. 
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 Fourier transform and k-space 
There are two important concepts that need to be explained in order to 
understand how MR images are reconstructed: k-space and Fourier transform. 
Since the reconstruction process involves the Fourier transformation of k-space 
in order to get an image, I will start with this.  
A very straightforward definition of k-space was quoted by NessAiver: “The 
MRI data prior to becoming an image (raw or unprocessed data) is what makes 
up k-space”2. This definition has the advantage of being a clear and simple, and 
is therefore a useful starting point, but in order to understand how the Fourier 
transformation works, the one given by Allen D. Elster, describing “k-space as 
an array of numbers representing spatial frequencies in the MR image”1 
introduces one key notion, that k-space is about spatial frequencies and it is 
these frequencies that will be transformed in order to produce an image, as can 
be seen in Figure 3-25. 
Figure 3-24 Spatial location sequence GS: slice selection gradient; GP: Phase gradient & GF: Frequency 
gradient (Posted on Pinterest by Christos Tsiotsios). 
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k-space is represented by a square, with kx and ky axes corresponding to x 
(horizontal) and y (vertical) axes in the actual image. However, as already 
mentioned, the axes in k-space represent spatial frequencies rather than 
positions, with each k-space point containing both phase and spatial frequency 
information about each pixel in the final image, as illustrated in Figure 3-26. 
So the centre of k-space comprises signals with low spatial frequencies 
(converting into general shapes and contours), while the high-spatial 
frequencies signals (holding information about edges, details, giving the image 
its sharpness) are located in the periphery. 
It is beyond the scope of this thesis to explain in details how the Fourier 
transformation works, but a brief explanation will be useful to understand image 
reconstruction. Joseph Fourier (1768–1830), a French mathematician and 
physicist, uncovered the fact that a complicated signal can be rewritten as the 
Figure 3-26 k-space and Fourier transformed image. As the double arrow indicates, the transformation 
works in both directions (From Elster1). Courtesy Allen Elster, MRIquestions.com 
Figure 3-25 Each point in k-space maps to every point in the image and vice-versa (From Elster1). 
Courtesy Allen Elster, MRIquestions.com 
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sum of a series of simple waves. In term of MRI signals, that means 
decomposing it into a sum of sine waves of different frequencies, phases, and 
amplitudes, which as shown above are all components of the signals.  
Concretely, Figure 3-27 shows how a complex wave is decomposed into its 3 
cosine waves before its time domain is transformed into a frequency domain. 
Having looked into k-space and Fourier transformation, it is worth having a 
quick peek at the whole process from acquisition. Figure 3-28 shows how the 
different spatial frequencies of a coronal slice of a brain are acquired by 
successively altering magnetic field gradients (open arrows in top three images) 
during frequency- and phase-encoding stages. The diagram only shows three 
gradients, but it is important to remember that a much larger number of 
gradients are necessary to fill k-space sufficiently to make image reconstruction 
possible.  
Figure 3-27 Fourier transform (FT): the wave is decomposed in its 3 cosine waved components (top) 
and (bottom) the Fourier transformation of the time domain in the frequency domain (From Gallagher 
[et al.]14). Reprinted with permission from American Journal of Roentgenology. 
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Now that we have seen how MR images are acquired and reconstructed, the 
next sections will introduced the different MRI techniques used for this thesis: 
diffusion-weighted magnetic resonance imaging (dMRI), phase-sensitive 
inversion recovery (PSIR) and magnetisation transfer ratio (MTR). 
 Diffusion-weighted magnetic resonance imaging 
Specific techniques are used to look at different aspects of the brain. In the case 
of diffusion-weighted magnetic resonance imaging (dMRI), it is a non-invasive 
method allowing in-vivo studies that can provide information on both white 
matter integrity and structural changes in the human brain. This is particularly 
relevant in the context of progressive or degenerative diseases, as it enables 
researchers and clinicians to assess changes occurring in patient’s brains at 
different time points, and thus to assess parameters such as disease progression 
or drugs efficiency. The fact that this technique is highly relevant for both 
Figure 3-28 Sequence from acquisition to MR image. A, B & C at the top represent different gradients, 
used during acquisition, while the corresponding images at the bottom show how they appear in k-space, 
before going through the Fourier transformation (FT) to produce the image of a coronal slice of the brain 
(Adapted from Gallagher [et al.]14)  Reprinted with permission from American Journal of Roentgenology. 
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clinical and research applications explains why it is not just widely used, but 
also gives rise to ever more complex innovations, from Tract-Based Spatial 
Statistics (TBSS), q-ball imaging or Neurite Orientation Dispersion and Density 
Imaging (NODDI), which is the technique used in Chapter 4. 
 The physics and representation of dMRI: 
dMRI is based on the fact that water molecules diffuse differentially in different 
tissue types, but also do so in a random and erratic way as illustrated in Figure 
3-29. This erratic motion is defined as a displacement distribution. In statistical 
terms, this displacement distribution describes the proportion of molecules 
shifted in a specific direction and to a specific distance15. Where there is pure 
liquid, such as in cerebrospinal fluid-filled regions, the absence of narrow 
barriers means that diffusion is the same in all directions and will have a 
Gaussian (bell shaped) distribution. A similar diffusion pattern is also found in 
spherical cell and in voxels covering randomly orientated axons. In all these 
cases, the 3D displacement distribution will have a spherical shape and is called 
isotropic.  
Figure 3-29 The red line shows the random trajectory of a diffusion-driven single water molecule. 
The molecular displacement during the diffusion time interval between t1 = 0 and t2 = Δ is 
represented by dotted white line (vector r) (From Hagmann [et al]15, ©RSNA, 2006). Reproduced 
with permission from RSNA 
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However, most neuronal tissues are formed of tightly packed fibres such as 
axons, and are frequently organised in bundles. When looking at diffusion that 
means that the movement of water molecules is highly constrained, largely by 
the cell membrane (Figure 3-30). This type of diffusion is described as 
anisotropic and will occur primarily along the tract length, as perpendicular 
diffusion is extremely restricted. Accordingly, the displacement distribution 
will have an ellipsoidal shape and no longer be Gaussian15-17. Practically this 
means that in brain tissues, diffusion is isotropic in cerebrospinal fluid as well 
as grey matter (GM), where the lack of precise orientation in the fibres results 
in random diffusion, but anisotropic along white matter tracts18,19. As for the 
source of diffusion within axons, myelin only play a small part in anisotropic 
diffusion, since it occurs mostly in the cell membrane, and primarily in the 
direction of the axon fibre. Microtubules and neurofilaments too seem to play 
only a minor role, while the function of cellular density and amount of 
myelination appears to be purely regulatory15,18. Obviously diffusion within 
cells occurs in three dimensions, and therefore a three-dimensional (3D) model 
is required to represent the probability of displacement or displacement 
distribution within three intersecting planes.  
Figure 3-30 A schematic longitudinal view of a myelinated axon, showing the different structures 
which could support diffusion along the axon direction and hinder perpendicular diffusion, thus 
resulting in anisotropic diffusion (From Hagmann [et al.]15, ©RSNA, 2006). Reproduced with 
permission from RSNA 
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As shown in Figure 3-31, this can be done using colour coding, and is applied 
to the different types of diffusion, which in this figure is the probability density 
function in a voxel containing either spherical cells or randomly oriented 
intersecting tubular structures (like axons). This is a good example of isotropic 
diffusion, similar to the unrestricted diffusion found in the CSF (but in this case 
is restricted by biological barriers) as it has a roughly Gaussian distribution with 
no preferential direction of diffusion. The vector r indicating the displacement 
distance15.  
Before looking at how diffusion in the type of complex environment found in 
biological tissue is modelled, it is useful to look at the model of diffusion in a 
homogeneous medium. There the Gaussian distribution will depend on the type 
of molecule, temperature and time allowed for diffusion. The parameter which 
controls the spread of Gaussian distribution, variance (σ2) depends on two 
variables: the diffusion time interval (Δ) and the diffusion coefficient D. The 
latter characterises either how easily molecules are displaced or the viscosity of 
the medium. This can be sum as: 
σ2 = 2 x D x Δ 
Figure 3-31 The colour coding used to indicate the probability diffusion level within a single voxel, 
from the highest in blue to lowest in red, with the full spectrum shown in the colour bar on the side. A 
3D diffusion probability density function in a voxel containing either spherical cells (top left) or 
randomly oriented tubular structures that intersect, such as axons (bottom left). The roughly bell shaped 
3D displacement distribution results in a symmetric image, as there is no preferential direction of 
diffusion. The distribution is similar to that in unrestricted diffusion, but narrower since biological 
barriers hinder molecular displacement. The centre of the image (origin of the r vector) indicates the 
proportion of molecules (n/N) not displaced during the diffusion time interval (From Hagmann [et al.]15, 
©RSNA, 2006). Reproduced with permission from RSNA 
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For water at 37º, the approximate value of D is 3 x10-3 mm2s-1, while for 
biological tissues these values are only about 10-50% as long, possibly around 
1.0 x 10-3 mm2s-1 1. 
A key feature of biological tissues is their heterogeneity, with multiple 
compartments with varying diffusivities. As mentioned above, neuronal tissues, 
which are the ones of interest in this thesis, have a fibrillar structure. In white 
matter, axons, along with the adjacent glial cells, are tightly packed bundles, 
with mostly coherently distributed fibres. Figure 3-32 clearly shows the 
ellipsoidal shape of the diffusion resulting from the hindrance enforced by the 
tissue microstructure (highly hindered in the perpendicular direction to the axon 
orientation). This is a good example of the anisotropic diffusion mentioned 
above, which is directionally aligned with the fibres bundle.  
This particular representation works well in voxels covering large tracts with 
the same orientation, but becomes much less straightforward as soon as there 
are crossing fibres. Figure 3-33 shows what happens to the diffusion probability 
density function when two bundles of fibres cross at a 90º angle15, resulting in 
a cross-shaped diffusion model. Even this, as we will see below, is a rather 
simple model since voxels often includes bundles of fibres with multiple 
orientations rather than just two. 
Figure 3-32 3D diffusion probability density function within a voxel in which all the axons are 
directionally aligned, resulting in a cigar shaped displacement distribution that is aligned with the axons 
(From Hagmann [et al.]15, ©RSNA, 2006). Reproduced with permission from RSNA 
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The final level that needs to be included in the analysis is the position of the 
voxel, this is another 3D vector designated as p. So for the full description of 
what is happening in each voxel, the position p is assigned a diffusion 
probability density function (f), with f(p,r) describing the proportions of 
molecules in a voxel at position p that have been displaced a distance r. These 
additional three dimensions pose another challenge for representation. As the 
most relevant information comes from determining the direction of the most 
rapid diffusion, which is likely to correspond with the axons orientation, an 
orientation distribution function (ODF) is computed. Here too colours are used, 
this time it is to code the diffusion direction along the x, y, z axes: [x,y,z] = 
[r,b,g,], where r = red, b=blue and g=green15. An example of what an orientation 
distribution function for a single voxel would look like is given in Figure 3-34, 
with a map of coronal section shown in Figure 3-35. 
Figure 3-34 3D diffusion probability density function within a voxel containing two populations of 
fibres crossing at a 90° angle, producing a cross shaped molecular displacement distribution (From 
Hagmann [et al.]15, ©RSNA, 2006). Reproduced with permission from RSNA 
Figure 3-33 An 
example of the 
computation of the 
orientation 
distribution 
function (ODF). 
distribution.  
(Adapted from 
Hagmann [et al.]15, 
©RSNA, 2006). 
Reproduced with 
permission from 
RSNA 
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 dMRI acquisition 
dMRI measures are based on the dephasing of protons spins following the 
application of diffusion-weighting gradients in varying directions. Scans are 
usually acquired using echo-planar imaging (EPI) involving a single 90º-180º 
pair of RF pulses, as well the diffusion gradients. Figure 3-36 illustrates a 3D 
dMRI spin echo sequence, with the diffusion-weighted (DW) gradients applied 
in all three directions. The DW gradients induce spatially-dependent phase shift 
and then reverse it. Consequently, static/non-diffusing spins return to their 
initial state, while spin that have moved because of diffusion will undergo a 
total phase shift leading to a decreased intensity of the measured MR signal16,20. 
The TE used is normally greater than 100ms. The protocol also needs to 
incorporates a varying number of sampled orientations, with values between 20 
and 60 gradient directions being among the most commonly used. 
Figure 3-35 ODF map of a coronal brain section, with some easily identifiable tracts: corticospinal 
tract (mostly blue) and corpus callosum (predominantly red). Other tracts, such as the cingulum, the 
arcuate fasciculus (primarily green), and the middle cerebellar peduncle (chiefly red) are more 
difficult to see (From Hagmann [et al.]15, ©RSNA, 2006). Reproduced with permission from RSNA 
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In order to measure the actual diffusion, at least two sets of images are 
necessary, beginning with one with no diffusion, known as b0. For the brain, 
the second one, which will used to determine the diffusion coefficient D in each 
voxel, consists of b-values varying between 700 and 1300 s/mm2, with 1000 
s/mm2 being the most commonly used one20. However, when it comes to 
measuring the actual diffusion from MRI scans, because diffusion in tissues is 
anisotropic, D is replaced by the apparent diffusion coefficient (ADC). 
 Apparent diffusion coefficient (ADC) and diffusion tensors 
ADC reflects the diffusion as it occurs in tissues, incorporating facts such as the 
hindrance caused by biological barriers, as well as other aspects also affecting 
the signal, such as cytoplasmic streaming, blood flow in the microcirculation or 
phase dispersion due to susceptibility effects. In anisotropic tissues such as 
white matter (WM), the ADC will vary with the direction in which it is 
measured (determined by the direction of the diffusion gradients used): fast 
along the axon, as it is the main direction of diffusion, and slower 
perpendicularly because it is highly restricted. In GM however, as diffusion is 
mainly isotropic, the direction of the diffusion gradients will hardly have any 
influence1,16. Besides while ADC can be used to map the mean diffusivity 
Figure 3-36 A 3D dMRI spin echo acquisition sequence, with the diffusion-weighted 
gradients represented as grey blocks included in each spatial encoding gradient (Adapted 
from Winston, 201216). Adapted with permission from AME Publishing Company 
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(MD), diffusion measurements are mostly done using a tensor model, 
commonly called diffusion tensor imaging (DTI). 
Tensors are based on measurements along 6 spatial directions: three eigenvalues 
(λ1, λ2, and λ3) and three eigenvectors (ε1, ε2, and ε3) which define the shape 
and orientation of the tensor (see Figure 3-37) and reflect the various diffusion 
properties of each voxel. 
 
(a) 
Figure 3-37 Tensors and ellipsoid. (a) The measures of diffusion along multiple axes, with the 
blue arrows on the left representing diffusion constants, while the figure on the right shows how 
the measurements are fitted into a diffusion tensor (b) The parameters required to mathematically 
describe a circle, an oval, a sphere and an ellipsoid. The eigenvalues λ1, λ2 and λ3 define the 
shape of the ellipsoid, while the eigenvectors ε1, ε2 and ε3 describe its direction (Adapted from 
Oishi [et al.], p. 3)19. Reproduced with permission from Elsevier 
ε 
ε 
ε 
(b) 
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Tensors are calculated using both eigenvalues (λ1, λ2, and λ3) and eigenvectors 
(ε1, ε2, and ε3) using a 3x3 covariance matrix (the whole process is shown in 
Figure 3-38), while ADC is the average of the eigenvalues (λ1,λ2,λ3). 
Eigenvalues are also used to calculate multiple diffusion measurements besides 
MD: longitudinal/axial diffusivity (AD), radial diffusivity (RD) and the most 
commonly used, fractional anisotropy (FA), which is one of the techniques 
applied in the next chapter.  
 Fractional anisotropy (FA) 
Fractional anisotropy measures the amount of diffusion asymmetry within a 
voxel, based on the relative difference between the largest eigenvalue when 
compared to the others: 
𝐹𝐹𝐹𝐹 =  �32�(λ1 − (λ))2 + (λ2 − (λ))2 + (λ3 − (λ))2λ12 + λ22 + λ32  
The value of FA varies between 0 and 1, with 0 representing perfect isotropic 
diffusion where all the eigenvalues are equal, while 1 will be an elongated 
ellipsoid where λ1 will be much larger than the other two eigenvalues. It is used 
to generate a map in which a grey-scale display of FA values represent the 
diffusion across the brain, with more anisotropic areas appearing brighter1,22 as 
can be seen in Figure 3-39. 
However, because tensors can only show the dominant fibre orientation, they 
only work well in those voxels where fibres mostly have a single orientation. 
They cannot be used to map voxels covering tracts with multiple orientations 
Figure 3-38 From gradients to tensors: how the different gradients are combined to calculate the tensor 
(From Tromp [et al.]21). Reproduced with permission from the authors. 
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or crossing fibres. Moreover, DTI models also proves inadequate for grey 
matter since diffusion there is mostly isotropic1,16. This the reason why new 
models, such as Neurite Orientation Dispersion Imaging (NODDI), the 
technique applied in the next chapter, have been developed. 
 Neurite Orientation Dispersion and Density Imaging (NODDI) 
NODDI was introduced and validated by Zhang and colleagues in 201223, 
offering a new way to model the microstructure of dendrites and axons, with 
the aim to offer more specific markers than standard indices from diffusion 
tensor imaging, such as fractional anisotropy or mean diffusivity.  
In order to achieve this, the NODDI tissue model uses three compartments 
representing the three main components of microstructural environment: intra-
cellular, extra-cellular and CSF. To obtain a good representation of the 
orientation dispersion in both grey and white matter, the model uses the concept 
of a zero radius cylinders or sticks to represent the intracellular space, followed 
by the application a Watson distribution to determine the orientation 
distribution23. The extra-cellular compartment and the CSF one are represented 
by Gaussian distribution, anisotropic for the first and isotropic for the second16. 
An illustration of the NODDI tissue model is shown in Figure 3-40.  
Figure 3-39 FA map, 
with the internal 
capsules and corpus 
callosum appearing 
particularly bright as 
highly organised tracts 
have high FA values. 
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3.3.5.1 NODDI maps 
Three parameters maps can be generated with the NODDI tissue model: 
orientation dispersion index (ODI), neurite dispersion index (NDI) and 
isotropic volume fraction (viso), which are shown in Figure 3-41. The estimates 
of tissue microstructure provided by the ODI and NDI maps make it possible to 
disentangle two key variables contributing to FA, therefore providing additional 
information about the nature of the changes observed25. The reason why this 
new information is particularly relevant is because of the lack of specificity in 
FA when it comes to identifying the causes underlying the observed 
changes22,26,27. 
Figure 3-40 The three different levels in the NODDI model, showing the contribution of the different 
components. First, the non-tissue compartment, essentially CSF, which has a purely isotropic diffusion 
and is modelled by Gaussian diffusion. Then the two tissue ones, using an anisotropic model for the 
extracellular tissues and sticks for the axons and dendrites (From Tariq [et al.]24). 
(a) (b) (c) 
Figure 3-41 NODDI maps: (a) ODI, (b) NDI, (c) viso (From Zhang [et al.]23). Reproduced with permission 
from Elsevier 
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3.3.5.2 NODDI acquisition 
The acquisition of images for NODDI requires at least two high angular 
resolution diffusion imaging (HARDI) shells for the optimal fitting to be 
obtained. For the purpose of this thesis, the technique was applied to single-
shell data to assess feasibility, as will be explained in the next chapter. 
 Phase-Sensitive Inversion Recovery (PSIR) 
As mentioned in section 3.2.5 on inversion recovery, PSIR is a reconstruction 
technique. The images are acquired using an inversion recovery sequence, with 
two separate interleaved acquisitions (Figure 3-42) and can have a high 
resolution. For example, for the study a voxel size of 0.5x0.5 mm in-plane and 
2 mm slice thickness was used. The interleaving is necessary when thin slices 
are required: as the RF has a Gaussian shape, while slices have a rectangular 
one, parts of the adjacent slices will get excited, thus causing partial excitation 
of adjacent slices ('cross-talk' effect). The two separate acquisitions mean that 
the cross-talk effect is prevented and also that slices are back to equilibrium by 
the time the second series of images are acquired. 
 
Figure 3-42 Slice interleaving used to avoid slices interference. Odd-
numbered slices (with 100% gaps) are obtained in one acquisition, followed 
by a second acquisition of even-numbered slices (From Elster1). Courtesy 
Allen Elster, MRIquestions.com 
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The other advantage of this technique is the high contrast resulting from the 
phase-sensitive reconstruction. The reason for this is that this reconstruction 
retains the positive and negative polarities of tissues. In other words, the 
magnetisation measured will go from negative to positive, differentiating 
between tissues with similar magnetisation but opposite polarities. This differs 
from the more traditional magnitude reconstruction used for IR, which does not 
take the polarity of the signal into account. So after the selective nulling, all the 
tissues will have positive signal intensities and therefore two tissues whose 
magnetisation at inversion time is equal but with opposite polarities will be 
represented in the same shade of grey and thus be indistinguishable1. The 
reconstructions and the contrasting results obtained can be seen in Figures 3-
43 and 3-44. 
Figure 3-43 Magnitude (left) and phase-sensitive (right) reconstructions (From Elster1). Courtesy 
Allen Elster, MRIquestions.com 
Figure 3-44 Magnitude and phase-sensitive reconstruction of the same IR signal (From Elster1). 
Courtesy Allen Elster, MRIquestions.com  
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 Magnetisation transfer ratio 
The last MRI technique used in the context of this thesis is magnetisation 
transfer ratio. In order to explain how this technique works, it is necessary first 
to look at the different sources of MRI signal. 
 Sources of MRI signal 
There are five main sources with enough 1H protons to be used for MR signals1, 
and four them are shown in Figure 3-45. They are as follows: 
 Free Water: In the brain, it is mostly the CSF, but it is also found in the 
cytosol. Just as in the rest of the body, this is largest and most important 
source of NMR signal. Moreover, because water molecules in this pool only 
bind transiently (which is why they are described as ‘free’), 1H protons will 
rotate very quickly and over a wide range of frequencies. Consequently, this 
pool has long T1 and T2 relaxation times. 
 Fat: The long chains of fatty acids found in tissues comprising large amounts 
of lipids (including triglycerides) are an important source of 1H protons, thus 
Figure 3-45 The major sources of protons at the origin of the MR signal or its modulation: free water, 
bound water, macromolecules, and fats. As lipid stores are usually in isolated compartments, they are 
separated by the dotted line (From Eslter1). Courtesy Allen Elster, MRIquestions.com 
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making a substantial direct contribution to the MR signal. As would be 
expected, motion of protons from this pool is relatively restricted, resulting 
in short T1 and T2 values (a few hundreds of ms and a few dozens of ms 
respectively). Tissues contributing to this pool include adipose and skeletal 
tissues, as well as bone marrow, but not cell membrane phospholipids or 
myelin (both have very short T2 values, so cannot be directly observed).  
 Macromolecules: This category includes molecules such as proteins, 
phospholipids or polysaccharides. Most 1H protons they contain will have 
highly restricted motion, resulting in very short T2 (μs or less) and signal 
decay so rapid that it is undetectable by conventional MRI techniques. They 
do however affect the speed at which protons within water molecules rotate, 
therefore increasing the signal produced.  
 ‘Bound’ water: This pool consists of water molecules bound to the surface 
of macromolecules (for example around the hydrophilic heads of 
phospholipids). Because hydrogen atoms binds at specific sites of the 
macromolecules, water motion becomes restricted, and thus the normally 
rapid rotation of water molecules is slowed down, shortening both T1 and T2 
values when compared to free water. The degree to which this occurs will 
depend on both the concentration and size of the macromolecules, as well as 
on the number of hydrophilic groups available to bind water molecules. 
Finally, and a key aspect for magnetisation transfer, ‘bound’ water hinders 
free water on its outer surface, thus creating a pathway for transfer of 
magnetisation between the macromolecular and free pools. 
 Small organic molecules: A wide range of small molecules such as amino 
acids, sugars, sodium and various metabolites such as N-Acetylaspartate 
(NAA), choline, creatine, etc. also emit MR signals which can be used in MR 
spectroscopy. It is important to note however that because their 
concentrations are so small when compared to water, the water signal has to 
be totally suppressed in order to measure them. A process that can be quite 
difficult to achieve, in particular in the spinal cord.  
84 
 Magnetisation Transfer 
As the discussion about the sources above suggests, there are two pools 
involved in magnetisation transfer: the bound pool consisting of bound water 
and the free pool, containing the free water. As can be seen in Figure 3-46, both 
are centred on the same Larmor frequency, but the bound pool has a broad range 
of resonance frequencies (<10-50 kHz) and a very short T2 (10-20 μs), while 
the frequencies range for the free water is extremely narrow (<0-100 Hz) and 
the T2 relatively long (>10-100 ms)1,28.  
Under normal MR conditions, magnetisation is exchanged between both pools 
so that they are in a state of equilibrium, with changes occurring in both pools 
when a RF pulse is applied. In order to use magnetisation transfer, this situation 
needs to be altered. This is done by selectively saturating the bound pool with 
an off-resonance RF pulse, known as the MT pulse. This can be achieved 
because of the broad frequencies range of the bound pool and will not affect the 
free water pool. The next stage consists of following the magnetisation transfer 
from the free pool to the bound one as the two pools return to equilibrium1,28. 
Figure 3-46 The frequencies range of the bound and free pools (Adapted 
from de Boer28). Reproduced with permission from the author. 
Macromolecule
Free water 
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De Boer28 offers an excellent explanation of the magnetisation transfer (MT) 
phenomenon by using a simplified model of a biological tissue containing a free 
pool made of four water molecules with four proton spins and a macromolecule 
with three proton spins as a bound pool. Figure 3-47 illustrates the different 
stages of MT from the pre-saturation equilibrium with a signal to noise ratio 
(S/N) of 4 to the new equilibrium post MT where it has decreased to 2. This is 
due to the partial saturation of protons in the free pool reducing the net 
magnetization of the free water pool when a RF pulse at the Larmor frequency 
is applied. This process is known as cross-relaxation and reduces the 
longitudinal magnetisation available for imaging. The new shorter longitudinal 
relaxation time is described as the apparent longitudinal relaxation time (T1sat). 
Having seen how MT works, how can it be used to improve MRI contrast? Once 
again, de Boer simplified models are very useful. In this case, two hypothetical 
tissues are used. As can be seen in Figure 3-48, the central tissue has the same 
structure as the previously used model, while the peripheral tissue consists of 
Figure 3-47 The 3 stages of MT shown in a simplified biological 
model consisting a macromolecule with three proton spins as a 
bound pool and a free pool made of four water molecules with 
four proton spins. The free pool protons with arrows facing up 
indicate units of measurable MR signal, while downward facing 
arrows indicate no MR signal. As mentioned in the text, the 
proton spins in the bound pool do not contribute to the MR signal. 
(Adapted from de Boer28). Reproduced with permission from the 
author). 
86 
four free water molecules with four spins. As both tissues have the same number 
of detectable spins, both will have a S/N of 4 and therefore be indistinguishable 
on an MR image. However, after selective saturation has been applied to the 
bound pool and MT exchange has occurred, the central tissue now has a S/N of 
2 while the peripheral tissue has not been affected. So now there is a new 
equilibrium situation in which there is a large contrast between the two tissues. 
 Cross-relaxation 
Cross-relaxation is the term used to describe the energy exchange between the 
bound and free pools occurring during MT, but what is the mechanism behind 
it? In the model above, the interactions have been described between a simple 
Figure 3-48 How MTR can improve MRI contrast. On the left, the two tissues will have the same S/N 
and therefore have a similar contrast on MR images, as shown at the bottom. On the right, the same 
tissues after MT has been applied: the two tissues now have different S/N and consequently, different 
contrast as can be seen in the diagram in the lower right (From de Boer28). Reproduced with permission 
from the author). 
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two pools representation, however as often the case when looking at biological 
tissues, things are slightly more complicated. The so-called free pool is in fact 
composed of two different ‘strata’: the largest part is made of fully mobile water 
molecules, but the water molecules closest to the macromolecule actually form 
an intermediate layer (see Figure 4-49), also known as hydration layer, and are 
less free than the fully free water, but nowhere as restricted as the water 
molecules in the bound pool. The initial transfer will occur between the bound 
water molecules and the transiently bound ones in the intermediate layer. The 
two layers from the free water exchange protons by diffusion, which is also how 
the magnetisation is transferred to the free water pool molecules, leading to the 
signal reduction mentioned above1,28,29. 
 Saturating pulses, on- and off-resonance pulses 
The last thing that needs to be looked into is the two key elements of the MT 
acquisition protocol: a saturating off resonance MT pulse is applied prior to the 
pulse sequence used to create the MT contrast. As mentioned above, the 
saturation pulses consist of RF pulses which are shifted 1000 to 25,000 Hz from 
Figure 3-49 The two layers found in the free water pool. The water molecules closest to 
the macromolecules are less mobile and play a central role in the magnetization transfer 
from the macromolecule to the free water molecules (Form Ester1). Courtesy Allen Elster, 
MRIquestions.com 
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the centre of the Larmor frequency, which will saturate protons in the bound 
pools through diffusion, before transferring to the free water pool and leading 
to the signal reduction (Figure 3-50). Following saturation, a standard 
acquisition pulse is applied. This sequence needs to be repeated in order to 
achieve a steady state of relaxation1,28-30. 
Finally, for the images themselves, the magnetisation transfer ratio (MTR) is 
based on the difference in intensity between the off-resonance and on- 
resonance images29. It is calculated as follows: 
100×(M0-Ms)/M0 
 where Ms and M0 represent signal intensities from images with and without 
pre-saturation pulses. The three different images can be seen in Figure 3-51.  
Figure 3-50 Effect of off-resonance pulse and MT on free pool 
(Adapted from de Boer28). Reproduced with permission from the 
author). 
(a) Figure 3-51 MT images: (a) MT off, (b) MT on, (c) MTR map acquired to look at the optic nerve. 
(b) (c) (a) 
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One of the key reasons why this technique is particularly valuable, and the 
reasons it was used in this thesis, is that it provides information about myelin 
integrity31. This is something that cannot be achieved with other MRI 
techniques and thus gives MTR its distinctive significance among the wide 
array of MR procedures available. However, it should also be noted that MTR 
is only 'semi-quantitative' as it is dependent on the parameters of the pulse 
sequence, which means that data will also vary with the sequence used, making 
comparison between studies difficult. 
 Conclusion 
Now that all the different MR techniques used in this thesis have been 
introduced, the next stage is to look at their application. The first one, which 
will be the topic of the next chapter, is diffusion MRI and NODDI. 
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Application of single-shell Neurite 
Orientation Dispersion and Density 
Imaging (NODDI) to MS 
4.1 NODDI 
As described in Chapter 3, diffusion magnetic resonance imaging (dMRI) 
provides a mean to probe microstructures of the human brain in a non-invasive 
way. It can be used to assess the condition of the brain microstructures in both 
healthy subjects and patients suffering from neurological conditions, including 
multiple sclerosis (MS)1. The most common application in the first group is to 
evaluate changes associated with ageing2,3, while in patients it is used to track 
the effects the disease and identify the areas most affected. Among disease 
related changes, those affecting neurites (the term use to cover both dendrites 
and axons) have proven particularly relevant. Thus a technique that can quantify 
morphological alterations in these structures could deliver new crucial data, in 
particular when it comes to detecting microstructural changes at an early stage 
(i.e. before they translate into visible damage such as lesions or plaques for 
example1). This would not only be useful for early diagnosis, but also open new 
prospects to understand disease mechanisms. 
The previous chapter described the numerous limitations of traditional dMRI 
techniques based on tensors, which techniques such as NODDI attempt to 
address. Therefore, in the context of a study looking at new imaging techniques, 
we thought it would be interesting to test whether NODDI could provide valid 
data when applied to images obtained with a single-shell acquisition rather than 
the optimised two-shells NODDI protocol described in Zhang's paper4. For this 
purpose, we used a selection of relapsing-remitting multiple sclerosis (RRMS) 
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patients and matched healthy controls who underwent dMRI scanning as part 
of a previous study5. The key idea behind this study was to compare the 
performance of NODDI indices to FA in the context of MS in order to see 
whether NODDI could detect both additional differences between patients and 
controls, and correlations with clinical changes that were not detected with FA. 
The notion that applying NODDI to single shell data may provide useful 
information is based on Zhang's paper, in which he demonstrated that single 
shell acquisition with b≥1000 s/mm2 can produce a good estimate of the 
orientation dispersion index (ODI)4. This was the first application of the 
technique in the context of MS, and among the first applications to clinical data. 
Since then, NODDI has been used to look various diseases and conditions, 
including Alzheimer’s disease6, epilepsy7-9, Parkinson’s disease10,11, stroke12 
and glioma13. It has also been applied to MS using a multiple shells acquisition 
protocols by Dr Wallace Brownlee14, who is also attached to the Queen Square 
MS Centre.  
In order to assess NODDI performance when looking at changes occurring in 
normal-appearing white matter (NAWM) and grey matter (GM) of RRMS 
patients, we used both ODI and the neurite density index (NDI), employing two 
different approaches. The first one was region-specific and consisted of 9 
regions of interest (ROIs) in both NAWM and grey matter. The second 
approach aimed to look at the whole brain, using voxel-based morphometry 
(VBM), building up on the results obtained with the ROIs. The aim was to find 
how much the two NODDI indices used would differ from FA, and whether 
these differences would furnish us with additional information on the 
underlying structural damage occurring in the NAWM and grey matter of 
RRMS patients, when compared to the more conventional DTI measures such 
as FA. 
92 
4.2 Methods 
4.2.1 Subjects  
26 RRMS patients and 26 age and gender matched healthy controls taken from 
a cohort study conducted between 2010 and 20125. Patients were diagnosed 
using the revised 2010 McDonald criteria, their mean age was 44.96 years 
(range 25-64), 18 were females and 8 males, the mean disease duration was 12.6 
years (range: 1-33), and the median EDSS 1.5 (range 1-6.5). A group 26 age 
and gender matched healthy controls with a mean age of 43.08 years (range: 
27-65), consisting of 14 females and 12 males, with no known neurological or 
psychiatric conditions, was also included. Patients also underwent cognitive 
tests, of which the following were used for this study: the symbol digit 
modalities test (SDMT)15, a story recall and the Paced Auditory Serial Addition 
Test (PASAT)16 as they were considered the most relevant in this context17. 
Clinical, cognitive and demographic data for the two groups are given in Table 
4-1. 
 RRMS patients Healthy controls 
Age (years) 44.96±10.03 43.08±8.92 
Gender (F/M) 18/8 14/12 
Median EDSS (range) 1.5 (1-6.5) N/A 
Disease duration (years) 12.6±9.58 N/A 
WM PD/T2 LL (ml) 13.64 ±18.148 N/A 
SDMT 49.28±14.44 N/A 
PASAT 33.69±18.71 N/A 
Story recall 30.88±11.90 N/A 
Abbreviations: EDSS: Expanded Disability Status Scale; WM PD/T2 LL: white matter PD/T2 lesion 
load. Values are means unless otherwise indicated 
All subjects were scanned on a clinical 3T TX Philips Achieva scanner with a 
32-channel head-coil and a dMRI imaging protocol that consisted of 61 b = 
1200 s/mm2 dMRI volumes and 7 non- dMRI (b=0) volumes (voxel resolution 
of 2x2x2 mm3). The number of sampled orientations for the dataset used was 
Table 4-1 Demographic and clinical data  
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61 while the optimised protocol has 30 in the first (low b-value) shell and 60 in 
the second (high b-value) shell. The images were eddy current corrected using 
FSL (FMRIB, Oxford, UK). 
4.2.2 NODDI fitting 
The optimised NODDI acquisition protocol4 requires two high angular 
resolution diffusion imaging (HARDI) shells with b-values of 711 and 2855 
s/mm2, while the data used was acquired with a single shell (b-value: 1200 
s/mm2). To compensate for the absence of a second b-shell, the volume fraction 
of the isotropic compartment was set at 0; this means that that the CSF was not 
fitted in the model used, thus reducing degree of variance in the NDI maps (CSF 
voxels have the default value of 0.70482 in ODI maps and 0 in NDI ones). 
To reduce the time taken for the fitting (6-7 hours), a brain mask based on the 
mean b0 (produced by averaging the seven b = 0 volumes) was created, using 
the BET tool in FSL with the -f value set at 0.3 (and in some cases 0.2) in order 
to ensure that the frontal lobes were fully included. This mask was then 
manually corrected in order to remove the superfluous areas included before 
using it for the fitting, which was thus limited to the brain.  
Two maps, the Orientation dispersion index (ODI) and the Neurite density 
index (NDI), which was called intra-cellular volume fraction (Ficvf) in Zhang's 
paper4, were used for the analysis.  
4.2.3 ROIs approach 
White matter Grey matter (each region in both hemispheres) 
Genu of corpus callosum Frontal lobes (middle or superior frontal gyrus)  
Body of corpus callosum  Occipital lobes (superior occipital gyrus) 
Splenium of corpus callosum Hippocampus 
Posterior limb of the internal capsule 
   
Thalamus (next to trigone of lateral ventricle) 
15 regions of interest (ROI) of 9 voxels commonly affected by MS were 
selected (see Table 4-2) and manually positioned on the mean b0 map using 
Jim v. 6.0 (Xinapse systems, Aldwincle, UK, http://www.xinapse.com). Great 
Table 4-2 Regions of interest used. 
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care was taken to avoid partial volumes in the genu and splenium, and whenever 
possible, the body of the corpus callosum. The broadest part of the posterior 
limb of the internal capsule was chosen for the same reason. Further checks 
were then conducted on both FA and ODI map to ensure that the whole mask 
was within the area of interest. The position of the white matter ROIs can be 
seen in Figure 4-1.  
For the patients, hyperintense lesions had been manually outlined by an 
experienced neurologist on proton density (PD) images using the semi-
automated edge finding tool from Jim v6.0. The lesion masks were then 
registered to the dMRI space and used to ensure that no ROI mask was 
positioned within a lesion. When that happened or when the lesion was 
sufficiently close to incur the risk of contamination, the position of the ROI was 
Figure 4-1 White matter ROIs: (a) in corpus callosum: genu (green), body (yellow) & splenium (blue); 
(b)-(d): internal capsules in mean B0, FA and ODI maps. 
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changed. There were 6 patients with lesions in the left internal capsules (two 
requiring mask repositioning, together with a patient who had a lesion just 
below the internal capsule), but only two patients with lesions on the right, 
including one who had bilateral lesions.  
Other ROIs repositioning was required in the WM of two patients: one had 
lesions both in the left internal capsule and the genu of the CC, while the other 
one had a lesion close to the body of the corpus callosum. One patient also had 
a highly atrophied corpus callosum, making the positioning of the ROIs in both 
the body and splenium quite difficult, and resulting in the possibility of some 
partial voxels. 
Thalamic ROIs had to be repositioned in one patient, the one with bilateral 
lesions in the internal capsules, who also had enlarged ventricles due to atrophy 
leading to a narrowing of the thalamus. Two other patients had lesions in the 
thalamus, but not in the mask area.  
For the cortical regions, the NDI maps (where CSF values was fixed at 0) were 
also used to ensure there was no CSF contamination of the ROIs (Figure 4-2). 
The thalamus was positioned next to the trigone of the lateral ventricle (Figure 
4-2). Finally, T1 images were used to locate the hippocampus as this cannot be 
done on the mean b0 map due to the low spatial resolution. The following 
procedure was used to ensure correct positioning of the ROI: the shape of the 
Figure 4-2 Grey matter ROIs: frontal lobes (yellow), occipital lobes (purple) and  
thalamus (red) in: (a) mean B0 & (b) NDI maps. 
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peduncles and position in relation to the cerebellum were used as landmarks to 
select the slice in the mean b0 map; the inferior (temporal) horn of the lateral 
ventricle was then compared between the T1 and mean b0 maps in order to 
locate the hippocampus (Figure 4-3).  
Two patients had lesions in the hippocampal region (one on the left and one on 
the right) necessitating some adjustment of the ROIs. Three patients had a lot 
of atrophy in the frontal lobes, one with some in the occipital lobes too. 
Each side of specific structures were analysed separately in order to assess 
lateral differences. Finally, the mean FA, ODI and NDI values for each region 
were calculated using Jim v. 6.0. 
  Statistics for ROIs approach 
The Mann-Whitney U test was used to compare ODI, NDI and FA between 
patients and controls. The correlations between FA, ODI, NDI and clinical 
scores were tested using Spearman's rho correlation coefficient. Results 
associated with p<0.05 were considered significant. 
Figure 4-3 Positioning 
of hippocampal ROI 
with T1 images: (a) & 
(c) axial and sagittal T1, 
(b) & (d) corresponding 
mean B0 slides. The 
cerebellum and the shape 
of the peduncles were 
two key landmarks used 
to identify the 
hippocampus. ( 
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4.2.4 Voxel based morphometry (VBM) approach 
Two important preparatory stages were necessary in order to apply VBM to the 
dataset. The first one was to fill the lesions to ensure they were not affecting the 
analysis since the aim was to detect changes in NAWM. For this purpose, the 
PD-weighted lesion masks underwent a symmetric and full affine co-
registration to the 3D-T1 images, using a pseudo-T1 image generated by 
subtracting the PD from the T2-weighted image18. The affine transformation is 
used to remove size differences between brains, thus making it possible to align 
the different brain maps.  
The lesion masks were then transformed from native space to 3D-T1 space 
using a nearest neighbour interpolation threshold, after which the 3D-T1 images 
were filled using a non-local patch match lesion filling technique19. Next comes 
the most crucial step: the registration. 
 Registration and normalisation 
This stage was necessary because VBM is based on group comparisons, in the 
case of this study, the patients group versus the healthy controls one. This type 
of comparison also meant that it was imperative to get this stage right as any 
distortion or aberration caused by either the registration or the normalisation 
would produce unsound results. As it will become clear below, this phase 
involved much complex processing and finding the right pipeline proved highly 
challenging as can be seen in some of the results shown in Figure 4-4. 
Figure 4-4 Distorted CC                                                                        ODI too blurred to be used 
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In some cases, problems only became apparent at the final stage, when the 
clusters generated by VBM appeared in the ventricles, outside the brain or as 
shown in Figure 4-5, slightly displaced.  
The final version of the pipeline used was as follow: for the patients, the lesion 
filled maps were used for the registration and each of the 61 diffusion-weighted 
images were registered to the non-diffusion-weighted b0. Each subject’s 3D-
T1-weighted images and dMRI data were registered following the protocol 
described in Muhlert et al.5. Pseudo-T1 images computed from the PD/T2-
weighted scans were used as an intermediate step, providing a contrast similar 
to the 3DT1-weighted image.  
Next, the MNI152 template (Montreal Neurological Institute) was registered 
nonlinearly to each subject’s lesion-filled 3DT1-weighted image. Thereafter, 
the 3D-T1-weighted images went through a symmetric and full affine 
registration to the pseudo-T1 image, while the T2-weighted images were 
nonlinearly registered to the dMRI maps. In order to transform the data from 
dMRI-space to MNI space, all the registration were concatenated. 
All the registrations were done using NiftyReg (http://niftyreg.sf.net), a 
software that implements symmetric and inverse-consistent registration, thus 
ensuring that the results are not biased towards the directionality of the 
registration process. The symmetric full affine approach20, with 12 degrees of 
freedom (DOF), which was used is based on the asymmetric block-matching 
The arrow points towards a cluster 
that is very likely to be the corpus 
callosum (CC). 
 
 
Figure 4-5 Displaced clusters. 
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approach initially described by Ourselin and colleagues21. It concurrently 
optimised the forward and backward transformations in an inverse-consistent 
manner. Thus, the 12 DOF transformation were parameterise as 3 translations, 
3 rotations in Euler angles, 3 scaling factors and 3 skew factors, and the full 
matrix was optimized directly. The non-rigid registrations were based on the 
fast free-form deformation (FFD) algorithm22  
An illustration of what that means concretely can be seen in Figure 4-6. This 
shows the key stages of the registration and transformations that were necessary 
in order to apply VBM. 
 Tissue segmentation 
In order to apply VBM, tissue segmentation resulting in the creation of distinct 
grey and white matter maps was necessary. This was done using Geodesic 
Information Flows (GIF)23. For the segmentation, GIF uses a template database 
as sources of information. The data is coded as local graph patches from which 
information propagates in voxel-wise annotations, such as tissue segmentation 
or parcellation, between morphologically dissimilar images. This is achieved 
by diffusing and mapping the available examples through intermediate steps, 
using a spatially-variant graph structure to assess connections first between 
morphologically similar areas and then between subjects from the database of 
images. This process allows the gradual diffusion of information to all the 
subjects, even in the presence of large-scale morphological variability such as 
greatly increased ventricles or brain atrophy, which could be due either to age 
or neurological diseases, and therefore creates more accurate maps. An 
illustration of the process can be seen in Figure 4-7.  
The template database used for this study has 95 MRI brain scans 
neuroanatomically labelled according to the Neuromorphometrics protocol. 
GIF is part of the NiftySeg (http://niftyseg.sf.net) software package and is 
available as online tool at http://cmictig.cs.ucl.ac.uk/niftyweb24.  
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Figure 4-6 Top: the different processing 
stages for VBM, from the creation of the 
pseudo-T1 to the transformation in MNI 
space.  
Bottom: FA, ODI and NDI segmented 
maps used, with the GM in the upper row 
and the WM in the lower one. 
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 Smoothing to parametric maps 
Once the registration and segmentation were completed, the subsequent steps 
followed the normal VBM pre-processing protocol, that is the creation of 
DARTEL (diffeomorphic anatomical registration through exponentiated Lie 
algebra)25 templates and normalisation to MNI space within SPM12 (statistical 
parametric mapping software; www.fil.ion.ucl.ac.uk/spm/software/spm12/, 
London, UK), with age and gender as covariates. Smoothing was done with a 
Gaussian FWMH (full width at half maximum) of 6x6x6 mm26. Both 
procedures were necessary in order to be able to obtain the parametric maps. 
The factorial design used for the statistics involved a two samples t-test, with 
age and gender entered as covariates and an explicit mask used to limit the 
analysis to the average grey or white matter tissue maps (based on the averaged 
SW segmented maps, thresholded at 0.15 and binarised). 
The contrasts used to generate the clusters were Patient values lower than 
Controls values and Patients values higher than Controls values in the GM and 
NAWM of FA, ODI and NDI maps. In each case, the family wise error (FWE) 
Figure 4-7 Stepwise information flows in geodesic propagation, between the neighbours of the target 
subject (adapted from Cardoso [et al]23) Copyright © 2015, IEEE. 
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correction was applied, with p set at 0.005 and only clusters with more than 15 
voxels used. The peak voxel of each of these clusters was spherically expanded 
to 8 voxels in diameter and the new masks were checked and manually 
corrected when they expanded beyond WM or GM. Figure 4-8 illustrate the 
process from the original clusters to the spherical masks.  
The correlations between FA, ODI, NDI and both clinical and cognitive 
assessments were tested using Spearman's rho correlation coefficient. Results 
associated with p<0.05 were considered significant. 
(a) 
(b) (c) 
Figure 4-8 VBM clusters and spherical masks. (a) Glass brain showing ODI WM clusters, (b) 
two of the clusters superimposed on the WM ODI map, (c) the spherical masks corresponding 
to the same clusters. The bottom one is an example of mask requiring manual corrections.  
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The regions in which the clusters/masks were localised were identified using 
the following atlases: 
 JHU ICBM-DTI-81 white-matter labels atlas. 
 JHU white-matter tractography atlas. 
 Jülich histological (cyto- and myelo-architectonic) atlas. 
 Harvard-Oxford Subcortical Structural Atlas (for deep GM). 
4.3 Results 
4.3.1 ROIs results 
The full results for all the ROIs used are shown in Table 4-3. In FA maps, 
values for patients were higher than controls in the right internal capsule (0.7 
vs 0.65, p=0.03). In ODI maps, values for patients were lower not only in the 
right internal capsule (0.13 vs. 0.16. p=0.0001), but also in the left internal 
capsule (0.13 vs 0.15, p=0.018) and the genu of the corpus callosum (0.08 vs 
0.10, p=0.023). Finally, in the NDI maps, patients values were lower in the genu 
of the corpus callosum (0.64 vs. 0.71 p=0.024) and in the right and left occipital 
cortex (0.54 vs. 0.60, p=0.023 and 0.52 vs. 0.58, p=0.041). 
For NDI, data from the left occipital lobe of 4 controls had to be excluded: the 
values were abnormally low when compared to the right occipital lobe. When 
the ROIs were checked, it became clear that their position were significantly 
different from the b0 maps, as can be seen in Figure 4-9. If all the ROIs are 
used, the average value for the left occipital lobe ROI in healthy controls is 0.54, 
while it is 0.60 on the right. To ensure that the problem was specific to the 
subjects with low values, the ROIs were also checked in the other controls NDI 
maps. The position of the ROIs in the NDI maps was very similar to those in 
the b0 ones. 
Correction for multiple comparisons was not deemed necessary as the ROIs 
used for comparisons between patients and controls were specifically placed in 
areas known to be affected by MS. This method, unlike a generic exploratory 
approach involving the whole brain, has a low likelihood of false positives. 
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Possible correlations between FA and ODI were also explored. In both patients 
and controls, lower FA values were associated with higher ODI ones for the 
majority of the ROIs (see Figure 4.10). NDI does not relate to FA in the way 
ODI does, so no correlation analysis was necessary there. In both patients and 
controls, negative correlations between FA and ODI were found in all GM 
regions (p=0.0001) and right internal capsule (for patients: Spearman’s rho:=-
0.54, p=0.004; for controls: r=-0.50, p=0.01). In controls, the left internal 
capsule ODI (r=-0.48, p=0.01) also correlated with FA. 
 
FA ODI NDI 
Patients Controls Patients Controls Patients Controls 
Mean 
(SD) Mean (SD) 
Mean 
(SD) Mean (SD) 
Mean 
(SD) Mean (SD) 
CC body 0.68  (0.11) 
0.70 
(0.049) 
0.12 
(0.031) 
0.13 
(0.020) 
0.63  
(0.17) 
0.68 
(0.097) 
CC genu 0.75 (0.081) 
0.77 
(0.050) 
0.086 
(0.033) 
0.10 
(0.021)* 
0.64  
(0.11) 
0.71 
(0.10)* 
CC splenium 0.74 (0.077) 
0.77 
(0.055) 
0.062 
(0.039) 
0.071 
(0.026) 
0.56 
(0.094) 
0.61 
(0.057) 
Left internal 
capsule 
0.67 
(0.066) 
0.64 
(0.051) 
0.13 
(0.025) 
0.15 
(0.024)* 
0.64  
(0.11) 
0.62 
(0.068) 
Right internal 
capsule 
0.71 
(0.057) 
0.65 
(0.054)* 
0.13 
(0.023) 
0.16 
(0.01)** 
0.70 
(0.071) 
0.69 
(0.069) 
Left frontal lobe 
left 
0.14 
(0.039) 
0.14 
(0.039) 
0.55 
(0.080) 
0.54 
(0.090) 
0.53 
(0.090) 
0.54 
(0.164) 
Right frontal lobe 0.13 (0.034) 
0.14 
(0.049) 
0.55 
(0.065) 
0.53 
(0.082) 
0.50  
(0.15) 
0.49  
(0.11) 
Left occipital 
lobe 
0.14 
(0.041) 
0.16 
(0.039) 
0.58 
(0.069) 
0.41 
(0.053) 
0.52 
(0.091) 
0.58 
(0.065)* 
Right occipital 
lobe 
0.16 
(0.042) 
0.18 
(0.049) 
0.56 
(0.065) 
0.43 
(0.046) 
0.54  
(0.11) 
0.60 
(0.072)* 
Left thalamus  0.26 (0.051) 
0.23 
(0.038) 
0.37 
(0.087) 
0.57 
(0.069) 
0.55 
(0.042) 
0.54 
(0.046) 
Right thalamus 0.26 (0.051) 
0.24 
(0.036) 
0.41 
(0.085) 
0.55 
(0.072) 
0.58 
(0.040) 
0.59 
(0.058) 
Left hippocampus  0.15 (0.065) 
0.13 
(0.041) 
0.53 
(0.087) 
0.56 
(0.097) 
0.48 
(0.096) 
0.48 
(0.061) 
Right 
hippocampus 
0.15 
(0.064) 
0.13 
(0.030) 
0.55   
(0.12) 
0.58 
(0.081) 
0.48 
(0.067) 
0.49 
(0.062) 
*p <0.05, **p<0.01, Mann Whitney test.  
Table 4-3 Results for the different ROIs in FA, ODI and NDI 
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For the correlations with clinical data in patients, no correlation were found 
between any of the MRI parameter and EDSS score in the ROIs data from FA 
and ODI maps. However, lower NDI values in the right occipital cortex 
correlated with longer disease duration (Spearman’s rho: -0.448, p=0.022).  
 
Figure 4-10 Occipital lobe ROIs in NDI and B0 maps, with average values for NDI showing differences 
between left and right hemisphere. 
Figure 4-9 Graph showing the correlations coefficients between FA & ODI values for the different ROIs. The 
body & genu of the CC, the two ROIs for which values did not correlate in both patients & controls, are clearly 
visible. In patients, the values for the left internal capsule & the right frontal lobe were also not correlated. r 
values ≧ - 0.4 are significant (p≦0.035). 
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4.3.2 Voxel-based morphometry results 
 
FA (Patients>Controls) 
Localisation Correlations 
Cluster 
1 
Body of the corpus callosum (towards 
the splenium)1. 
Delayed story recall (r= 0.548, p=0.006) 
and the Symbol Digit Modalities Test 
(SDMT) (r= 0.469, p= 0.021). 
Cluster 
2 
Left anterior corona radiata1 and left 
inferior fronto-occipital fasciculus2. 
SDMT (r= 0.484, p= 0.017) 
Cluster 
3 
Right posterior thalamic radiation, 
including optic radiation1 and right 
fronto-occipital fasciculus2. 
SDMT again (r= 0.741, p>0.001) and 
disease duration (r= -0.527, p= 0.007) 
 
ODI (Patients<Controls) 
Localisation Correlations 
Cluster 
1 
Left optic radiation, connecting to 
primary (V1) and secondary (V2) visual 
cortex3 and left forceps major, left 
inferior longitudinal fasciculus and left 
inferior fronto-occipital fasciculus2. 
Delayed story recall (r= -0.548, p=0.006) 
and EDSS score (r= 0.428, p= 0.033) 
Cluster 
2 
Right forceps major, right inferior 
longitudinal fasciculus and right inferior 
fronto-occipital fasciculus2, possibly 
connecting to secondary visual cortex3. 
Paced Auditory Serial Addition Test 
(PASAT) (r= 0.434, p=0.030) and SDMT 
(r= -0.526, p= 0.028) 
Cluster 
3 
Body of the corpus callosum (very 
central when looking at length of CC)1, 3. 
SDMT (r= -0.483, p= 0.017) and disease 
duration (r= 0.625, p= 0.001) 
Cluster 
4 
Right inferior longitudinal fasciculus2, 
possibly connecting to V43. 
Delayed story recall (r= -0.428, p=0.037) 
and SDMT (r= -0.467, p= 0.021) as well as 
EDSS score (r= 0.516, p= 0.008). 
Cluster 
5 
Right posterior thalamic radiation, 
including optic radiation1, right inferior 
fronto-occipital fasciculus, right inferior 
longitudinal fasciculus, right superior 
longitudinal fasciculus and right forceps 
major2,  possibly connecting to V23 
Age (r= -0.470, p= 0.018) 
 
NDI (Patients<Controls) 
Localisation Correlations 
NAWM 
Splenium (left, but very close to 
midline)1, left forceps major2, body of the 
corpus callosum3 
No correlation found 
GM Left hippocampus4 Delayed story recall (r= -0.429, p=0.032 and SDMT (r= -0.551, p=0.004). 
Table 4-4 Localisation of the clusters and correlations in FA, ODI, and NDI maps. The clusters are listed 
by decreasing size. Comparison between each clusters and all cognitive tests were made. Only those for 
which a significant correlation with the cluster was found are reported here. 
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Clusters showing areas of differences between patients and healthy controls 
were found in all three maps, however the exclusion of clusters of less than 15 
voxels only apply to the ODI maps, which were also the maps in which the 
largest number of clusters were generated. The full results are given in Table 
4-3. Clusters were found in all maps for the NAWM, and one cluster was found 
in the GM in NDI maps. In FA maps, the values were lower for patients than 
controls, while the opposite occurred in the ODI and NDI maps, were values 
were higher for patients than controls.  
As the family wise error (FWE) correction incorporated in SPM was applied 
when using VBM to identify clusters where values differed between patients 
and controls, further corrections for multiple comparisons was not necessary. 
However, without FWE, such corrections would have been necessary due the 
high level of false positives produced by VBM when generating uncorrected 
clusters map. 
Correlations with clinical and cognitive data were found for all the clusters with 
the exception of the one found in the corpus callosum in NDI maps. EDSS and 
disease duration were the two clinical measurements that most commonly 
correlated with the areas where differences between patients and controls were 
found, while for the cognitive assessments, the most common correlations were 
with SDMT and the delayed story recall. The full results for both the clinical 
and cognitive data correlations are shown in the right column of Table 4-3. 
 Discussion 
Both NODDI and DTI (on which FA is based) can be used to highlight changes 
in brain microstructure, particularly areas of damage not visible with 
conventional sequences. To understand the import of the results from both 
approaches, and whether or not NODDI provides convincing results and how it 
compares to more traditional approach such as FA, it is worthwhile to briefly 
revisit what the different maps are measuring.  
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Fractional anisotropy, or FA, reveals the incidence of diffusivity along one 
direction and will therefore be higher in areas with large tracts and few crossing 
fibres. Subsequently, areas with a large amount of crossing fibres or fanning 
axons will have lower FA values, which is why results from FA maps require 
cautious interpretation. Nevertheless, overall, a decrease in FA has been found 
in NAWM of MS patients27,28: it has been suggested that these decreases are 
associated with demyelination and changes in axonal integrity, including 
Wallerian degeneration, as well as other types of NAWM damage, such as a 
diffuse axonopathy29-31. However, there also appears to be a general agreement 
about a lack of specificity when it comes to the type of changes underlying a 
decrease in FA values32-34. A further point of discussion is whether changes 
detected in NAWM using FA maps are linked to the occurrence of lesions or 
develop separately30,31. 
This leads to the question of whether the indices provided by NODDI could be 
more specific as well as more sensitive than FA measurements. Clearly from 
the results of this study, ODI in particular appears to have a greater sensitivity 
to subtle changes in NAWM. ODI indicates the degree of dispersion of axons 
and dendrites and NDI the density of axons and dendrites, both based on an 
intracellular compartment model. The fact that ODI is inversely correlated to 
FA4,35, thus suggesting that an increase in axonal dispersion underlie a decrease 
in FA, is a further illustration of the lack of specificity of FA metrics mentioned 
above. However, while ODI may offer further information on fibres orientation, 
and therefore resolved one of the issues linked to FA (i.e. the link between 
increased neurite dispersion and decreased FA), it does not appear to be affected 
by the degree of myelination. In a study looking at myelin density in a mouse 
model, as well as comparing imaging results with histological data from human 
brains, Sepehrband and colleagues show that their evaluation of myelin density 
only had a weak correlation with ODI metrics35. In other words, ODI maps 
provide additional information on tissue microstructure, but only about the 
degree of axonal dispersion found within a specific voxel rather than on the 
condition of myelin. This does not make the information obtained from ODI 
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maps of less interest, but should be kept in mind when interpreting the meaning 
of the results. Nevertheless, the increase in axonal dispersion that underlies not 
only ODI, but is also likely to be an important factor in FA36, may well be due 
to axonal or dendritic loss (the latter would potentially explain the greater 
sensitivity of ODI maps when compared to FA observed in this study). 
Moreover, such changes in tissue microstructure are clinically relevant in their 
own rights. 
The decrease in ODI values, together with the decrease in NDI, found in the 
genu of the corpus callosum with the ROIs approach is the most unexpected 
one. In a study looking at different parts of the corpus callosum, Lin and 
colleagues found reduced FA in the genu37, which is what would be expected 
and would likely correlate with an increase in ODI. Clearly, the decrease in 
axonal dispersion detected is likely to be due to changes in the degree of fanning 
that characterise this area of the CC. Such changes may well be caused by 
axonal loss, which in turn would explain the decrease in density detected by the 
NDI metrics. 
On the other hand, the increased ODI found in the body corpus callosum 
detected with VBM, which was also found in a study applying NODDI to 
Alzheimer’s disease (AD)6, is likely to reflect the increased disorganisation of 
fibres, possibly due to a reduction of axonal volumes as there was also a 
decrease in NDI values. It is worth noting that the changes in the body of the 
corpus callosum were also detected in the FA maps when VBM was used, but 
the two NODDI metrics give a more precise indication of the likely cause 
underlying such changes.  
The reason why there were so few areas of differences detected by NDI metrics 
is likely to be due to the fact that NDI estimates of the neurite density is based 
on the intracellular volume as a fraction of the non-CSF compartment4 and the 
proper fitting of this compartment was severely limited by the impossibility to 
fit the CSF when using single-shell data. Consequently, it is very likely that this 
partial fitting significantly reduced the sensitivity of the NDI maps, and 
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therefore reduced the amount of data that could be extracted from these maps. 
Nevertheless, since the clusters are located in areas known to be affected by 
MS, they can be regarded as valid, but are likely to be an underestimation. 
Additionally, as noted above, the axonal dispersion underlying ODI is an 
important component of FA. Zhang and colleagues clearly showed that this fact 
led to an inverse correlation between FA values4, something that was found in 
this study too, showing that single-shell ODI metrics closely match those 
obtained from an optimised multiple-shells protocol. 
A final result from the ROIs approach that requires some comments is the 
increased FA found in the right internal capsule. As already mentioned, the most 
common change detected in FA of MS patients NAWM is a decrease, as was 
the case with the VBM results, therefore this result may seem surprising. Still, 
a similar asymmetrical difference was found by Roosendaal and colleagues38 
using TBSS. They suggest that the increased FA may be due to brain atrophy 
and subsequent impaction of WM fibres. Another possible explanation may be 
a loss of crossing fibres, as there is a clear reduction in the fibres dispersion 
since the ODI values for the internal capsules were lower in patients than 
controls in both hemispheres.  
The only results found in grey matter were from the NDI maps, which is not 
surprising as a change in neurite density is easier to measure in the intricate GM 
than a decrease or increase in dispersion. Moreover, both results are in areas 
that are known to be affected by MS. The ROIs in the occipital lobe were in the 
area of the primary visual cortex (V1), in which abnormalities such as 
degeneration and atrophy have been detected by previous studies39,40. Similarly, 
the hippocampus has likewise been shown to be affected by demyelination41-43. 
Interestingly, while most studies find bilateral changes, Audoin and 
colleagues40 also found MTR changes solely in the left hippocampus of MS 
patients. 
Overall, it is also interesting to note that the results obtained with VBM in both 
the FA and ODI maps are very similar to those obtained using TBSS on FA 
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maps by Roosendaal and colleagues38, thus offering further evidence of the 
validity of single-shell NODDI results. Interestingly they also looked at 
correlations with cognitive assessments, if different ones from those used in this 
study, and found correlations between a letter-digit substitution test and a 
decrease in FA in the left side of the body of the CC. 
Numerous correlations were found between the results obtained using VBM 
and cognitive assessments. How do they compare with other studies? And can 
it be said that they offer further evidence that single-shell NODDI can provide 
useful information? Of particular interest is the large number of areas found to 
correlate with SDMT: the three areas of changes detected by FA, three of the 
five ones detected by ODI and the left hippocampus with NDI. This fits well 
with the fact that SDMT has been shown to be particularly sensitive when 
applied to MS patients, which is one of the reasons why it was chosen for the 
Brief International Cognitive Assessment for MS (BICAMS)44. One of the areas 
with which it correlates is the corpus callosum, in which changes have been 
repeatedly correlated with multiple cognitive assessments28, but also 
specifically with SDMT45-48. Similar NAWM areas have been found by studies 
looking at cognitive deficit in MS, using SDMT and other tests49,50, including 
one also showing a correlation with the hippocampus51. So for this part too, the 
results obtained from the single-shell NODDI metrics can be considered 
reliable, which is particularly encouraging since all areas of change detected 
with ODI also correlated with cognitive or clinical measurements. 
Altogether, NODDI metrics in general, and ODI in particular, were more 
sensitive than FA, something which was also found in a study of microstructural 
changes related to ageing that used a multiple HARDI shells protocols, offering 
further evidence that the results obtained from single shell data mirror those 
ensuing from an optimised acquisition protocol52. 
ROIs vs VBM: The ROIs approach was part of the initial exploratory section of 
the study, used to find out whether the application of NODDI to single HARDI 
shell data was feasible, and the results from this stage led to the decision to 
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apply VBM in order to gain further understanding of what could be achieved 
with NODDI. The fact that in this case the VBM approach was the most 
sensitive and also detected more areas in NAWM where changes occurred in 
patients makes the use of this approach especially worthwhile.  
It should be noted that while, just as was the case with the ROIs approach, more 
areas of change were detected by ODI metrics than FA, there is one area, the 
corona radiata, which was detected in FA maps only. This suggests that there 
may even be a degree of complementarity between FA and the NODDI metrics, 
as in this case the decrease in FA was not caused by an increase in neurite 
dispersion. 
As for the reason why the results differ between ROIs approach and VBM, it is 
likely to be connected to the transformations, smoothing and statistical 
significance thresholds linked to FWE correction necessary for the application 
of VBM, which would make changes occurring in small regions less detectable. 
Billet and colleagues made a similar observation when they compared their 
ROIs and voxel-based analyses36. It is however surprising that VBM detected 
changes in the body and splenium of the corpus callosum that were not detected 
by the ROIs approach. However, the latter was potentially limited by the small 
size of the ROIs used, and it is quite possible that if an ROI incorporating the 
whole splenium had been used, the same differences could have been found. As 
far the body of the corpus callosum is concerned, the large amount of atrophy 
observed in some patients may also have contributed to the VBM results. 
4.5 Conclusion 
The results from both the ROIs and VBM approaches demonstrated that 
NODDI can be applied to single HARDI shell data and that ODI and NDI may 
detect regions of diffusion abnormalities in RRMS patients that are not visible 
in FA maps. Furthermore, the areas detected in NODDI maps with VBM 
revealed correlations with both cognitive and clinical measurements, showing 
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that they are clinically relevant. This means that NODDI can be retrospectively 
applied to existing dataset for new analyses.  
Future studies, with either single or multiple HARDI shells protocols could use 
NODDI for differentiation between MS and NMO, in particular to look for 
subtle changes in normal appearing WM, especially in the early stages of both 
diseases. Multiple-shells protocols may also detect more changes in normal 
appearing GM, as the fitting of the CSF compartment will provide more 
sensitive NDI maps. Besides, as suggested by Grussu and colleagues, there may 
well be some limitations in the ODI maps that needs to be kept in mind while 
applying NODDI to single-shell data, in particular if the b-value is low53. Even 
so, this study shows that while keeping limitations in mind is important, 
applying NODDI to single-shell provides new and relevant data when 
compared to FA. 
NODDI is only the first MRI techniques used in this thesis. The next chapter 
will look at the application of phase-sensitive inversion recovery (PSIR) in MS 
and NMO patients with the aim to investigate cortical and leucocortical lesions 
in both groups. 
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Can phase-inversion recovery (PSIR) 
detect cortical lesions in NMOSD patients 
or are they specific to MS? 
 Introduction 
As explained in Chapter 3, phase-sensitive inversion recovery (PSIR) is a 
reconstruction technique which allows a very high resolution: for the purpose 
of this study, the voxel size is 0.5x0.5 mm in-plane, with 2 mm slice thickness. 
The other advantage of this technique is that it has a high contrast, making it 
possible to detect lesions not visible with other MR techniques, especially in 
the cortical grey matter. Cortical lesions are particularly difficult to detect as 
they do not enhance after gadolinium administration and have been shown by 
post-mortem studies to be highly underestimated on MRI1. Even with 7T 
scanner, as a recent study using double-inversion recovery (DIR) to look for 
cortical lesions in MS patients and comparing the results with histology found, 
only about 60% of lesions were detected2.  
While a 2007 study by Nelson and colleagues did not find a significant 
difference in cortical lesions detection when comparing PSIR with DIR in MS 
patients3, a study published in 2012 by Sethi and colleagues showed a threefold 
increase in intracortical (IC) and leucocortical (LC) lesions detection with PSIR 
when compared to DIR4. Similar results were obtained by Favaretto and 
colleagues who found a fourfold detection increase in detection of IC, LC and 
juxtacortical (JC) lesions when comparing PSIR with DIR5. Based on these 
studies, it seemed interesting to look at IC, LC and JC lesions in NMOSD 
patients to see whether any IC or LC lesions would be detected.  
A further point of interest is the ongoing debate on whether or not cortical 
lesions do occur in NMOSD patients: a study by Calabrese and colleagues using 
DIR, published in 2012, did not find any cortical lesion in a group of 30 
115 
NMOSD patients6. Previous studies which looked at cortical atrophy7, or 
applied spectroscopy to normal appearing grey matter did not find changes in 
cortical grey matter8 either, nor did two studies conducted on 7T scanners detect 
any cortical lesions (but they used solely conventional protocols such as T1, T2, 
T2* and FLAIR for one study9, and just T2 for the other10). Only one study, by 
Kim and colleagues11, did detect cortical lesions in NMOSD patients with 
FLAIR, but those Korean patients were much younger than patients in Europe 
or the Americas, ranging from 15 to 36 years, compared to a mean age varying 
from mid-forties to early fifties in most NMOSD studies, thus may have a 
slightly different pathology. Popescu and colleagues provide further evidence 
of the absence of cortical lesions in a study in which histology was performed 
on post-mortem tissues of NMOSD patients and failed to find any intracortical 
or leucocortical lesions, or to detect cortical demyelination12.  
On the other side, a study using diffusion metrics found significantly increased 
mean diffusivity (MD) in the parietal and temporal areas of the cortex13, while 
two studies by Rocca and colleagues also detected changes in GM: one using 
fMRI found significant functional alterations in cortical areas when comparing 
NMOSD patients to healthy controls14, while the other, using magnetisation 
transfer ratio (MTR) combined with MD, also found increased MD as well as 
decreased MTR in normal appearing GM (NAGM)15. Finally, a study by Saji 
and colleagues16, which used histology, confirmed Popescu12 findings that 
cortical demyelination does not occur in NMOSD patients, nor was there any 
oligodendrocyte loss, but they found other changes. Specifically, when 
comparing NMOSD patients to healthy controls, they uncovered an increase 
meningeal inflammation, a loss of AQP4-negative immunoreactivity in 
astrocyte processes of layer I, a decrease in cortical neurons density in layers 
II-IV, as well as a large increase of microglial activation in layer II.  
So can PSIR detect any abnormalities in NMOSD patients cortex or will it 
confirm the 7T studies that there is no detectable cortical lesions? 
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 Methods 
 Subjects 
Written, informed consent was obtained from all participant, and this study was 
approved by the NRES Committee London Bloomsbury (Formally London 
REC 2 Ethics Committee). RRMS patients were diagnosed using the revised 
McDonald criteria17, while the NMOSD diagnosis was based on the criteria 
proposed by Wingerchuk and colleagues in 200618. 19 NMOSD patients, aged 
between 21 and 70 years, and 19 MS patients, aged between 26 and 55 years, 
with a similar gender ratio and disease duration, as well as 23 healthy controls, 
aged between 23 and 68 years, were consecutively recruited. 17 of the NMOSD 
patients were AQP4 positive, while one of the two AQP4 negative was MOG 
positive. The full details for each group are given in Table 5-1.  
 RRMS patients 
n=19 
NMOSD patients 
n=19 
Healthy controls 
n=23 
Age (years) 41.28 ±9.86 52.72±11.69 36.87±8.92 
Gender (F/M) 15/4 16/3 12/9 
Median EDSS (range) 2.5 (1-7.5) 4.25 (2-6.5) N/A 
Disease duration 8.83±6.20 7.89±6.92 N/A 
AQP4+ N/A 17 N/A 
Table 5-1 Demographic and clinical data. 
 
5.2.1.1  Exclusions 
Three NMOSD patients and one MS patient had to be excluded as the amount 
motion artefacts rendered the scans uninterpretable. In one case, the patient kept 
her head still for half of the scan, but because of the two separate interleaved 
acquisitions, there was a succession of one good quality slice followed by a 
blurred one (Figure 5-1), making it impossible to assess whether a lesion was 
going over more than one slice or checking whether it could be an artefact, an 
important issue in some regions as will become clear below. Therefore the 
whole scan was excluded. 
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 Image acquisition 
The brain MRI scans were acquired on a 3T Achieva system with dual-transmit 
technology (Philips Healthcare, Best, The Netherlands) using a 32-channel coil. 
For the purpose of this study, both a T2-weighted turbo spin echo and PSIR 
scans were acquired, using the following sequences: 
(i) axial 2D turbo-spin-echo (TSE) PD/T2-weighted sequence, with TR 
= 3500 ms; TE1/TE2 = 15/85 ms; echo train length = 10 echoes; 
FOV = 240×180 mm2; voxel size = 1×1×3  ml; number of 
excitations (NEX) = 1; 50 contiguous slices, and  
(ii) axial 2D turbo-spin-echo (TSE) IR sequence with phase-sensitive 
reconstruction, with TR = 7304 ms; TE  = 13 ms; TI = 400 ms; echo 
train length = 8 echoes; FOV = 240×180 mm2; voxel size = 
0.5×0.5×2  ml; number of excitations (NEX) = 1; 75 contiguous 
slices. 
 Lesions marking 
The lesions in the PD/T2 scans were marked by two neurologists, Dr Floriana 
de Angelis and Dr Rosa Cortese, using JIM version 6.0 (Xinapse systems, 
http://www.xinapse.com). The lesion load from these scans was used for 
comparative purposes and to calculate the percentage of juxtacortical lesions. 
Five types of lesions were marked on the PSIR scans and are defined as follow: 
intracortical (IC), leucocortical (LC), juxtacortical (JC), deep grey matter 
(DGM) and cerebellar (CB). Intracortical lesions were entirely located in the 
cortex, while leucocortical ones either involved both cortex and juxtacortical 
white matter or the lesion border appeared to break the GM-WM boundary. 
Finally, juxtacortical lesions involved white matter only, directly abutting the 
cortex but without any cortical involvement. For the last two categories, deep 
grey matter ones were those found in any DGM structures, while those found 
in the cerebellum were not separated in GM and WM categories due to their 
rarity. 
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The lesions marking was done blindly to disease type, using JIM version 6.0 
(Xinapse systems, http://www.xinapse.com), and was checked throughout for 
quality assurance by an experienced neuroradiologist, Professor Tarek Yousry. 
Careful attention was paid to avoid marking artefacts (Figure 5-2a), which were 
often observed in regions such as the insula, anterior temporal lobes and medial 
frontal lobes. For this purpose, the slices adjacent to suspected lesions were 
crucial, and one of the key reasons why interleaved blurred slices made whole 
scans unusable. A further potential source of error was the iron deposits in the 
basal ganglia, which look like lesions as can be seen in Figure 5-2b. Another 
common occurrence that initially caused confusion was the high visibility of 
perivascular or Virchow-Robin spaces, which appear in increased numbers in 
MS patients19 and can easily be mistaken for lesions20, as can be seen in Figure 
5-3. 
(a)  
Figure 5-2 (a) Easily identifiable artefact due to the presence of other artefacts in the skull, but also a 
good illustration of how similar to lesions they can appear; (b) Iron deposits & PVS in deep grey matter. 
(b) 
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There had been very few previous studies using PSIR to look at MS patients 
lesions, and none to look at NMOSD patients. Therefore the guidelines applied 
to identify cortical lesions independently on PSIR were those proposed by Dr 
Varun Sethi and Professor Tarek Yousry in 201221, which for the cortical and 
leucocortical lesions, were as follow: 
• Lesions are hypointense relative to the surrounding normal cortex. 
• They must involve the cortex in part or whole, and have the following 
characteristics: 
a) Be confined to the cortex to be classified as intracortical (IC). 
b) If it involves both cortex and juxtacortical WM, it is classified as 
leucocortical (LC) 
• If it is small or ill-defined on a single slice, it must be visible on at least 
one other contiguous slice. 
• Equivocal lesions must be confirmed through retrospective detection of 
signal abnormality compatible with a lesion found at the same location 
on the corresponding T2-weighted images. 
Figure 5-3 Examples Virchow-Robin spaces (VRS) (arrows). In the second images, only 3 VRS have an arrow, 
but more can be seen, in particular in similar places in the other hemisphere. 
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They also proposed the following exclusion criteria: 
• Partial volume effects caused by adjacent cerebrospinal fluid, verified by 
reviewing adjacent PSIR slices and corresponding T2-weighted scans. 
This issue is particularly common in sulcal regions, as well as at the 
temporal poles and near the vertex. 
• Artefacts, which can at times be recognised by their symmetrical 
appearance. 
• Vessels, visible as very thin linear hypo-intensities, especially when they 
do not follow the direction of the cortical ribbon. Cortical lesions can 
also have a curvilinear or linear appearance, but are less thin and always 
follow the direction of the cortical ribbon. 
• Virchow-Robin spaces, which are particularly common in regions such 
as the insula and temporal poles. This is particularly true when linear and 
numerous, giving them a mesh-like or bundle-like appearances (seen in 
both patients and controls). 
Figure 5-4 Two slices in the same MS patient showing the large confluent lesions that were excluded from the 
analysis. These lesions extended over multiples slices and had a total volume of 0.2871 ml. 
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An additional exclusion criterion specific for this study was used in the case of 
one MS patient who had very large confluent lesions, which were juxtacortical 
in some slices (Figure 5-4). Since this type of lesions does not occur in 
NMOSD patients, their inclusion as JC lesions would have greatly increased the 
difference between the two groups and therefore biased the analysis. For this 
reason, these lesions were excluded from the analysis. 
In order to assess how the different types of lesions may differ between MS and 
NMOSD patients, we looked at the following criteria: 
• Numbers of lesions of each types (IC, LC, JC, DGM and CB) in each 
patient. Since the number of lesions given by JIM is dependant on the 
number of slices on which lesion masks have been inserted (a lesion 
going over 3 slices for example will be counted as 3 lesions), the number 
of lesions were manually counted so that lesions running over multiple 
slices were considered as a single lesion. This also make it possible to 
calculate an average lesion volume for each type of lesion. 
• The total lesion load for each specific type of lesions. 
 Statistics 
Multiple linear regressions adjusted for age and gender were used to compare 
the different types of lesion between MS and NMOSD patients. The following 
comparison were made: 
• T2 lesion load in MS and NMOSD. 
• Lesion load for each type of lesions (IC, LC, JC, DGM and CB) in MS 
and NMOSD. 
Results associated with p<0.05 and 95%CI were considered significant. 
For the comparison of the numbers of lesions found at each location (IC, LC, 
JC, DGM and CB) in MS and NMOSD patients, negative binomial regression 
was used. Negative binomial regression is similar to Poisson regression, used 
for counts and rate, with the advantage that negative binomial regression can 
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allow for between-subject differences in probability of having a lesion. These 
negative binomial models report ratios of lesions counts. 
The last part of the statistics did investigate the lesion types as potential markers 
of NMOSD vs MS for diagnosis. For this purpose, logistic regression with the 
following markers was used: T2 lesion loads and for each type of lesions 
marked in the PSIR images, the lesion loads and lesion numbers. Odds ratios of 
patients being MS rather than NMOSD were then calculated from the fitted 
model coefficients. Finally, the classification performance of the model used 
was assessed with a probability cut off of 0.5. 
 Results 
As can be seen from Table 5-2, each type of lesions was found in both groups, 
including intracortical ones, but all were much more common in MS patients 
than in NMOSD ones. Examples of each types of lesions from both groups of 
patients can be seen in the figures below: intracortical in Figure 5-5, 
leucocortical and juxtacortical in Figure 5-6, cerebellar in Figure 5-7 and deep 
grey matter in Figure 5-8. Both deep grey matter and cerebellar lesions were 
rare, and in the case of the latter, two patients had what appear to be atypically 
large lesions (Figure 5-7, (d) & (e)), but due to the small number of patients 
affected, it is not possible to assess how unusual such lesions are. 
 RRMS patients NMOSD patients 
WM PD/T2  19/19  17/19 
PSIR IC  16/18  6/16 
PSIR LC 12/18  4/16 
PSIR JC  14/18  6/16 
PSIR DGM 4/18  1/16 
PSIR CB 6/18  3/16 
 
 
 
Table 5-2 Number of MS and NMOSD patients in whom lesions were detected on 
the PD/T2 and PSIR scans. WM: white matter; IC: intracortical; LC: leucocortical; 
JC: juxtacortical; DGM: deep grey matter; CB: cerebellum.       
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The full data for the lesion load, lesion numbers for each type of lesions are 
given in Table 5-3.The average PD/T2 lesion load was much higher in MS 
patients than NMOSD ones, as was to be expected: 5.080±4.841 ml vs 
1.049±1.550 ml respectively, a highly significant difference of 4.030 ml (95% 
CI 1.596, 6.465), p=0.002. This value is the unadjusted difference as it was not 
significantly affected by adjustments for age, gender and duration, the same 
apply to the subsequent results.  
As can be seen from the data in Table 5-3, the standard deviations for both 
group were high, particularly so for the NMOSD group. From individual 
patients data given in Table 5-4 and Table 5-5, it is very clear that there was a 
lot of variation between patients PD/T2 lesion load. In MS patients it was 0.125 
ml to 14.774 ml, while in NMOSD patients with PD/T2 lesions it ranged from 
0.00350 ml to 5.234 ml. 
Figure 5-5 Examples of intracortical lesions: (a) & (b) in MS patients, (c) & (d) in NMOSD patients. 
(a) (b) 
(c) (d) 
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(a) 
(c) (d) 
(e) (f) 
(b)  
Figure 5-6 Examples of leucocortical (red) and juxtacortical (blue) lesions. As can be seen 
from (c) & (d), finding both types of lesions together was not unusual. (a), (c) & (e) are from  
MS patients, (b), (d) & (f) from NMOSD patients. 
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(b) 
(d) (e) 
(a) 
(c) 
Figure 5-7 Examples of cerebellar lesions: (a) & (b) in MS patients, (c) 
in a NMOSD patient; (d) &(e) show what could be atypical lesions due 
to their size in MS & NMOSD patients respectively. 
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 RRMS patients NMOSD patients p values 
WM PD/T2 LL (ml) 5.080±4.841  1.049±1.550 0.002 
PSIR IC LL (ml) 0.118±0.116 0.0353±0.0846 0.025 
PSIR IC, average no of 
lesions (range) 
5.611±4.937  
(0-18) 
2.063±4.3123  
(0-17) 0.033 
PSIR LC LL (ml) 0.164±0.184 0.0290±0.0651 0.009 
PSIR LC, average no 
of lesions (range) 
4.333±4.4985 
(0-13) 
0.938±1.982 
(0-7) 0.05 
PSIR JC LL (ml) 0.560±0.663 0.0616±0.103 0.006 
PSIR JC, average no of 
lesions (range) 
9.222±9.915  
(0-35) 
1.813±3.619  
(0-13) 0.002 
PSIR DGM LL (ml) 0.0265±0.0935 0.00108±0.0043* n.s. 
PSIR DGM, average 
no of lesions (range) 
0.333±767  
(0-3) 
0.125± 0.500* 
(0-2) n.s. 
PSIR CB LL (ml) 0.0447±0.105 0.0225±0.0830 n.s. 
PSIR CB, average no 
of lesions (range) 
1.056±2.014  
(0-6) 
0.5±1.317 
(0-5) n.s. 
The average IC lesion load was also much higher in MS patients than NMOSD 
ones: 0.118±0.116 ml vs 0.0353±0.0846 ml respectively, a highly significant 
difference of 0.0830 ml (95% CI 0.0112, 0.155), p=0.025.  
(a) (b) 
Figure 5-8 Examples of lesions in the deep grey matter: (a) in an MS patient, (b) in an NMOSD 
patient. 
Table 5-3 Results for the different types of lesions.  
WM: white matter; LL: lesion load; IC: intracortical; LC: leucocortical; JC: 
juxtacortical; DGM: deep grey matter; CB: cerebellum; Ave.: average. * indicates data 
coming from a single patient 
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Age Gender EDSS 
Dis. 
Dur.   
(y) 
PD/T2 
LL (ml) % JC 
IC 
lesions 
no 
IC LL 
(ml) 
LC 
lesions 
no 
LC LL 
(ml) 
JC 
lesions 
no 
JC LL 
(ml) 
DGM 
lesions 
no 
DGM 
LL  
(ml) 
CB 
lesions 
no 
CB LL 
(ml) 
21 F 2.5 2.5 5.234 2.43 4 0.070 4 0.0597 7 0.128 0 0 0 0 
50 M 3 10 0.556 33.72 4 0.043 2 0.210  2 0.188 2 0.0172 2 0.0206 
53 F 6 3 0.158 40.50 4 0.059 2 0.0246 5 0.0640 0 0 0 0 
69 F 6.5 2 2.810 Excluded due to motion artefacts 
53 F 6 3 0.0714 0 0 0 0 0 0 0 0 0 0 0 
52 F 4 6 0.00350 0 0 0 0 0 0 0 0 0 0 0 
37 F 4 3 0 0 0 0 0 0 0 0 0 0 1 0.00643 
56 F 6 2 0.610 0 0 0 0 0 0 0 0 0 0 0 
63 F 6.5 14 4.351 3.22 0 0 0 0 1 0.140 0 0 0 0 
41 F 3 4.5 0.398 0 0 0 0 0 0 0 0 0 0 0 
66 M 3.5 15 1.343 27.31 3 0.044 7 0.170 13 0.367 0 0 5 0.333 
51 F 6 6 0.191 0 0 0 0 0 0 0 0 0 0 0 
52 F 2 17 0.385 34.52 0 0 0 0 1 0.0989 0 0 0 0 
48 M 2 7.5 0.0291 0 17 0.340 0 0 0 0 0 0 0 0 
57 F 5.5 4 0.0716 0 0 0 0 0 0 0 0 0 0 0 
54 F 2 4.5 0.287 0 0 0 0 0 0 0 0 0 0 0 
70 F 4.5 10.5 1.613 Excluded due to motion artefacts 
57 F 5.5 29 0.750 0 1 0.00984 0 0 0 0 0 0 0 0 
48 F 6.5 14 0 Excluded due to motion artefacts 
Table 5-4 Full results for NMOSD patients.  
WM: white matter; LL: lesion load; % JC: percentage of LL that is juxtacortical; IC: intracortical; LC: leucocortical; JC: juxtacortical; DGM: deep grey matter; 
CB: cerebellum. The two highlighted patients are AQP4-, the excluded one is MOG+. Results in italics indicate patients with atypical results and in bold patients 
where the average load for that type of lesions was particularly large but the group is too small to say whether the values are atypical.  
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Age Gender EDSS 
Dis. 
Dur.   
(y) 
T2L (ml) % JC 
IC 
lesions 
no 
IC LL 
(ml) 
LC 
lesions 
no 
LC load 
(ml) 
JC 
lesions 
no 
JC LL 
(ml) 
DGM 
lesions 
no 
DGM 
LL  
(ml) 
CB 
lesions 
no 
CB LL 
(ml) 
36 F 4 13 3.132 13.51 6 0.103 8 0.145 13 0.423 1 0.0350 5 0.406 
24 M 4.5 4 6.562 4.46 18 0.354 13 0.537 8 0.292 1 0.0252 0 0 
50 F 2.5 26 7.222 16.52 11 0.212 13 0.322 35 1.193 0 0 6 0.217 
30 F 1.5 6 0.287 0 1 0.0318 0 0 0 0 0 0 0 0 
55 M 7 15 3.378 5.33 2 0.0493 4 0.137 7 0.180 0 0 0 0 
35 F 1 5 2.399 4.99 11 0.187 0 0 1 0.120 0 0 0 0 
48 F 1.5 10 6.465 9.56 4 0.0651 7 0.222 8 0.618 0 0 0 0 
43 F 3 15 14.774 11.77 8 0.115 9 0.465 19 1.738 0 0 0 0 
54 M 7.5 9 0.602 58.49 12 0.380 0 0 7 0.485 0 0 0 0 
54 F 1.5 5 3.868 15.32 5 0.114 2 0.0512 16 0.592 0 0 5 0.0570 
34 M 4 14 1.488 0 6 0.255 1 0.0951 0 0 1 0.0177 0 0 
38 F 1.5 6 0.368 72.97 2 0.0437 2 0.0660 3 0.269 0 0 0 0 
31 F 3.5 2 0.214 0 4 0.0829 0 0 0 0 0 0 0 0 
42 F 1 5 7.814 2.06 1 0.00614 5 0.321 3 0.161 0 0 1 0.0148 
48 F 1.5 5 14.275 9.77 2 0.01378 6 0.110 19 1.394 0 0 1 0.01600 
48 F 2.5 13 0.125 0 0 0 0 0 0 0 0 0 0 0 
47 F 4 5 12.943 17.71 8 0.118 8 0.483 24 2.292 3 0.399 1 0.0945 
26 F 1.5 1 5.524 5.82 0 0 0 0 3 0.321 0 0 0 0 
46 F 2 14 0.734 Excluded due to motion artefacts 
Table 5-5 Full results for MS patients.  
WM: white matter; LL: lesion load; % JC: percentage of LL that is juxtacortical; IC: intracortical; LC: leucocortical; JC: juxtacortical; DGM: deep grey matter; 
CB: cerebellum. Results in italics indicate patients with atypical results and in bold patients where the average load for that type of lesions was particularly 
large but the group is too small to say whether the values are atypical. 
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Just as it was the case for the PD/T2 lesion load, there was a very large 
variability between patients: from 0.00614 ml to 0.380 ml in the 16 MS patients 
with IC lesions and 0.00984 ml to 0.340 ml in the 6 NMOSD patients in this 
category (the highest load is in a patient who also has an unusually high number 
of lesions). The average number of IC lesions was also 2.72 times higher in MS 
patients than in NMOSD ones (95% CI 1.09, 6.82; p=0.033), with a large range 
for each groups too, as the numbers in patient who had lesions ranged from 1 to 
18 in MS patients and 1 to 17 in NMO ones. 
A larger lesion load average in MS patients was also found when looking at LC 
lesions: 0.164±0.184 ml vs 0.0290±0.0651 ml, that is a difference of 0.134 
(95% CI 0.0360, 0.234), p=0.009. Here too, there was an extensive variability 
in load between patients in both groups, ranging from 0.0512 ml to 0.537 ml in 
the MS patients, and from 0.0246 ml to 0.170 ml in the NMOSD patients with 
LC lesions.  
The difference in average lesion numbers too was significant, with 5.79 times 
more LC lesions in MS patients than in NMOSD ones (95% CI 1.70, 19.69; 
p=0.05), again with a large span in MS patients with lesions ranging from 1 to 
17, while numbers were more similar in 4 NMOSD patients who had such 
lesions: 2-7 (three of the patients had between 2-4 lesions). 
The last type of lesions where large numbers were found in MS patients is 
unsurprisingly the juxtacortical ones, where the average lesion load in MS 
patients was 0.560±0.663 ml compared to 0.0616±0.103 ml in NMOSD ones, a 
difference of 0.498 ml (95% CI 0.156, 0.840), p=0.006. Here too, as the 
standard deviations suggest, the variation between patients was very large: 
ranging from 0.120 ml to 2.292 ml in MS patients and 0.0640 ml to 0.367 ml in 
NMOSD patients. 
The difference between the average number of lesions was even larger, as in 
MS patients it was 9.222±9.915 compared to 1.813±3.619 in NMOSD patients, 
that is 5.98 times more JC lesions in MS patients when compared to NMOSD 
ones (95% CI 1.94, 18.38; p=0.002). These numbers also varied a lot between 
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patients, with the patient with the highest number of lesions in both group being 
potential outliers. The range was particularly large in MS patients, from 1 to 35 
lesions, and even if the patient with 35 lesions was considered as an outlier, the 
range still goes to 24. In NMOSD patients, the range was from 1 to 13 lesions, 
or from 1 to 7 if the patient with 13 lesions was considered as an outlier. 
As an exploratory analysis, the percentage of WM lesion load that is 
juxtacortical was calculated for each patient. The results for both groups were 
once again extremely wide ranging, from 2.6% to 72.97% in MS and 2.43% to 
40.50 % in NMO.  
Deep grey matter lesions were extremely rare: they were found in only 4 of the 
18 MS patients and in 1 NMOSD. The average lesion load for the MS patients 
was 0.0265±0.0935 ml, compared to 0.00108±0.0043 ml for the two lesions 
found in the NMO patient. The difference did not reach significance, very likely 
due to a lack of statistical power. The same applies unavoidably to the lesion 
numbers, but even with a larger number of patients, it may not become 
statistically different as three of the MS patients who had this type of lesions 
had only one lesion and the last one had 3, suggesting that the numbers would 
remain very low. The load range was also large, varying from 0.0177 ml to 
0.0350 ml in the patients with a single lesion, while the load for the NMOSD 
patient was 0.0172 ml, and for the MS patient with particularly large lesions 
0.399 ml.  
The last group of lesions, which were rare too, consisted of those found in the 
cerebellum, which were only slightly more common than the deep grey matter 
ones, as they were found in 6 MS patients and 2 NMOSD ones. The average 
lesion load for the MS patients was 0.0447±0.105 ml, compared to 
0.0225±0.0830 ml for the NMO patients. Again, the difference was not 
statistically different. The same unsurprisingly applies to the lesion numbers, 
for which the average for each group were as follow: 0.333±767 in MS patients 
and 0.500±1.317 ml in NMO ones. As for the ranges, 3 MS patients had a single 
lesion, which had a volume between 0.0148 ml to 0.0945 ml, while for the 
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others, two had 5 lesions with a load ranging between 0.0570 ml and 0.406 ml, 
and the remaining one had 6 lesions with a load of 0.217. For the three NMOSD 
patients, one had a single lesion with a volume of 0.00643 ml, one had 2 lesions 
with a lesion load of 0.0206 ml, while the last one had 5 lesions with a lesion 
load of 0.333 ml.  
Some patients appear to have what could potentially be unusually large lesions, 
examples of which are shown in Figure 5-7 (d) & (e), like the MS patient with 
a single lesion that has a volume of 0.0945 ml and the NMOSD patient with the 
5 lesions. The two lesions affecting the cerebellar GM visible in Figure 5-7 (e) 
are particularly good examples as their volumes are 0.163 ml and 0.120 ml. The 
third lesion was only found on this slice and is therefore much smaller (0.0350 
ml).  
The average sizes for each type of lesions was also calculated and are shown in 
Table 5-6. None were significantly different between NMOSD patients and MS 
ones, but here too this may be linked to a lack of statistical power due to the 
small numbers involved. It should also be noted that the average LC lesion size 
in NMOSD is markedly influenced by one patient who has only two lesions, 
but very large ones, and is potentially atypical. If he is excluded, the average 
lesion size decreases to 0.0172±0.00631 ml, and like the other types of lesion 
becomes smaller than the average size in MS patients. 
Table 5-6 Average size for the types of lesions.  
WM: white matter; LL: lesion load; IC: intracortical; LC: leucocortical; JC: juxtacortical; 
DGM: deep grey matter; CB: cerebellum; Ave.: average.  
* indicates data coming from a single patient. 
 
 RRMS patients NMOSD patients 
Average lesion size for IC (ml) 0.0205±0.00918 0.0146±0.00385  
Average lesion size for LC (ml) 0.0330±0.0155 0.0391±0.0441 
Average lesion size for JC (ml) 0.0673±0.0309  0.0653±0.0527 
Average lesion size for DGM (ml) 0.0527±0.0539 0.00861* 
Average lesion size for CB (ml) 0.0423±0.0365 0.0278±0.0337 
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The last stage of the analysis was looking at which types of lesion was the best 
indicator of patients being MS rather than NMOSD. Unsurprisingly, based on 
the lesion loads and lesion numbers results above, it was the juxtacortical 
lesions which came out as the most reliable marker. When looking at the JC 
lesion load, the odd ratio of a patient being MS rather than NMOSD was 2.06 
(p=0.019) per additional 0.1 ml of lesion load, while each additional lesion 
generates an increase in the odd ratio of 1.22, p=0.030. Both set of values were 
then tested to find their sensitivity and specificity, as well as how good they 
would be at classifying the patients. The JC lesion load had a very high 
specificity: 88%, a quite good sensitivity at 72%, and incorrectly classified only 
5 patients out of 34, a 79% correct score. The number of JC lesions proved less 
useful as a marker, since the specificity was down to 81% and the sensitivity to 
56%, with only 68% of patients correctly classified. The effect of age, gender 
and duration was also tested, and while gender and duration did not influence 
the outcomes, adjusting for age substantially improved all results, with 
specificity now reaching 94%, sensitivity at 89%, and the rate of correctly 
classified patients 91%.  
 Discussion 
The difference in the WM lesion load is what is expected22 since these lesions 
need to be nonspecific (i.e. not fulfilling of MS diagnosis criteria) to fulfil the 
criteria for an NMO diagnosis18,23, something which continues to be true for the 
revised criteria published in 201524, with some qualifications since it is now 
accepted that some NMOSD patients will have MS-like lesions.  
Undeniably, the most interesting findings are the detection of both intracortical 
and leucocortical lesions in NMOSD patients. The number of NMOSD patients 
with IC lesions was much smaller than it was for MS: 37.5% compared to 89% 
in MS, and these lesions were also less numerous and of smaller size. This also 
true for the leucocortical lesions, which were found in only 25% of NMOSD 
patients compared to 67% of MS ones, and again were much less numerous. 
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So while the fact that a patient has this type of lesions may not be as good a 
criterion as previously thought to exclude a diagnosis of NMOSD, the lesions 
were clearly different between the groups, with the greater lesion load found in 
MS patients not only linked to the higher number of lesions but also potentially 
to the IC lesions being on average larger in MS patients than in NMOSD ones. 
As mentioned above, the average lesion volume for LC lesions in NMOSD 
patients is markedly affected by a single patient who has two very large lesions. 
Also more data is needed to get enough statistical power to find whether this 
difference is significant or not. These are nevertheless new and interesting 
findings which would warrant further investigations. 
Another interesting difference between groups is in the numbers of LC vs IC 
lesions. Most MS patients with LC lesions have at least as many of them as they 
have IC ones; whereas there is more variations among NMOSD patients. Two 
patients have twice as many IC lesions than they LC ones, while for the 
remaining two, one has the same number for both types and the other is the only 
one with more LC than IC lesions.  
In both groups, a few patients have IC but not LC lesions. The two NMOSD 
ones falling in this category do not have any JC lesions either, even though both 
have deep WM lesions visible on the PD/T2 scans. In the MS group, 4 patients 
fall in this category, two of which also have JC lesions. Again, for all of them 
deep WM lesions were visible on the PD/T2 scans. These differences in lesions 
distribution are interesting as two pathways leading to the formation of cortical 
lesions in MS have been described, only one of which appear to apply to 
NMOSD. The first and most common one is perivenular, with the myelin-
scavenging inflammatory cells proliferating along an inflamed central vein, 
resulting in IC, LC and JC lesions1 as illustrated in Figure 5-9. The second 
comes from leptomeningeal inflammation which, in MS patients, triggers 
plaque-like demyelination in the subpial layer of the cortex. Saji and colleagues 
suggest that the second process is also occurring in NMOSD patients, but 
without causing demyelination16.  
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The distribution patterns of the lesions detected in MS patients may suggest that 
patients with IC lesions but no LC and JC ones have exclusively subpial lesions, 
while in NMOSD the meningeal inflammation may be at the origin of the purely 
IC lesions. However, it appear unlikely to be at the origin of the LC ones as Saji 
and colleagues only found the changes in layers II-IV16. Further histology 
would be required to gain a fuller understanding of potential mechanisms 
behind this type of lesions. 
Since it appears that cortical lesions do indeed occur in NMOSD patients, why 
did previous studies using either MRI or histology failed to find them? To begin 
with the histology study by Popescu and colleagues, they only looked for 
cortical demyelination and did not think that the astrogliosis and neuronal 
pathology they observed in NMOSD patients were particularly relevant, though 
admitting they may underly the imaging abnormalities found in previous 
studies12. So while  their findings about the absence of demyelination were 
confirmed, the lack of examination of other cortical changes identified may 
explain why they did not detect the cortical alterations reported by Saji and 
colleagues16.  
What about the two studies using 7T scanners and the one using DIR? And why 
did Kim and colleagues find cortical lesions on a 3T scanner when none were 
found on 7T? To begin with the study Kim and colleagues11, besides the fact 
Figure 5-9 Formation of IC, LC and JC demyelinating lesions in MS. The meningeal inflammation is 
also thought to be involved in NMOSD cortical lesions, however without causing demyelination. 
(Adapted from Absinta [et al.]1). Reproduced with permission from Nature Publishing Group 
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that the patients were much younger than in most studies, it is also important to 
note the really small number of patient in whom lesions were detected (only 6 
out of 194 or just 3.1%), as well as the fact that these patients were scanned 
during the acute phase of the disease, with only one being treated at that time. 
Furthermore, when four of them had a follow-up scan, they found that the 
lesions had either disappeared or were markedly attenuated, suggesting that 
cortical lesions can only be detected on FLAIR scans during the acute phase. 
This is in agreement with the results of Huh and colleagues, who also found 
some cortical lesions in NMOSD at onset in a cohort of patients with a median 
age of 43.87±12.31 years22. Besides, insofar as 7T scanners are concerned, it is 
important to note that while a higher SNR is achieved, generating images with 
enhanced spatial resolution, it does not necessarily yield higher contrasts 
between lesional and normal appearing tissue25. Consequently, lesions such as 
those found in the cortex may not be visible on either T2, T2* or FLAIR scans, 
even at 7T. As for the last MRI study looking for cortical lesions, it used DIR 
and FLAIR6. Since cortical lesions are likely to be visible on FLAIR scans only 
during the acute phase and, besides the fact that DIR only detects a particularly 
low percentage of cortical lesions4, the absence of demyelination in NMOSD 
cortical lesions is likely to make them be even more elusive on this type of 
scans26. It therefore seems unsurprising that Calabrese and colleagues did not 
find any, as even if they were there, they would not have been detectable.  
The remaining two, much rarer, types of lesions, the deep grey matter and the 
cerebellar ones, are at least non-controversial as they have been previously 
found in both MS and NMOSD patients22,27,28. Moreover, it is not just their 
infrequency that makes them less relevant as potential markers to differentiate 
between the two diseases: two studies made comparisons between MS and 
NMOSD, one looking at lesion frequencies in both DGM and the cerebellum22, 
the other at lesions size in DGM29, and both failed to find any significant 
difference.  
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 Conclusion 
Based on the results of this study, the use of PSIR to look for markers to 
differentiate between MS and NMOSD appears promising. However these 
results need to be validated on a larger cohort. A combination of post-mortem 
scanning and histology would also be particularly interesting in order to gain a 
better understanding of the pathological changes underlying the intracortical 
and leucocortical lesions in NMOSD patients. An analysis of the lesion 
distribution could also be useful, in particular if a post-mortem study is 
envisioned, in order to find out if lesions in NMOSD patients occur more 
frequently in some areas than in others. This information could then be used for 
histology, which could then potentially be performed on existing brain bank 
tissues. 
Furthermore, it would be interesting to use the enhanced contrast offered by the 
PSIR images (and therefore the possibility of a more accurate segmentation) to 
calculate the cortical volume in both group of patients, as well as in healthy 
controls, in order to find out whether a more accurate measure of cortical 
volumes could detect further thinning in the NMOSD group when compared to 
healthy controls, since some was found by Calabrese and colleagues6.  
All these suggestions are for future studies. As for this thesis, the next chapter 
will look at the optic nerve, using magnetisation transfer ratio (MTR) to assess 
changes occurring in patients with and without optic neuritis, and see whether 
they differ sufficiently between NMOSD and MS to become potential markers. 
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Optic neuritis in MS and NMOSD: looking 
for differences between diseases using 
MTR of the optic nerve and optic 
coherence tomography (OCT) 
 Introduction 
As described in Chapter 2, optic neuritis (ON) is common in both MS and 
NMOSD patients and includes primary inflammation, demyelination as well as 
axonal damage of the optic nerve1. It also tends to be more aggressive in 
NMOSD, with a much smaller proportion of patients making a full recovery: 
60% of NMOSD patients suffer from either unilateral or bilateral blindness after 
a median of 7.7 years from disease onset, compared to only 4% of MS patients 
after 15 years2.  
 Why use magnetisation transfer ratio (MTR) of the optic nerve? 
As discussed in Chapter 3, section 5, MTR can be used to assess myelin 
integrity by measuring the exchange of proton between the two 'pools' existing 
in biological tissues (free water and macromolecules such as proteins or 
membrane lipids). Maps, based on the signal intensities and showing the 
estimated MT ratio, are then produced. In the context of optic neuritis, the fact 
that both the optic nerve myelin (through demyelination followed by 
remyelination) and axonal density are affected by the disease makes MTR a 
particularly promising approach to assess changes in myelin and axonal 
integrity4,5. 
As Klistorner and colleagues observe, previous studies using MTR to look into 
the optic nerve inflammation have produced inconclusive results when it comes 
to determine whether a decrease in average MTR is correlated to demyelination 
or axonal loss. Their own study suggests that MTR is associated with axonal 
degeneration rather than demyelination5. If their conclusions are correct, then 
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MTR should be a particularly appropriate technique to detect differences 
between NMOSD and RRMS, as studies looking at the retinal nerve fibre layer 
(RNFL) thickness found a significantly higher reduction in NMOSD patients 
when compared to MS ones7-11. This finding is of direct relevance when looking 
into the application of MTR to the optic nerve, as a reduction in RNFL thickness 
is also a measure of axonal loss12. Therefore it would be expected that a larger 
MTR decrease would be found in NMOSD patients with ON when compared 
to MS-ON patients. 
 Optic nerve anatomy 
In order to understand how the MTR measurements were made, as well as some 
of the problems encountered with the registration in particular, it is worth 
having a brief look at the anatomy of the optic nerve. As can be seen in Figure 
6-1a, the optic nerve starts at the back of the eye, enters the skull through the 
optic canal and ends at the optic chiasma. The optic nerve itself is composed of 
bundles surrounded by the dura (Figure 6-1b). As the images acquired were 
coronal, they show ‘slices’ of the optic nerve from the back of the eye to 
theoretically the optic canal part, but in practice the optic nerve becomes more 
difficult to differentiate from the surrounding tissues when it reaches the optic 
D 
Optic canal 
Optic chiasma 
(a) (b) 
Figure 6-1 (a) Optic nerve (Adapted from Schimming [et al.]3); (b) Schematic cross-sectional view of the 
optic nerve head. Central retinal artery in red, retinal nerve fibre layer (N) and bundles (A) within the optic 
nerve, separated by glia (G). The sclera (S) and dura (D) surround the eye and optic nerve respectively 
(Adapted from Levin6). 
Permission for 
reproduction not 
granted. 
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canal, due to a decrease in contrast as the meningeal layers get thinner, as can 
be seen in Figure 6-2. 
A further difficulty, at the level of both image acquisition and registration, is 
that any eye movement during the scan will lead to motion in the optic nerve, 
as can easily be imagined from Figure 6-1. This causes two different types of 
problems: from the acquisition point of view, too much motion will result in 
blurred images that will be useless as the boundary between the dura/CSF and 
optic nerve is no longer visible; for registration, as a collection of fixed points 
within the images are used for repositioning, the fact that the exact position of 
the optic nerve will vary means than an accurate registration is very difficult to 
achieve, as will be illustrated below. 
 Optical coherence tomography (OCT) 
Optical coherence tomography (OCT) is a non-invasive technique providing 
high resolution in vivo images of the retina, either cross-sectional or 3D. It is 
similar to ultrasound, but uses light reflections instead of acoustic echoes to 
acquire scans and can generate images of the microstructure of posterior ocular 
structures such as the RNFL, optic disc and macula.  
It had been used to look at NMOSD and MS patients with a history of optic 
neuritis and significant differences in both macular and RNFL thickness were 
found when the two groups were compared7-11,13. Thus it appeared that in the 
Figure 6-2 T2 images of the optic nerve (a) intra orbital, with the dura and CSF clearly 
visible as a white ring around the optic nerve; (b) inside the optic canal: even with a 
subject who kept her eye very still as is the case here, the boundary between the optic 
nerve and the dura becomes blurred. 
(b) (a) 
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context of this study, it would interesting to assess whether these measurements 
would correlate with changes in the MTR of the optic nerve.  
 Methods 
 Subjects 
Written, informed consent was obtained from all participant, and this study was 
approved by the NRES Committee London Bloomsbury (Formally London 
REC 2 Ethics Committee). RRMS patients were diagnosed using the revised 
McDonald criteria14, while the NMOSD diagnosis was based on the criteria 
proposed by Wingerchuk and colleagues in 200615. 19 NMOSD patients, aged 
between 21 and 70 years, and 19 MS patients, aged between 26 and 55 years, 
with a similar gender ratio and disease duration, as well as 23 healthy controls, 
aged between 23 and 68 years, were consecutively recruited. 17 of the NMOSD 
patients were AQP4 positive, while one of the two AQP4 negative was MOG 
positive. Not all patients had a history of optic neuritis and none of those who 
had did suffer from a recent attack (past 12 months). The full details for each 
group are given in Table 6-1. 
 RRMS patients 
n=19 
NMOSD patients 
n=19 
Healthy controls 
n=23 
Age (years) 41.28 ±9.86 52.72±11.69 36.87±8.92 
Gender (F/M) 15/4 16/3 12/9 
Median EDSS (range) 2.5 (1-7.5) 4.25 (2-6.5) N/A 
Disease duration 8.83±6.20 7.89±6.92 N/A 
WM PD/T2 LL (ml) 5.08±4.84 1.05±1.55 N/A 
AQP4+ N/A 17 N/A 
ON (bilateral) 10(1) 12(6) N/A 
Table 6-1 Demographic and clinical data 
6.2.1.1  Exclusions 
Two controls and one NMOSD patient had to be excluded due to the amount 
motion artefacts, which either made the scans unusable or the MTR maps were 
deemed unreliable. Additionally, the scans for one eye in a control and in an 
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MS patient had to be excluded due to acquisition problems (control) and quality 
issues with the MToff/MTon registration (patient). In these two cases, only data 
from one eye was used instead of an average of both eyes.  
 Image acquisition 
Using a 3 T Philips Achieva MRI system with dual-transmit technology (Philips 
Healthcare, Best, Netherlands) and the manufacturer's 32-channel head coil, the 
optic nerves were imaged in the coronal-oblique plane (i.e. slices perpendicular 
to the nerve) from the back of the globe to the optic chiasm. The following 
sequences were acquired: for use with positioning, (i) an axial 2D turbo-spin-
echo (TSE) PD/T2-weighted sequence, with TR = 3500 ms; TE1/TE2 = 15/85 
ms; echo train length = 10 echoes; FOV = 240×180 mm2; voxel size = 1×1×3 
mm3; number of excitations (NEX) = 1; 50 contiguous slices, and (ii) a sagittal 
3D-turbo field echo T1-weighted with TR = 7 ms; TE = 3.1 ms; TFE=230; TI: 
834 ms; FOV = 256×256 mm2; voxel size = 1×1×1 mm3; number of excitations 
(NEX) = 1; 180 contiguous slices (iii) for cross-sectional area, and for each 
optic nerve separately, a coronal-oblique fat-suppressed TSE T2-weighted, with 
slice 1 within the globe and slice 2 at the beginning of the anterior portion of 
the optic nerve, TR = 3000 ms; TE = 80 ms; echo train length = 15 echoes; FOV 
= 160×160 mm2; voxel size = 0.5×0.5×3 mm3; number of excitations (NEX) = 
3; 20 contiguous coronal slices (iv) for MTR imaging, again for each optic nerve 
separately, using the same positioning than for the TSE-T2w (achieved by 
copying the geometry between the two scans), consisting of a 3D slab-selective 
FFE sequence with two echoes (TR = 49 ms, TE1/TE2 = 3.6/6 ms, flip angle α 
= 9°), performed with and without Sinc-Gaussian shaped MT saturating pulses 
of nominal α = 360°, offset frequency 1 kHz, duration 16 ms. Twenty slices 
were acquired in the coronal-oblique plane, with FOV = 160 × 180 mm and 
acquisition matrix 212× 212 (voxel size 0.75 × 0.75 × 3 mm3 reconstructed to 
0.5 × 0.5 × 3 mm3), NEX = 2, SENSE acceleration factor = 2, scanning time = 
7 min. An example of the field-of-view box used is shown in Figure 6.3. The 
total scan time for the protocol, (iii) and (iv), was ~ 14 minutes per optic nerve. 
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The scans were performed asking the subjects to keep their eyes closed. The 
MTR protocol was originally developed for the spinal cord16. 
Two sets of MT images were acquired for each eye to obtain a better SNR. 
 Registration 
As explained in the anatomy section, the optic nerve is a mobile structure, which 
makes achieving a good registration extremely challenging. One of the key 
problems was that the position of the optic nerve could differ quite substantially 
between the MToff and MTon maps. Consequently, three different registration 
pipelines were applied in the context of this study. The first one, which was 
developed for a previous study, proved unsatisfactory. When looking at the 
different stages, two problems were detected that could easily be addressed: the 
images were cropped before the registration was done, thus significantly 
reducing that amount of information available for this procedure. The second 
was that the MToff and MTon images were registered to the T2 ones. Since the 
T2 images were used purely to enhance the accuracy of the positioning of the 
ROIs in the optic nerve, this process introduced further distortions in the final 
MTR maps without bringing any advantage. Registering the T2 images to the 
MT ones caused a small loss in quality, but too small to affect their usefulness 
for the required purpose. Besides these changes, the number of degrees of 
freedom used was also increased from 6 to 12. 
Figure 6-3 Positioning of the field of view box for the left optic nerve. 
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The full revised pipeline was as follows: the two MToff, the second MTon and 
the T2 images were affine registered to the first MTon image. The two MToff and 
two MTon images were then averaged in order to create a single MToff and MTon 
set of images (needed to produce the MTR map). The next stage consisted of 
cropping these three sets of images and then creating the MTR maps using the 
following calculation: 
100×(MToff - MTon)/ MToff  
The maps obtained with this registration pipeline were used to delineate the 
ROIs and for the initial analysis.  
The third registration pipeline was introduced at a late stage, in a further attempt 
to reduce the effect of motion. Just as in the NODDI study, this was done using 
the NiftyReg software package (http://niftyreg.sf.net), which implements a 
symmetric and inverse-consistent registration that ensures the results are not 
biased towards the directionality of the registration process. The new pipeline 
was as follow: the first stage consisted of rigidly aligning the MToff and MTon 
maps from the two acquisitions. Then, the transformation to the half-way space 
between first and second MT acquisition was computed, before moving the four 
set of images (two MTon and two MToff) to this space. Next, the means of MTon 
and MToff images were computed. These averaged MToff and MTon images were 
used to compute the MTR maps with the calculation shown above. Finally, the 
T2 images were registered to the mean MTon using a rigid transformation.  
The ROI masks also underwent a rigid registration similar to the one for the T2 
images so that they could be automatically applied to the MTR maps (this was 
necessary as the software JIM 6.0 allows partial voxels but not NiftyReg). The 
final stage was the computation of the means and standard deviations for the 
masked areas in the MTR maps, removing the 2% of outliers. 
For both pipelines, the same process was performed for both the left and right 
eye. 
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 ROIs positioning 
Initially, the ROIs were manually delineated, however this was changed in order 
to increase reproducibility, and the automated contour detecting function in JIM 
6.0 (Xinapse systems, http://www.xinapse.com) was used instead. In most 
subjects, the T2 maps were used to position the ROI (for 6 patients, 3 MS and 
3 NMOSD, the quality of the T2 images was too poor), with the Contour ROIs 
centred in the optic nerve. As at least part of the dura was often included in the 
ROI due to insufficient contrast for automatic boundary detection, the erosion 
function was used to reduce the ROI size until only the optic nerve was 
included. Further repositioning using the averaged MToff and MTon was often 
Figure 6-4 ROI positioning (a) T2 map, with the original ROI using the automatic contour detection 
(yellow) and the eroded one (red) (b)-(d) MToff, MTon and MTR maps showing the position of the 
original ROI from the T2 map (red) and the repositioned one (blue). As can be seen, the ROI has 
been eroded further to ensure that only optic nerve tissue is included. 
(b) 
(d) 
(a) 
(c) 
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required due to the imperfect registration between the T2 and averaged MT 
images (Figure 6-4). In some cases, ROIs had to be discarded because of the 
poor quality of either the MToff or MTon. Further checks were made using a 
coloured version of the MTR maps as this allowed detection of contrast 
irregularities that are not easily visible on a greyscale map (Figure 6-5). 
An additional advantage of the use of the automated detection was that more 
ROIs could be incorporated, including in the optic canal and in some cases even 
in the intra-cranial part of the optic nerve. Nevertheless, the number of ROIs 
inserted in each eye varied between subjects, in part because motion artefacts 
often limited the amount of ROIs that could be placed in the anterior portion of 
the optic nerve, but also because the length of the nerve varies across subjects. 
The number of ROIs per subject ranged from 3 (in only three nerves) to 12 (in 
only two nerves), with an average and a median of 7 on both sides. Most ROIs 
were placed in the orbital section of the optic nerve, but some were in the optic 
canal. In two controls and one MS patient, one ROI was placed in the intra-
cranial section of the optic nerve in at least one eye. The positioning was done 
while being blinded about the ON status of each nerves.  
The average data from all ROIs was used for the analysis, but the values for 
each individual ROI were checked and, in the cases where inconstancies were 
found (like sudden large increases or decreases in values), the position of the 
ROI was checked again and corrections made where necessary. 
Figure 6-5 Details of grey scale and colour MTR maps. Subtle changes in the contrast are more 
visible in the colour map. This was used to assess the quality of the MTR maps when there were 
uncertainties due either motion artefacts or registration issues in the MToff and MTon maps. 
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 Protocol validation 
In order to assess intra-subject variability related to scan-rescan reliability, 5 
healthy controls (HC), 3 females, 2 males, were scanned 3 times with a 
minimum interval of two weeks between scans. The full data can be seen in 
Table 6-2, while Figure 6-6 show how the values compared across scans 
between subjects for both left and right eyes. 
Age Gender 
Left eye, 
scan 1 
(SD) 
Left eye, 
scan 2 
(SD) 
Left eye, 
scan 3 
(SD) 
Right 
eye, scan 
1 (SD) 
Right 
eye, scan 
2 (SD) 
Right 
eye, scan 
3 (SD) 
27 M 31.98 (4.63) 
34.45 
(5.90) 
32.67 
(6.66) 
32.89 
(6.76) 
34.71 
(5.05) 
32.32 
(4.60) 
27 F 33.20 (5.20) 
32.17 
(3.82) 
35.10 
(3.46) 
33.82 
(5.71) 
34.47 
(7.28) 
34.95 
(4.60) 
50 F 34.09 (7.66) 
33.02 
(4.28) 
36.61 
(6.27) 
31.10 
(6.10) 
30.14 
(4.38) 
30.18 
(4.65) 
32 F 32.10 (6.37) 
33.78 
(4.02) 
35.10 
(5.34) 
35.04 
(8.06) 
33.71 
(4.83) 
34.03 
(4.61) 
27 M 37.65 (6.26) 
37.16 
(8.18) 
35.58 
(6.64) 
33.52 
(4.68) 
35.50 
(6.55) 
35.13 
(6.80) 
Table 6-2 Demographics and data for repeats of healthy controls 
Statistical analysis to assess the amplitude of the measurement error was done 
using interclass correlation coefficient (ICC) and coefficient of variation 
(COV). Statistics were based on the standard deviation (SD), which 
characterises biological variability in between-subject comparisons, as some 
degree of variations is to be expected, but corresponds to a measurement error 
when looking at variability within subjects across repeats, as such 
measurements should not fluctuate. The two approaches make different 
Figure 6-6 MTR values across scans in the left and right eyes. L=left; R=right 
M
TR
_ 
Scans 
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assessments. 1-ICC gives the within-subject variance (the square of the within-
subject SD) as a proportion of the total variance, which consists of the biological 
variability between subjects together with the measurement of variability within 
subjects. The reason why two types of statistical tests were used is because 1-
ICC can be misleading when applied to small samples of healthy subjects with 
very little biological variability, as is the case here. The ICC is 0.31, and since 
the proportion of variability due to measurement error is equal to 1-ICC, it is 
0.69. This means that 69% of the total variance is attributed to measurement 
error.  
For the coefficient of variation (COV), the within-subject SD, as a proportion 
of the mean value of the measure, is averaged across subjects. Its calibration in 
this context is much broader as it corresponds to the scale of what is measured. 
So as the mean value for all repeats in both eyes is 34.5, a within-subject SD of 
around 1 will be calibrated as 1/34.5. As it is very small, it implies that there is 
very little measurement error. An additional advantage of COV is, that unlike 
ICC, it is not as affected by sample size. The measurement error found using 
this approach was indeed much smaller as the COV was 0.044. In other words, 
the measurement error, which here is represented by the within subject SD, is 
just 4.4% of the mean.  
This means that MTR measurements can reliably detect differences that are of 
a larger order of magnitude than the within-subject SD, but would not be 
effective at detecting more subtle changes. For the measurements made here, 
the average within-subject SD is 1.52, so much smaller than the average 
differences detected between affected nerves in patients and those of healthy 
controls, which are -4.92 for MS and -7.77 for NMOSD. 
 Visual assessment  
Visual acuity for each patient eye was tested, using ECTRS letter charts, both 
with and without pinhole correction (the best result was used), the low contrast 
Sloan letter charts (1.25% and 2.5% contrasts) and the Farnsworth-Munsell 
100-hue test. Visual assessments were not made on healthy controls as these 
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tests are routinely used in clinical contexts, have a standardised format with the 
accuracy of their scoring well established. 
 Optical coherence tomography (OCT) 
In order to measure the retinal nerve fibre layers (RNFL) and macular thickness, 
high resolution spectral domain optical coherence tomography (OCT) images 
were acquired with a Spectralis OCT device (Heidelberg Engineering, 
Heidelberg, Germany) equipped with an image alignment eye tracking-software 
(TruTrack, Heidelberg Engineering, Heidelberg, Germany). Furthermore, the 
automatic real time (ART) enable the acquisition of a specific number of frames 
per scans as will be explained below. For the purpose of this study, both patients 
and controls underwent OCT scanning using the following protocol:  
• For the RNFL, the scan is circular with a diameter of approximately 3.5 
mm, centred on the middle of the optic disc (Figure 6.7a), with 100 
frames. 
• For the macular thickness, the scan is centred on the fovea (20 x 20° field) 
and the images acquired in a series of 25 sections comprising 9 frames 
each (Figure 6.7b).  
The RNFL scans were particularly difficult to acquire because the 100 frames 
needed in a single sequence requires subjects to keep their eye very still for a 
Figure 6-7 The areas of measurement in images of the fundus: (a) RNFL, measured in a circular 
scan centered on the optic disc; (b) macular thickness. 
(a) (b) 
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longer period. By comparison, the macular scans are automatically paused 
between sections if there is too much eye movements. This does not completely 
solve the problem as some scans had missing data for some sections, but it 
makes the acquisition much more straightforward than it was for the RNFL. 
There, the combination of difficulties in keeping the eye still with problems 
linked to partial or near total sight loss (which made it difficult for patients to 
see the fixation point) meant that data was only acquired for a limited number 
of patients (9 NMOSD out of 19). The curvature of the retina in subjects who 
are either very longsighted or very short-sighted is also an issue and made it 
impossible to acquire RNFL scans for 3 healthy controls. 
Further scans had to be excluded as they did not meet the quality control 
requirements, as stated in OSCAR-IB Consensus17: either the signal strength 
was below 25dB or there were technical issues such as poor focus or the scan 
was not properly centred.  
 Statistics 
Multiple linear regressions adjusted for age and gender were used to compare 
the MTR, OCT and visual assessment values between the different groups.  
For MTR data comparisons: 
• Affected optic nerve in NMOSD and MS patients vs. optic nerve in HC 
• Affected optic nerve in NMOSD patients vs affected optic nerve in MS 
patients. 
• In both NMOSD and MS patients: unaffected vs affected optic nerve. 
Additional tests were made to assess whether residuals were normally 
distributed, and some slight heteroscedasticity linked to age was found. To 
correct for this, a heteroscedastically-robust test (robust standard error 
estimates) was used. Heteroscedasticity refers to a spread that is uneven and 
irregular, and finding it for some of the values meant that variances differ 
substantially either between subject groups or across values of a regression 
variable. The reason why it needed to be corrected for is because one of the 
crucial outputs of linear regressions is the residual, that is the difference 
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between the observed value of the dependent variable and the predicted value. 
Linear regression models assume that residuals will be scattered with similar 
variability across the range of predicted values, therefore the presence of 
heteroscedasticity can seriously affect both significance tests and confidence 
interval estimations. 
Moreover, further tests were made to assess the hypothesis that 4 subjects were 
unduly influential, and showed that they did indeed have a conservative effect, 
reducing both the size and significance of the differences between NMOSD 
patients and both MS patients and healthy controls (i.e. the reduction of MTR 
in NMOSD is larger when compared to MS and healthy controls when these 
influential subjects are excluded). Concretely, this means that the detected 
difference between NMOSD and MS patients is robust even if it failed to reach 
significance. 
For OCT data, each comparison was made for both the macula and RNFL: 
• Affected eye in NMOSD and MS patients vs. eye of HC. 
• Affected eye in NMOSD patients vs affected eye in MS patients. 
• In both NMOSD and MS patients: unaffected eye vs affected eye. 
For the visual assessments: 
• In NMOSD and MS patients affected eyes, correlation with MTR. 
Results associated with p<0.05 and 95%CI were considered significant.  
 Results 
Table 6.3 and 6.4 give the full results for the MS and NMOSD patients 
respectively, including the visual assessments and OCT measurements for both 
the macula and the RNFL. Table 6.5 contains the MTR data and OCT 
measurements for the healthy controls.  
Unless patients had unilateral ON, an average of the values from both nerves was used 
for the analysis, as the two nerves from the same subject cannot be considered as 
independent. The absence of independence is further supported by the fact that 
changes were also found in unaffected nerves of NMOSD patients with unilateral ON. 
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Age Gender EDSS 
Dis. 
Dur. 
(y) 
VA 
L 
VA 
R 
1.25% 
Sloan 
Chart 
L 
1.25% 
Sloan 
Chart 
R 
2.5% 
Sloan 
Chart 
L 
2.5% 
Sloan 
Chart 
R 
100 
hue 
test L 
100 
hue 
test R 
ON 
L 
ON 
R 
No 
sl. 
L 
No 
sl. 
R 
MTR L (SD) MTR R (SD) 
RNFL
Ave  
L 
RNFL
Ave  
R 
Macula
(mm3)L 
Macula
(mm3)R 
21 F 2.5 2.5 0.14 0 0 0 0 0 12.17 15.87 Y Y 6 6 26.77 (4.63) 31.74 (8.89) 72 86 8.23 7.97 
50 M 3 10 0.14 -0.12 2 25 7 34 18.22 12.33 Y N 7 8 22.83 (8.08) 30.92 (6.42) 54 90 7.81 8.56 
53 F 6 3 -0.1 -0.12 32 31 38 37 8.94 8.25 N N 4 5 33.96 (6.45) 30.12 (7.13) 77 85 8.67 8.82 
69 F 6.5 2 0 0.1 0 0 0 6 15.1 15.23 N N 10 6 29.67 (7.09) 32.42 (6.28) N/A N/A N/A N/A 
53 F 6 3 0.2 0.1 0 8 0 3 7.48 6.63 N N 9 8 34.05 (7.50) 30.80 (5.53) N/A N/A N/A N/A 
52 F 4 6 1.14 1.7 0 0 0 0 N/A 29.39 Y Y 12 11 26.13 (8.40) 22.84 (4.62) N/A N/A N/A N/A 
37 F 4 3 1.52 0.92 0 0 0 0 24.49 22.09 Y Y 10 8 25.74 (6.02) 25.71 (6.67) N/A N/A 7.33 7.37 
56 F 6 2 0.02 0.12 19 19 18 17 8.49 11.31 N N 8 8 35.59 (7.18) 31.27 (6.28) 102 108 9.27 9.33 
63 F 6.5 14 0.1 0 0 0 0 0 12.00 14.83 N N 9 10 31.29 (6.85) 29.22 (6.45) N/A 53 N/A 7.04 
41 F 3 4.5 0 0 0 0 0 0 N/A 11.49 Y Y 12 9 22.26 (5.18) 25.60 (6.78) 104 97 8.71 8.5 
66 M 3.5 15 0.04 0.02 13 17 19 23 6.63 4.47 N Y 9 9 34.19 (6.94) 29.67 (6.82) N/A N/A 8.71 8.72 
51 F 6 6 0.2 0.14 10 14 18 19 10 9.38 N Y 7 3 31.54 (7.22) 26.31 (9.66) N/A N/A N/A 8.16 
51 F 2 17 1.7 0.14 19 0 34 0 N/A 8.25 Y Y 6 7 23.70 (3.13) 30.58 (6.04) 97 95 8.87 8.83 
48 M 2 7.5 -0.1 -0.12 22 15 29 20 4.47 6.00 N N 5 7 31.89 (5.61) 33.07 (8.77) 46 33 7.43 N/A 
57 F 5.5 4 0.02 0.52 10 0 17 0 16.00 21.82 Y Y 10 9 25.92 (5.08) 26.37 (7.09) N/A 85 N/A 8.29 
54 F 2 4.5 1.7 -0.1 16 0 37 0 N/A 4.00 Y N 8 10 25.18 (3.91) 27.09 (4.92) 74 N/A 7.53 7.75 
70 F 4.5 10.5 0.14 0.14 10 5 23 21 15.23 14.42 Y N 5 6 26.67 (5.52) 33.88 (6.72) 88 N/A 7.69 N/A 
57 F 5.5 29 0.12 1.7 15 N/A 32 N/A 9.59 N/A N Y 8 4 32.162 (4.98) 22.85 (5.29) N/A N/A 8.06 7.93 
Table 6-3 Full results for NMOSD patients, with the data for the affected eyes and nerves highlighted.  
The patients in blue are the two AQP4-, the one in italic is MOG+. Abbreviations: Dis. dur.: disease duration; VA: visual acuity; ON: optic neuritis; No sl.: number of slices; RNFL: 
retinal nerve fibre layers ; Y: Yes; N: No; L: left; R: right 
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Age Gender EDSS 
Dis. 
Dur. 
(y) 
VA 
L 
VA 
R 
1.25% 
Sloan 
Chart 
L 
1.25% 
Sloan 
Chart 
R 
2.5% 
Sloan 
Chart 
L 
2.5% 
Sloan 
Chart 
R 
100 
hue 
test L 
100 
hue 
test R 
ON 
L 
ON 
R 
No 
sl. 
L 
No 
sl. 
R 
MTR L (SD) MTR R (SD) 
RNFL
Ave  
L 
RNFL
Ave  
R 
Macula
(mm3)L 
Macula
(mm3)R 
36 F 4 13 0 -0.14 24 28 22 28 13.42 11.31 Y N 5 3 24.56 (7.61) 30.01 (9.81) 73 104 8.51 8.99 
24 M 4.5 4 N/A N/A 0 0 4 0 10.77 11.14 Y Y 5 5 23.18 (7.10) 27.44 (5.99) 63 61 8.18 7.99 
50 F 2.5 26 -0.1 0.12 11 14 21 25 N/A N/A N N 8 7 32.60 (6.60) 35.44 (10.57) N/A N/A 8.58 8.30 
30 F 1.5 6 0 0.12 7 6 23 15 7.75 8.00 N Y 6 5 31.16 (6.06) 36.36 (6.74) 102 98 8.75 8.71 
55 M 7 15 -0.11 0 4 4 3 4 10.20 10.58 N N 5 5 36.88 (5.57) 33.43 (5.75) 101 N/A 7.45 8.11 
35 F 1 5 -0.12 -0.14 19 16 23 29 12.65 12.65 N N 7 6 31.18 (3.69) 33.23 (4.26) 106 104 9.97 9.81 
48 F 1.5 10 -0.2 0.12 0 10 0 34 N/A 9.38 Y N 7 6 31.59 (6.20) 32.31 (8.26) 46 68 7.15 7.62 
43 F 3 15 0 0 35 35 38 38 15.49 12.81 Y N 5 5 23.20 (6.72) 29.74 (6.86) 88 91 8.63 8.74 
54 M 7.5 9 0 0.04 N/A 36 N/A 38 31.81 9.80 Y N 9 9 28.74 (4.79) 35.17 (10.48) 93 97 N/A 9.17 
54 F 1.5 5 -0.14 0 24 27 25 28 12.49 12.96 N N 6 8 30.20 (9.18) 35.80 (8.88) 85 97 8.42 8.54 
34 M 4 14 0.12 0.12 17 19 30 34 11.83 10.58 U U 6 6 28.57 (5.17) 33.44 (7.54) 87 87 8,35 8.39 
38 F 1.5 6 -0.12 -0.16 31 19 37 32 5.29 6.63 Y N 7 9 32.36 (4.44) 32.31 (5.50) 83 59 9.16 8.50 
31 F 3.5 2 0.04 0.1 27 27 35 34 9.59 9.80 N N 5 7 34.26 (4.89) 29.45 (4.27) 108 108 N/A N/A 
42 F 1 5 -0.2 -0.1 22 24 24 34 8.72 9.80 N Y 7 9 34.19 (6.89) 33.28 (4.94) 96 102 8.35 8.39 
48 F 1.5 5 -0.04 -0.16 5 0 17 13 9.59 8.72 N N 6 5 32.21 (3.78) 26.04 (6.09) 91 95 8.22 8.32 
48 F 2.5 13 -0.1 0.04 0 0 9 11 12.33 13.56 Y N 7 8 34.70 (4.38) 31.86 (7.50) 85 89 8.57 8.71 
47 F 4 5 -0.1 0 29 29 39 30 8.00 8.25 N N 7 0 33.01 (4.33) N/A 100 106 8.36 8.45 
26 F 1.5 1 0 -0.1 23 34 29 29 7.75 7.21 U U 8 8 30.28 (6.94) 31.47 (6.41) N/A N/A 8.06 7.88 
Table 6-4 Full results for MS patients, with the data for the affected eyes and nerves highlighted.   
Abbreviations: Dis. dur.: disease duration; VA: visual acuity; ON: optic neuritis; No sl.: number of slices; RNFL: retinal nerve fibre layers; L: left; R: right; U: ON status uncertain. 
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Age Gender No sl. L 
No 
sl. R MTR L (SD) MTR R (SD) 
RNFL
Ave  
L 
RNFL
Ave  
R 
Macula 
(mm3) 
L 
Macula 
(mm3) 
R 
32 M 7 8 30.30 (5.60) 35.12 (7.34) 98 92 8.72 8.65 
38 F 7 7 33.12 (6.69) 31.52 (6.20) 80 85 8.24 8.25 
29 F 8 8 36.69 (4.79) 33.27 (6.22) N/A N/A N/A N/A 
29 M 8 8 33.62 (8.26) 32.66 (7.80) 112 108 8.9 9.06 
42 F 6 8 31.87 (8.20) 34.37 (6.98) 106 105 8.75 8.75 
28 M 7 8 32.44 (6.53) 32.80 (10.76) 104 105 8.79 8.62 
27 F 6 8 33.56 (4.20) 31.36(6.55) 100 100 8.96 8.97 
27 M 6 9 35.63 (7.57) 34.59 (7.59) 128 124 8.71 8.75 
27 F 6 7 30.71 (6.17) 33.74 (5.70) 91 94 8.03 7.95 
52 F 5 7 34.95 (5.46) 35.01 (6.74) 98 101 9.34 9.46 
36 M 9 9 34.49 (5.12) 35.87 (7.56) 111 115 9.10 9.18 
23 F 8 7 32.62 (4.20) 32.74 (5.74) 114 112 9.15 9.17 
28 F N/A 8 N/A 33.46 (7.37) N/A N/A 8.33 8.29 
24 F 5 5 32.94 (6.67) 30.30 (7.54) 103 104 8.46 8.47 
23 M 9 8 33.07 (8.70) 30.95 (7.33) N/A N/A N/A N/A 
50 F 4 4 30.97 (6.54) 31.10 (5.00) 81 86 8.94 8.89 
27 M 9 9 31.17 (5.82) 32.11 (6.35) 95 92 8.55 8.58 
27 M 7 8 34.87 (5.30) 31.68 (5.93) 100 100 8.69 8.79 
32 F 7 8 34.45 (4.42) 36.41 (8.54) 96 N/A N/A 7.14 
62 M 6 7 34.95 (6.75) 33.69 (8.02) N/A N/A 7.86 7.77 
68 F 7 8 34.23 (5.12) 33.72 (4.36) N/A N/A N/A N/A 
57 F 7 7 35.31 (5.01) 32.19 (5.68) N/A N/A N/A N/A 
60 F 3 4 36.53 (7.57) 33.72 (4.36) 107 106 8.88 8.90 
Table 6-5 Full results for healthy controls. Abbreviations: No sl.: number of slices; RNFL: 
retinal nerve fibre layers; L: left; R: right  
 MTR data between group comparisons 
Table 6.6 and Figure 6-8 shows the results for the MTR data comparison 
between the various groups. As expected, the differences between the MTR of 
affected nerves in both MS and NMOSD patients when compared with healthy 
controls was highly significant (-4.92, p<0.001, 95% CI -7.19, -2.66 for MS vs 
controls and -7.77, p<0.001, 95% CI -10.02, -5.52 for NMOSD vs controls).  
Healthy 
controls NMOSD MS 
(n=45) Affected nerves (n=18) 
Unaffected 
nerves (n=18) 
Affected 
nerves (n=10) 
Unaffected 
nerves (n=25) 
33.33±2.27 25.94±2.64 31.80±2.20 28.37±3.65 32.64±2.55 
Table 6-6 Average MTR values and standard deviations for each group. The n corresponds to 
the number of optic nerves included in each group. 
When the initial comparison between the MTR of affected nerves in MS and 
NMOSD patients was made, it also came out as significant (-2.85, p=0.032, 
95% CI -5.44, -0.26). After the application of the heteroscedastically-robust 
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test, the difference between MS and NMOSD was downgraded to borderline 
significant (-2.85, p=0.08, 95% CI -6.07, 0.37). 
The comparison of unaffected nerves in NMOSD and MS patients with healthy 
controls was straightforward and required no further adjustment. Interestingly, 
the difference found between the MTR of MS patients unaffected nerves and 
those of healthy controls was borderline significant (-1.33, p=0.058, 95% CI -
2.70, 0.48), and became highly significant when the unaffected nerves of 
NMOSD patients were compared to those of both healthy controls (-3.59, 
p<0.001, 95% CI -5.24, -1.93) and MS patients (-2.26, p=0.007, 95% CI -3.87, 
-0.66).  
The last comparison for the MTR was between the affected and unaffected 
nerves in patients with unilateral optic neuritis. There were only 15 patients 
contributing to this analysis, 6 NMOSD patients and 9 MS ones. While 
comparing all affected nerves with all unaffected nerves without separating 
NMOSD and MS patients gave a statistically significant lower MTR value in 
the affected nerve (-3.15, p=0.018, 95% CI -5.66, -0.63), once the test was run 
Figure 6-8 Graphs showing the group comparisons for the MTR data. Except for patients with unilateral 
ON, values for both nerves were averaged. ** p<0.001, except for NMOSD vs. MS unaffected nerves, 
p=0.007, * p=0.05  HC: healthy controls 
Borderline  
Borderline  
Borderline  
** ** 
** 
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on each group of patients separately, the statistical power became insufficient 
and the difference fell below the significance level. However, lower MTR value 
in the affected nerves of NMOSD patients remained borderline significant when 
compared to the values for the unaffected nerves (-3.59, p=0.064, 95% CI -7.42, 
-0.25).  
 RNFL and macula between group comparisons 
The RNFL thickness of affected eyes in both patients groups was significantly 
lower when compared to healthy controls eyes, with the adjusted values as 
follow: for NMOSD patients -29.4 (p=0.009, 95% CI -50.3 to -7.9) and for MS 
ones -22.2 (p=0.012, 95% CI -39.1 to -5.3).  
No significant difference was found between healthy controls eyes and affected 
eyes for macular volumes.  
When comparisons were made between affected eyes RNFL thickness of the 
two patient groups, no significant differences were found either. However, as 
far as the RNFL thickness of NMOSD patients is concerned, the very limited 
data acquired is likely to have played a part in this lack of difference. 
 Visual assessments: between group comparisons and correlations with 
MTR 
Visual acuity was significantly lower in NMOSD patients when compared to 
MS ones: -0.82, p=0.009, 95% CI -1.40, -0.24. On the other hand, none of the 
results of other tests (Sloan 1.25%, Sloan 2.5% and the Farnsworth-Munsell 
100-hue test) were significantly different when the two groups were compared.  
Correlations were also made between the data for the visual assessments and 
the MTR data without group subdivision by patient types. Highly significant 
correlations between the MTR results (p <0.001) and visual acuity measured as 
well as the different visual assessments were found. The full details for each 
test are given in Table 6-7.  
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Test Regression coefficient 95%CI 
Visual acuity -0.071 -0.087 to -0.055 
Sloan 1.25% 1.153 0.918 to 1.389 
Sloan 2.5% 1.338 1.0135 to 1.662 
Farnsworth-Munsell 100-hue test -0.755 -0.934 to -0.576 
Table 6-7 Correlations between MTR data and the different visual assessments in the affected 
eye/nerve of all patients without sub-group division. p <0.001 for all correlations. 
 Discussion 
 MTR 
The results for the optic nerve MTR are the most interesting part of this study. 
While the loss of significance in the comparison between affected nerves of MS 
and NMOSD patients after the correction for heteroscedasticity linked to age 
has to be acknowledged, it is also not entirely surprising if the small size of the 
groups is taken into account. There were only 10 MS and 12 NMOSD patients 
with optic neuritis to contribute to this analysis. However, as mentioned above 
the fact that a subgroup of 4 patients had a particularly high impact on the 
outcome suggests that the difference is nevertheless valid and could potentially 
become significant with larger groups of patients and the subsequent increase 
in statistical power.  
It should also be stressed that the ROIs were always very conservative, as those 
in which lower values could potentially be linked to quality issues were 
discarded.   
From a methodological point of view, matching MS and NMOSD patients for 
age would solve the heteroscedasticity issue, especially since it appeared that 
MTR values in WM and GM may be affected by ageing18. However finding 
enough RRMS patients who are in their late forties to early sixties may prove 
difficult since, due to the earlier onset of the disease, most patients in that age 
group are likely to be in the secondary progressive phase of the disease. 
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The differences in the affected optic nerve MTR between healthy controls and 
patient groups were as expected. While there had not been any previous study 
using MTR to look at changes in the intra-orbital optic nerve of NMOSD 
patients, there have been studies done in MS5,19-23, the earliest one, from Thorpe 
and colleagues24 dating back to 1995. Most of them found decreases in the 
affected optic nerves when compared to healthy controls. Only one study, by 
Frohman and colleagues25, did not detect any differences between affected optic 
nerves in MS patients and healthy controls, and that could be due to 
methodological issues, as unlike the other studies, they did not use a ROIs 
approach.  
The fact that MTR measurements were highly correlated with decreased visual 
acuity and other visual tests further validate them by demonstrating a clear link 
between pathological changes in the optic nerve measured with magnetisation 
transfer and loss of visual acuity caused by optic neuritis. These correlations, 
which are also in line with previous studies findings20,22,23, demonstrate that the 
changes measured in the optic nerve using MTR are clinically relevant.  
Finally, it is worth noting that at individual patients level, 5 affected optic 
nerves (out of 11) in the MS group had MTR values that are within the healthy 
nerve range (from 31.59 to 36.36), as can be seen in Table 6-4. This too is in 
line with the findings of longitudinal studies which show progressive recovery 
12 months after the acute phase scans22,26. One more interesting observation at 
individual patients level is that such recovery appears to be less common in 
NMO patients (see Table 6-3) as only two out of 17 affected optic nerves had 
MTR values falling within the healthy range (31.74 and 30.58). This chimes 
with the fact that optic neuritis is more severe in NMOSD patients than in MS 
ones and a full recovery rarer2,27,28. 
Possibly the most interesting finding of this study is the significant differences 
found between unaffected optic nerves in MS and NMOSD patients and the 
optic nerves of healthy controls, as well as the significant difference between 
the unaffected nerves of the two patients groups. This suggests that undetected 
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subclinical changes are occurring in those patients, something which could 
potentially be clinically useful and was previously observed in MS patients’ 
optic nerves by Trip and colleagues23. The possibility of subclinical changes 
occurring in the optic nerve of non-ON NMOSD patients was also suggested 
by studies looking at non-affected eyes using OCT in patients with LETM29,30, 
in a study comparing RNFL and fovea of NMOSD patients (with and without 
ON) to healthy controls31 and in one combining double inversion recovery 
(DIR) of the optic nerve with OCT measurements of NMOSD patients with 
mostly unilateral ON32. 
Nevertheless, while the fact that the existence of such sub-clinical pathology 
had been found with other techniques is promising for the validity of our data, 
these results would need to be further investigated, both by scanning a larger 
group of patients and by investigating the mechanisms underlying these 
abnormalities. The latter could be done in a post-mortem study combining MRI 
with histology: since it is established that lower MTR values occur in areas 
where there is a reduction in the proportion of water bound molecules relative 
to the number of macromolecules, it can be assumed that the underlying cause 
would be a loss of tissue microstructure integrity21 which should be detectable 
at microscopic level.  
Another way to take this further would be to include the optic chiasma, the optic 
tract and optic radiation in the study, as it had been suggested that they are 
commonly affected in NMOSD patients33-36. Furthermore, to be clinically 
useful, a benchmark would need to be established, and for this a lower 
measurement error is likely to be needed, as well as automated image 
processing pipelines to make the analysis less time consuming. Even taking into 
account the above mentioned requirements, these findings could well become 
useful both to distinguish between MS and NMOSD and to help diagnose 
NMOSD following an attack of optic neuritis sometime in the future.  
 
160 
 OCT  
Based on previous studies results, RNFL thickness was expected to be thinner 
in the affected eyes of NMOSD patients than in those of MS patients7-11,37-41. 
However, as mentioned above, the amount of data acquired for NMOSD 
patients was very limited due either to their inability to keep their eyes still or 
vision that was too poor for OCT scans to be performed.  
The fact that so many studies managed to acquire data on NMO patients raised 
questions about our acquisition protocol. Comparing how the RNFL scans were 
acquired across studies is highly complex due to the variety of OCT systems 
available, which all appears to have very different settings. So the only 
comparisons possible were with studies which also used an OCT-Spectralis 
system, and even there, the number of frames used for the acquisition was not 
always specified. For the three studies that give this information, Martinez-
Lapiscina and colleagues40 used 100 frames as we did, however Outteryck and 
colleagues42 and Hadhoum and colleagues32 used at least 50 frames, suggesting 
that they had to lower the number of frames acquired for some patients. Such a 
reduction in the number of frames would significantly decrease the amount of 
time needed for the scan and may therefore have made a difference for some of 
the patients who had difficulties keeping their eyes still for a long period of time 
(the acquisition of 100 frames can be quite long as the system automatically 
pauses if there is too much movement). 
There is also the possibility that changes in the RNFL are not as clear cut as the 
above mentioned studies would suggest. A longitudinal study by Manogaran 
and colleagues43, looking at the RNFL thickness of NMOSD patients with ON 
over four years did not find any changes over that period, while a study 
comparing OCT with pattern electroretinogram (PERG) in NMOSD, LETM 
and MS patients did not find a significant difference in RNFL thickness between 
NMOSD and MS affected nerves44. Similarly, a study by Fernandes and 
colleagues29 did not find any significant difference in RNFL thickness in 
affected eyes of MS and NMOSD patients, except when comparing patients 
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with a single episode of ON, though in a study by Lang and colleagues the 
difference for the same comparison did not reach significance45. Then there is 
also a study by Martinez-Lapiscina and colleagues40 that found significant 
differences only for AQP4-IgG patients with ON or a study done by Outteryck 
and colleagues where the difference in the average RNFL ceased to be 
significant once it was adjusted.  
Interestingly, two groups found differences when looking at the inner nuclear 
layer (INL) or RNFL quadrants: Fernandes and colleagues29 show that INL was 
thicker in NMOSD patients than in MS ones, while Outteryck and colleagues38 
found significant differences in both RNFL quadrants and macular layers 
between NMO and MS. This suggests that it could be worthwhile to do further 
analysis on the acquired data, using segmentation to collect new data from 
individual macular layers and examining the data available from the RNFL 
quadrants. The latter have been successfully used in some studies already7,9,10,13, 
often uncovering more significant differences between MS and NMOSD than 
when looking at RNFL thickness as a whole. If segmentation is done, the retinal 
ganglion cell layer (RGCL), sometimes grouped with the INL as RGCL+, is 
likely to be of particular interest since significant differences between affected 
eyes of NMOSD and MS patients were found there too13,46.  
 Conclusion 
The retina and visual pathway are structures that can provide useful information 
on NMOSD, both with and without ON. They may also offer useful ways to 
differentiate between the NMOSD and MS in the future. However, as the 
discussion of OCT findings clearly shows, such differentiation remains highly 
complex and proper validation of novel techniques is crucial before developing 
clinical applications. 
A further reminder of the intricacies involved in most studies looking for 
markers that could differentiate between NMOSD and MS. The potential 
usefulness of the findings presented in this thesis, together with a general 
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evaluation of the suitability of the different MR approaches for clinical use, will 
be the focus of the following chapter. 
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Conclusion 
 Overview 
This thesis applied different MRI techniques or analysis methods to data from 
both MS and NMOSD patients in order to look for markers that could be helpful 
to differentiate between the two diseases. As noted in the introductory chapter 
on NMOSD, radiological characteristics detected on MRI scans have become a 
fundamental part of the criteria used in the new diagnosis developed by an 
International Panel for NMO Diagnosis (IPND) and published in 20151. The 
inclusion of these criteria highlights the role played by MR techniques in 
furthering our understanding of both MS and NMOSD, as well as in detecting 
new markers. However, the limitations of MR techniques should also be 
acknowledged, especially the importance of using the correct method when 
looking for something specific, like cortical lesions in NMOSD for example, 
which were not detected on 7T scanners2,3, but were found using phase sensitive 
inversion recovery (PSIR) for this thesis. The other important caveat when 
using MR scans is image processing, in particular procedures like registration, 
normalisation and segmentation, which will be discussed further below. 
Nevertheless, this thesis shows that new approaches can bring useful further 
insights with potential clinical applications. 
 NODDI 
Neurite Orientation Dispersion and Density Imaging (NODDI) is a novel 
diffusion MRI technique devised to analyse the microstructure of dendrites and 
axons, which provides more specific metrics than standard indices from 
diffusion tensor imaging, such as fractional anisotropy (FA) or mean diffusivity 
(MD). As such, it could provide new markers to differentiate between MS and 
NMOSD, since as mentioned in Chapter 1, there should be much less change 
in the NAWM of NMOSD patients than in MS ones. The work done for this 
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thesis was an exploratory study, applying NODDI to a dataset of RRMS 
patients. The aims were to assess whether NODDI could provide additional 
information about changes occurring in grey matter and normal-appearing 
white matter (NAWM) of RRMS patients when compared to what is detected 
in FA maps, as well as the performance of NODDI on single HARDI-shell data 
since the technique requires at least two shells for optimal results. Two 
approaches were used, regions of interest (ROIs) and voxel based morphometry 
(VBM). The key findings were as follow: 
 ROIS 
• Increased FA in the left internal capsule 
• Decreased ODI in left and right internal capsules 
• Decreased ODI and NDI in the genu of the corpus callosum 
• Decreased NDI in the left and right occipital lobes 
No correlations were found between EDSS scores, clinical scores and all the 
above parameters, except for the lower NDI values in the right occipital cortex, 
which correlated with longer disease duration. 
 VBM 
FA: three clusters were found: 
i. Body of the corpus callosum 
ii. Left anterior corona radiata and left inferior fronto-occipital fasciculus 
iii. Right posterior thalamic radiation.  
All three clusters correlated with the Symbol Digit Modalities Test (SDMT). 
The first also correlated with the delayed story recall and the last with disease 
duration. 
ODI: Five clusters were found: 
i. Left optic radiation 
ii. Right forceps major, right inferior longitudinal fasciculus and right 
inferior fronto-occipital fasciculus 
iii. Body of the corpus callosum 
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iv. Right inferior longitudinal fasciculus 
v. Right posterior thalamic radiation, right inferior fronto-occipital 
fasciculus, right inferior longitudinal fasciculus, right superior 
longitudinal fasciculus and right forceps major. 
Clusters ii, iii and iv correlated with SDMT, while correlations with the delayed 
story recalled and EDSS were also found in clusters i and iv, with the Paced 
Auditory Serial Addition Test (PASAT) in cluster i and with age in cluster v.  
NDI: Two clusters were found:  
i. Splenium, left forceps major, body of the corpus callosum 
ii. Left hippocampus 
No correlation found for the white matter cluster, but the hippocampal one also 
correlated with SDMT as well as the delayed story recalled. 
The results from both approaches show that the application of NODDI to single 
HARDI shell data is feasible and that ODI and NDI detected regions of 
diffusion abnormalities in RRMS patients not visible in FA maps. The areas 
affected by MS detected in the NODDI maps with VBM also correlated with 
both cognitive and clinical measurements, suggesting that they too are clinically 
relevant. Still, the usefulness of NDI maps when applied to single shell data is 
more limited when compared to the optimised multi-shells protocol, due to the 
impossibility to fit the CSF. This particularly affects NDI estimates of neurite 
density as they are based on the intracellular volume, estimated as a fraction of 
the non-CSF compartment4. 
These findings show that while there are some limitations, the application of 
NODDI to single HARDI shell data can provide new and relevant data when 
compared to FA. This means that it can be retrospectively applied to existing 
dataset for new analyses, thus a similar exploratory study to assess whether it 
could detect additional differences between NMOSD and MS could be 
performed. If this proved successful, further studies using multiple HARDI 
shells protocols should be conducted as the application of NODDI with a fully 
optimised protocol may potentially detect subtle changes in NAWM, especially 
in the early stages of both diseases, as well as more changes in normal appearing 
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GM since the fitting of the CSF compartment will provide more sensitive NDI 
maps. 
 Phase-sensitive inversion recovery (PSIR) 
PSIR has been shown to be more sensitive than double-inversion recovery 
(DIR) when used to detect cortical lesions5,6. The aim of this study was to assess 
whether this increased sensitivity would lead to the detection of cortical lesions 
in NMOSD patients, as well as assessing potential differences in juxtacortical, 
deep grey matter and cerebellar lesions in MS and NMOSD. Cortical lesions 
were divided in two categories: intracortical for those lesions found entirely in 
the cortex and leucocortical for those comprising a combination of cortical grey 
matter and white matter. Juxtacortical lesions were exclusively white matter but 
abutting to the cortex.  
This approach was particularly relevant in the context of this thesis since there 
is an ongoing argument about whether or not NMOSD causes abnormalities in 
cortical grey matter. This question became even more relevant after the 
publication of the new diagnosis criteria for NMOSD in 2015, as cortical lesions 
are listed as a one of the ‘red flag’ characteristics that are unlikely to be found 
in NMOSD1. 
For the cortical lesions, both intracortical (IC) and leucocortical (LC) were 
much more common in MS patients than NMOSD ones, but they were 
nevertheless found in both groups. 16 out of 18 MS patients had IC lesions 
compared to 6 out of 16 NMOSD ones. LC lesions were found in slightly fewer 
patients in both groups: 12 MS ones and just 4 NMOSD ones.  
White matter lesions are very common in MS and indeed such lesions were 
detected in all patients using the PD/T2 scans. And while they were also found 
in most NMOSD patients (89.5%), the actual lesion load was much lower when 
compared to MS. It is therefore not surprising that the number of NMOSD 
patients with juxtacortical (JC) lesions was much smaller than the MS one 
(77.8% of MS patients vs 37.5% of NMOSD ones).  
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Lesions were also found in the deep grey matter (DGM) and cerebellum, but 
were rare in both groups since only 22.2% of MS patients had DGM lesions and 
33.3% had cerebellar ones, compared to 6.3% NMOSD patient with DGM 
lesions and 18.8% with cerebellar ones. 
Lesion loads and lesion numbers for each type of lesions were also analysed 
and their usefulness as potential markers assessed. Both loads and numbers of 
IC, LC and JC lesions were significantly higher in MS patients when compared 
to NMOSD ones. The differences between the two groups when looking at 
DGM and cerebellar lesions did not reach significance, quite possibly due to 
the very small numbers of patients with these types of lesions.  
The average size of each type of lesions in MS and NMOSD patients was also 
calculated. IC lesions were smaller in NMOSD patients than MS ones, but this 
too did not reach significance level, again potentially due to the small numbers 
of NMOSD patients with such lesions. The average volume of LC lesions was 
similar in both groups, but the NMOSD average was greatly influenced by a 
single patient with particularly large lesions. If excluded from the analysis, the 
average LC lesion size for the NMOSD groups is also much lower than the MS 
average. The average juxtacortical lesion size, on the other hand, was very 
similar in both groups. 
When looking at the lesion load and lesion numbers as potential markers that 
could be used to differentiate between MS and NMOSD, the most accurate 
results were attained using the JC lesions, with the lesion load as the one with 
both the greatest sensitivity and greatest specificity: 88% and 72% respectively, 
incorrectly classifying only 5 patients out of 34, a 79% correct score. When 
adjusted for age, which was shown to have a strong influence, the results were 
even better: specificity reached 94% and sensitivity 89%, giving a rate of 
correctly classified patients of 91%. 
While those results are very interesting and potentially useful to differentiate 
between NMOSD and MS, there is a big caveat: the huge variations between 
individual patients. This means that while the data is useful for group analysis, 
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and could be applied in contexts such as clinical trials, it would be much more 
difficult to find benchmarks that could be used at the level individual patients 
for diagnosis purposes, especially since this variability appears to be 
independent of disease duration. 
Furthermore, these findings need to be assessed on a much larger cohort of 
NMOSD patients to determine how common cortical lesions are in NMOSD, 
something that cannot be done with such a small group of patients. 
 Magnetisation transfer ratio (MTR) on the optic nerve  
In order to assess the existence of measurable differences in abnormalities 
resulting from attacks of optic neuritis in NMOSD and MS patients, two 
different approaches were used: optical coherence tomography (OCT) to 
measure changes in retinal thickness (both in the retinal nerve fibre layers 
(RNFL) and the macula) and MTR to look at alterations in the optic nerve 
myelin. This was completed by a series of visual acuity tests. 
The RNFL thickness of affected eyes was found to be significantly lower in 
both patients groups when compared to healthy controls eyes, but no significant 
difference was found between the two patient groups. The latter is likely to have 
been affected by the fact that only very limited data was acquired from NMOSD 
patients. The reason for this was partly due to the more severe vision loss 
recorded in NMOSD patients, particularly those with bilateral optic neuritis, 
which made the acquisition of images especially difficult. Less affected patients 
also often had problems keeping their eyes sufficiently still to allow the 
acquisition of images of the required quality. These two issues severely limit 
the usefulness of RNFL measurements when high quality images are needed to 
make comparisons between patients possible. 
For the macula, no significant difference was found between affected eyes and 
healthy controls eyes. 
Of the visual assessments made (visual acuity, Sloan 1.25%, Sloan 2.5% and 
the Farnsworth-Munsell 100-hue test), only visual acuity was significantly 
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different between NNOSD and MS patients. There was also a highly significant 
correlation between the MTR results without group subdivision by patient types 
and visual acuity as well as the different visual assessments. 
The MTR results, on the other hand, were more promising as not only a highly 
significant difference was found between the MTR of affected nerves of both 
MS and NMO patients when compared with healthy controls, but when the 
initial comparison between the MTR of affected nerves of MS and NMOSD 
patients was made, it too came out as significant. However, when a necessary 
correction for age was made, the difference became only borderline significant. 
Matching NMOSD and MS patients could have avoided this issue, although this 
is something that is difficult to achieve due to earlier age of onset in MS and 
the evolution of the disease towards a secondary progressive course that is no 
longer similar to NMOSD. 
Still, the most interesting MTR result is the fact that the difference between the 
MTR values of the unaffected nerves of NMOSD patients and those of both MS 
patients and healthy controls was highly significant. This suggests the existence 
of undetected subclinical changes are occurring in those patients, something 
which could potentially be clinically useful, but not necessarily for diagnosis 
purposes as it was previously observed in MS patients’ optic nerves by Trip and 
colleagues7. 
Like the PSIR results, these findings need to be investigated further on a larger 
cohort. This validation, combined with scanning patients during the acute phase 
of optic neuritis, could potentially result in the establishment of a benchmark 
MTR value below which, when combined with one or more other supporting 
criteria, NMOSD rather than MS would be the most probable diagnosis. The 
possibility of subclinical changes in unaffected nerves of NMOSD patients, if 
confirmed, could offer new insights in disease mechanisms and would clearly 
warrant further investigations. 
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 Clinical application 
Beyond the issues of validation, could these techniques be used in a clinical 
context? The question of image processing has been briefly mentioned in the 
introduction of this chapter. This is a potentially a major concern when 
translating these techniques to the clinic. As was made clear in both the NODDI 
and MTR chapters, image registrations were necessary for both the VBM part 
of the NODDI study and to obtain MTR values. Both were particularly 
challenging to achieve and required the development of a substantial amount of 
pipelines, together with time consuming quality assessments, before the most 
suitable processing was found. This kind of work is possible in an 
interdisciplinary research group like the Queen Square MS group, where 
computer scientists specialized in image processing can solve the kind of 
complex problems encountered in the context of this thesis, but would not be 
achievable in a clinical context. Therefore, for these techniques to be useful for 
diagnosis or other assessments, further automation of the processing will be 
necessary. Automated pipelines are currently being developed within the Queen 
Square MS group, so maybe in a not too distant future, it may indeed become 
possible to use some of these techniques in a clinical context, provided of course 
that the findings presented in this thesis are validated by larger cohort studies. 
 Future Studies 
 Changes in normal appearing white matter 
It has been repeatedly shown that there is a larger WM lesion load in MS 
patients than in NMOSD ones, as confirmed by the studies included in this 
thesis. Pathological changes occurring in the normal-appearing white matter 
(NAWM), on the other hand, have been less scrutinized and it would therefore 
be of particular interest to investigate those using emerging MR techniques. 
One of them would be NODDI, with an optimised multiple HARDI shells 
protocol, as suggested in Section 7.2, but there is also a new technique, multi-
compartment microscopic diffusion imaging8, introduced by Kaden and 
colleagues in 2016, which has not yet been used in a clinical context. The key 
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difference between this technique and NODDI is that this new method uses 
Spherical Mean Technique (SMT). SMT is based on the fact that, for a given b-
value, the spherical mean of the diffusion signal over the gradient directions is 
not dependent on the microdomain orientation distribution (it is important to 
note that a voxel will contain a large population of microdomains). This should 
result in maps of the neurite density and compartment-specific microscopic 
diffusivities that are not affected by crossing fibres and orientation dispersion. 
This is a problem that is not fully solved by NODDI, which uses a single and 
fixed intrinsic diffusivity for nervous tissues and measures axon orientation 
distribution with a single Watson distribution. Consequently, the maps obtained 
using SMT should provide more accurate descriptions of tissues microstructure 
than those obtained from NODDI and therefore have the potentials to detect 
further subtle changes in normal-appearing brain tissues.  
The SMT model requires at least two b-shells and like NODDI uses a multi-
compartment approach, with both an intra-neurite and an extra-neurite domains. 
No myelin compartment is included because the T2-relaxation time of the water 
found between the myelin layers is so short (much shorter than the echo time of 
standard clinical scans) that it does not contribute to the measured signal8. As 
mentioned above, this technique has not yet been applied in a clinical context, 
therefore a pilot study based on previously acquired data with a multi b-shells 
protocol optimised for NODDI in MS patients could be used to assess its worth 
before applying it to a new cohort of MS and NMOSD patients. Such a study 
would also allow adjustments/optimisations of the acquisition protocol in order 
to obtain the optimal results from SMT. 
Another emerging technique that could provide interesting information about 
changes occurring in NAWM is quantitative susceptibility mapping (QSM), 
which is based on the phase of susceptibility weighting imaging (SWI) and 
provides quantitative measurements9. It gives a measure of the average 
magnetic susceptibility distribution in each voxel10 and can therefore be used to 
gain information about microstructural changes. It should be added that QSM 
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can also supply information about the nature of WM lesions in MS patients9, 
and could therefore be used to compare WM lesions in both MS and NMOSD 
patients to see whether there are differences in the magnetic susceptibility 
distribution in the lesional tissue between these two disorders. 
Different imaging techniques could also be combined, together with techniques 
such as MTR or MR spectroscopy, in order to get a broader representation of 
microstructural changes in NAWM caused by both MS and NMOSD. 
 Changes in cortical and deep grey matter  
It would worthwhile to assess whether multi-compartment microscopic 
diffusion imaging can provide additional information about changes occurring 
in both cortical and deep grey matter. This could be combined with PSIR to 
measure cortical thickness, as the greater contrast should provide better 
segmentation than what can be achieved with T1 images. 
QSM has also been shown to detect changes in iron content in deep grey matter9 
and could therefore potentially identify subclinical changes in these regions. 
Similarly, it has been shown that it can be used to measure susceptibility values 
of cortical veins, which again could potentially uncover subclinical changes11.  
 Visual pathway: from optic chiasma to primary visual cortex 
Changes have been observed in both the optic chiasma and optic tracts of 
NMOSD patients, but rarely in MS12,13, while a study by Zhao and colleagues 
found higher MD in the optic radiations of NMOSD patients when compared to 
healthy controls14. This suggests that it could be worthwhile to apply MTR to 
the whole optic pathway rather than just the optic nerves, to see whether the 
posterior sections could offer a more accurate way to distinguish between the 
two diseases. This should be completed by an investigation of whether the 
changes measured in patients who had no clinically diagnosed episode of ON 
also occur in the optic chiasma and beyond.  
In this context too, multi-compartment microscopic diffusion imaging could be 
used to see if changes can be detected in the optic chiasma and beyond in both 
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NMOSD and MS patients who had at least one episode of optic neuritis as well 
as those who did not. This could complement the MTR approach when 
assessing whether such changes occur in both types of patients, or  whether they 
are specific to NMOSD. 
The field of new MR techniques is evolving rapidly. It is highly likely that more 
new techniques will emerge in the near future that will allow further 
explorations of subtle changes caused by neurological diseases, including MS 
and NMOSD. 
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